Multimorbidity and medication management in general practice; a challenge for GPs by Sinnige, E.J.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/176471
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.

  
 
 
 
 
 
 
MULTIMORBIDITY 
AND MEDICATION MANAGEMENT  
IN GENERAL PRACTICE; 
a challenge for GPs 
 
 
 
 
 
 
 
 
Judith Sinnige 
 The research presented in this thesis was conducted at the Scientific Institute for Quality 
of Healthcare (IQ Healthcare), and the Netherlands institute for health services research 
(NIVEL). IQ Healthcare is part of the Radboud Institute for Health Sciences (RIHS), one of 
the approved research institutes of the Radboud university medical center, Nijmegen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cover : Roel ter Voort, Voorts 
Lay-out: Judith Sinnige 
Print:  ProefschriftMaken 
ISBN:   978-94-6295-715-2 
 
 
 
© E.J. Sinnige, Beverwijk, 2017. 
 
 MULTIMORBIDITY  
AND MEDICATION MANAGEMENT  
IN GENERAL PRACTICE; 
a challenge for GPs 
 
 
 
 
 
Proefschrift 
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen 
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken, 
volgens besluit van het college van decanen 
in het openbaar te verdedigen op 
dinsdag 31 oktober 2017 
om 14.30 uur precies 
 
door 
Elisabeth Johanna Sinnige 
geboren op 3 oktober 1986 
te Beverwijk 
 Promotoren:   Prof. dr. G.P. Westert 
    Prof. dr. F.G. Schellevis (VU Medisch Centrum) 
 
Copromotoren:   Dr. J.C.C. Braspenning 
    Dr. ir. J.C. Korevaar (NIVEL, Utrecht) 
 
Manuscriptcommissie: Prof. dr. M.G.M. Olde Rikkert 
    Prof. dr. W.J.J. Assendelft 
    Prof. dr. R.J. van Marum (VU Medisch Centrum) 
 
 CONTENTS 
 
Chapter 1 General introduction 7 
   
Chapter 2 The prevalence of disease clusters in older adults with 
multiple chronic diseases – A systematic literature review. 
PloS ONE. 2013; 8(11): e79641 
21 
   
Chapter 3 Multimorbidity patterns in a primary care population aged 55 years and 
over. 
Family Practice. 2015;32(5):505-513 
43 
   
Chapter 4 Inter-practice variation in polypharmacy prevalence amongst older 
patients in primary care. 
Pharmacoepidemiology and Drug Safety. 2016;25(9):1033-1041 
63 
   
Chapter 5 Medication management strategy for older people with polypharmacy 
in general practice: a qualitative study on prescribing behavior in 
primary care. 
The British Journal of General Practice. 2016;66(649):e540-e551 
83 
   
Chapter 6 Clinical Medication Reviews in the general practice population: 
who and why? 2017. 
Submitted 
101 
   
Chapter 7 General discussion 115 
   
Chapter 8 Summary 135 
   
 Samenvatting 141 
   
 Appendices  149 
   
Chapter 9 List of publications  159 
   
 Dankwoord  163 
   
 About the author 169 
   
 RIHS PhD portfolio 171 
 
  
 
  
 
Chapter 1 
General introduction 
 
 
Chapter 1 
8 
GENERAL INTRODUCTION 
Primary health care is characterized by providing general medicine, by its person-
centered and integrative approach to the patient and by the principle of continuity of 
care[1, 2]. The general practitioner (GP) -or family physician or family doctor- therefore, 
sees patients from all ages with a broad range of health problems and health conditions. 
Due to the aging population[3], which is the consequence of an increase in life 
expectancy, and a decrease in mortality by improvements in medical care, the patient 
population in a general practice becomes relatively older. A substantial part of these 
older patients visits the practice for management of one or -more likely -, multiple chronic 
diseases, like diabetes mellitus, chronic obstructive pulmonary disease (COPD) or 
osteoarthritis. Having multiple chronic diseases impedes daily life for these patients; they 
experience a lower quality of life, functional limitations, psychosocial problems, and they 
have higher rates of health care utilization[4-10]. As a consequence, the presence of 
multiple chronic diseases introduces many challenges for the GP. Management of this 
specific patient group often means the prescription of multiple medications, so one of 
the GP’s major challenges concerns medication management. This thesis focuses on the 
prevalence of patterns of chronic diseases in general practice, as well as the complexity 
of medication management in older patients with multiple chronic diseases. 
 
Prevalence and patterns of multimorbidity  
The presence of multiple (chronic) diseases within one person is known as 
multimorbidity. This concept was first introduced by Van den Akker and colleagues in 
1996[11], and was derived from Feinstein's original definition of comorbidity which was 
described as 'any distinct additional entity that has existed or may occur during the clinical 
course of a patient who has the index-disease under study'[12]. Multimorbidity can be 
distinguished from comorbidity by the fact that it does not include a specific index-
disease (e.g. an asthmatic patient with co-occurring heart failure and osteoarthritis), see 
Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic overview of the concepts multimorbidity and comorbidity (Boyd & Fortin, 2010)[13]. 
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As of the unprecedented increase in chronic degenerative disorders in society, research in 
the field of multimorbidity has received increasing attention over the last few decades. 
The relevance of these studies is underlined by the generally high prevalence rates of 
multimorbidity. However, since the definition of multimorbidity is operationalized 
differently in prevalence studies[14-18], this has led to a considerable range in assessed 
prevalence rates of multimorbidity; from around 20-30% in persons from all ages, to 55-
98% when focusing on persons aged 60 years and older[14, 19]. Next to differences in 
defining multimorbidity, research outcomes on multimorbidity vary due to differences in 
the chosen study population (e.g. general population vs. chronically ill population), the 
healthcare setting (e.g. general practice setting vs. ambulatory care setting), or data 
source (e.g. medical record data vs. survey data)[20]. Thus, as a result of the 
heterogeneity in the measurement of multimorbidity there remains uncertainty about the 
precise extent of multimorbidity in general practice.  
In everyday practice, GPs respond on patients’ reason for encounter by taking into 
account their additional prevalent problems and diseases. They manage a patient with a 
specific combination of diseases instead of a multimorbid patient itself. Information 
about the prevalence of multimorbidity patterns seems therefore particularly relevant for 
GPs. For instance because they would be able to anticipate on certain diseases which turn 
out to be more likely to occur in a certain multimorbidity pattern. Available studies on this 
topic either focused solely on disease pairs -which might not reflect the true situation as 
older patients often have more than two diseases[21, 22]-, or reported very broad -not 
practically manageable- disease patterns[23, 24]. Thus, practical evidence on manageable 
and realistic multimorbidity patterns is still lacking.  
 
Multimorbidity and polypharmacy 
Patients with multimorbidity commonly use several medications simultaneously, which is 
also referred to as polypharmacy. Often, polypharmacy is defined as the chronic use of at 
least five different medications[25-27]. An Italian study found that around 46% of a 
primary care population aged 65 years and over received five different medications in 
2005[25], and there is evidence that the prevalence of polypharmacy has increased in the 
last decennium[27]. Older patients using several medications are at increased risk for 
(potentially) inappropriate prescribing. This refers to the use of medications that should 
be avoided, and doses or frequencies of medications that should not be 
exceeded[28, 29]. Besides the increased risk for inappropriate prescribing, polypharmacy 
is associated with poor medication adherence, an increased risk for adverse drug events, 
and unplanned hospitalizations[26, 30]. Thus, attention for appropriate management and 
medication prescribing is essential. 
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Management of older patients with multimorbidity and polypharmacy 
Management of older patients with multimorbidity and polypharmacy, like their 
medication management is not that simple or apparent for GPs[31-33]. In general, the 
structure of the current health care system hinders GPs to adequately manage older 
patients with multimorbidity. For instance, GPs experience a lack of time during a regular 
(10-minute) consultation to adequately manage the problems of patients with 
multimorbidity, and this high workload is also perceived by patients[34-36]. Further, 
fragmentation and poor coordination of care is not uncommon since patients with 
multimorbidity are often seen by several health care providers, working both in primary 
as well as in secondary care[32, 37-40]. In addition, health care providers experience poor 
inter-professional communication, for instance between GPs and medical specialists, or 
between GPs and pharmacists[34, 41, 42]. The disease-centered approach characterizing 
the current health care system also complicates management of patients with 
multimorbidity and polypharmacy[43-45]. This approach means that traditionally, medical 
care is focused on the prevention, diagnosis, and treatment of single diseases, and that 
the accompanying clinical practice guidelines (CPGs) are centered around a single 
condition[46]. GPs are encouraged to adhere to these CPGs, which have been developed 
in all areas of medicine as a means to improve quality of care[47, 48]. However, in every 
day practice -where multimorbidity is common-, the question rises whether and to what 
extent these guidelines support multimorbidity management[31-33, 49-51]. Prescribing 
medications according to recommendations in CPGs may result in an excessive amount of 
medications with the increased risk for drug interactions, poor adherence and adverse 
effects[26]. To illustrate, when adhering to the CPGs a 79-years old patient with Diabetes 
Mellitus type 2, COPD, osteoporosis, osteoarthritis, and hypertension was recommended 
to take twelve different medications in nineteen doses per day, on five different 
moments of the day[31]. GPs therefore, often balance between adhering to the available 
disease-specific CPGs and providing patient-centered care[31, 33, 45, 49, 52]. Above all, in 
this older patient group other considerations can become complementary or even 
superior to medical motives, for instance patients’ quality of life, their preferences or 
their expectations. Due to a lack in guidance and the patient-specific circumstances, it is 
challenging to convert these factors into appropriate medical practice[32, 37, 39].  
 
Variation in medication prescribing between physicians 
In older patients with multimorbidity and polypharmacy, periodic adjustment of the 
prescribed medications is necessary, because of regular changes in conditions of life and 
treatment effects. Due to the fact that it is not always possible to adopt the 
recommendations on medication prescribing stated in the single-disease CPGs, GPs 
sometimes experience a lack of confidence or clinical competence to manage older 
patients with multimorbidity adequately; there seems to be clinical uncertainty[34, 41]. 
For instance, at moment when deliberating on stopping a prescribed medication. 
Moreover, a logical result of the limited applicability of practice guidelines, the availability 
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of multiple treatment options, and the influence of the physician and patient themselves 
on the treatment, is variation in medical practice between physicians. Variation in the 
(number of) prescribed medications to patients with similar characteristics is not 
necessarily worrisome if it is justified. GPs often have grounded reasons for adding -or 
not- a subsequent medication to a patient who already uses several medications[39, 41]. 
In order to elucidate the ‘not-rational’ part of medication prescribing variation, a better 
understanding of the rational part of medication prescribing variation is needed. 
Furthermore, little is known on how GPs assess the benefits and harms of available 
treatment options and by what kind of factors medication management is influenced. So, 
evidence is lacking or inconclusive on the process of medication management for this 
patient group in general practice[43]. 
 
Decision making tools for medication management in general practice 
Despite the increasing prevalence of multimorbidity and the challenges it provides for 
care providers, only a few effective interventions to improve outcomes for patients with 
multimorbidity exist, with only three focusing specifically on medication 
management[53, 54]. Tools or support centered around medication management of 
patients with multimorbidity seem urgent, and for providing optimal pharmaceutical care 
in this patient group inter-professional collaboration is desired, by involvement of 
pharmacists. An effective method to improve or strengthen medication prescribing, 
involving several health care professionals, is to give audit and feedback[55]. Feedback 
and audit appears to be most effective when provided regularly by a colleague health 
professional or supervisor, and efficient prescribing and dispensing of medications is 
most efficient when audit meetings have strict rules around medication choices[56-58]. In 
the Netherlands, these audit meetings (in Dutch: FTO) are increasingly organized, 
however, there is variation in the organization level and frequency of these meetings[57]. 
Computer decision support systems incorporated in GPs’ and pharmacists’ electronic 
health record system have proven to reduce the use of potentially inappropriate 
medications[59, 60], but there is the problem of ignoring the (many) medication 
prescribing alerts the system gives[59]. Screening tools can also assist GPs and 
pharmacists in the process of identifying potentially inappropriate prescribing and 
prescribing omissions. Examples are the Medication Appropriate Index[61], the Beers’ 
criteria[62], and the more European focused STOPP/START-criteria[63, 64]. The 
STOPP/START-criteria were also incorporated in the Dutch multidisciplinary guideline on 
polypharmacy, which is focused on the performance of clinical medication reviews (CMR) 
among the elderly[65, 66]. A CMR is a ‘critical examination of a patient’s medications 
-involving the patient, GP and pharmacist-, with the objective of reaching an agreement with 
the patient about treatment, optimizing the impact of medications, minimizing the number 
of medication related problems and reducing waste’[67]. Performing CMRs have positive 
effects on the number of drug related problems, patient satisfaction with the 
medications, and medication adherence. However, conclusive positive effects of CMRs on 
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clinical outcomes such as reduced hospital admissions or mortality rates are still 
lacking[68-71]. Furthermore, more practically, it still seems hard to select patients eligible 
for a review based on the available patient information recorded in pharmacists’ and GPs’ 
electronic health record systems[72, 73]. So, there is still room for improvement in the 
process of performing CMRs in older patients with polypharmacy, as well as in studies on 
effectiveness of CMRs on patient outcomes. In sum, tools and decision aids on 
management or medication prescribing are available. Yet, positive effects of these tools 
are inconclusive, there are practical problems or there is few evidence of the use or 
implementation of these tools in daily practice.  
 
 
Research objective and research questions: 
The aim of this thesis is to identify and clarify the challenges and complexity of managing 
older patients with multimorbidity in general practice, with a special focus on medication 
management. Expanding our knowledge as regards these facets can contribute to new 
insights for practice and scientists in the fields of multimorbidity and polypharmacy, and 
can improve patient’s health care.  
With this specific objective in mind, the following research questions were formulated, 
focused on older patients in general practice: 
1. In an international perspective, which disease combinations are most prevalent?  
2. What is the multimorbidity rate in patients with common chronic diseases in the 
Netherlands, and what kind of multimorbidity patterns occur in older patients with 
specific chronic diseases? 
3. What is the variation between general practices in polypharmacy rates of older 
patients? 
4. What is the GP’s medication management strategy for patients with 
multimorbidity and polypharmacy? 
5. What is the target group eligible for a medication review, from the GP’s and 
pharmacist’s perspective, and what are practical barriers and facilitators for 
performing a medication review? 
 
 
Outline of this thesis: 
Chapter 2 covers research question one and describes the prevalence rates of disease 
combinations found in the literature, and the methodological issues related to determine 
prevalence rates of disease combinations. Chapter 3 covers research questions two and 
examines the prevalence of multimorbidity patterns in an older primary care population 
(aged 55 years and over) by using electronic health record data of GPs within a 10-year 
period. Chapter 4 covers research question three and focuses on polypharmacy among 
older patients, and the variation of polypharmacy prevalence rates between general 
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practices by combining general practice data and pharmacy data. In chapter 5 research 
question four is answered and explores the views of GPs on medication management in 
older patients with multimorbidity and polypharmacy. Chapter 6 covers research question 
five and describes the practical organization of medication reviews in older patients and it 
explores the potential target group for a medication review by comparing the views of 
GPs and pharmacists with criteria for identifying patients potentially in need for a 
medication review. This thesis closes with a summary and general discussion of the main 
findings and provides recommendations for practice and research, which are presented in 
chapter 7 and in chapter 8. 
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General practice care in the Netherlands 
In the Netherlands all inhabitants are obligatory insured for a basic health care insurance 
package that includes -among others-, care provided by the GP. Costs for treatment that are 
not covered within the basic package can be reimbursed via a supplementary voluntary health 
insurance. No payment is required for consulting a GP in the Netherlands. All inhabitants are 
listed in a general practice, but they are free to select their GP of choice; usually they choose a 
GP from a practice located in their own neighborhood. Similar to countries like Norway, the 
United Kingdom and Italy, a full gatekeeping system is in place in the Netherlands. This means 
that patients are required to have a referral from their GP for access to most medical 
specialists[74, 75]. In general practice care, patient records are considered vital as they 
comprise all information that is essential to provide adequate medical care. To date, virtually all 
GPs in the Netherlands use an electronic medical record system to register the relevant medical 
information of their patients who consult them. A favorable effect of the gatekeepers role of 
the GP is that electronic medical record data of general practices are most likely to be a 
complete source of information related to patients’ chronic conditions, prescriptions and 
referrals[76]. Practices differ in size and in the different professions involved in the practice 
team. Small practices will consist of only one GP with a practice assistant, while larger practices 
include several GPs, supporting (specialized) nursing staff, and additional professions. A small 
part of the practices are also licensed to dispense medication prescriptions. In the Netherlands 
in 2014, 22% of the practices were considered single-handed practices, while 40% and 39% 
considered duo- and group practices, respectively[77]. Of all registered Dutch patients, 76% 
contacted a GP in 2014, with an average of four consultations per patient per year. The average 
consultation rate was 13 for patients aged 85 years and older. Most often, patients consulted 
the GP for problems related to the musculoskeletal system, the skin, and the respiratory 
system[78]. When medications are prescribed by the GP, they are usually dispensed by a 
pharmacist in a community pharmacy (i.e. a pharmacy that carries a stock of medications for 
dispensing and is open to the public). Around 60% of the patients between 18 and 64 years 
received at least one medication prescription in 2014. For patients 65 years and older this was 
90%[78]. The most frequently prescribed medication was a proton-pump-inhibitor, a group of 
drugs that reduces gastric acid production; on average 15% of the patients received a 
prescription. Additional frequently prescribed medications were non-steroidal inflammatory 
drugs (NSAID) and antibiotics[78].  
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ABSTRACT 
 
Background: Since most clinical guidelines address single diseases, treatment of patients 
with multimorbidity, the co-occurrence of multiple (chronic) diseases within one person, 
can become complicated. Information on highly prevalent combinations of diseases can 
set the agenda for guideline development on multimorbidity. With this systematic 
review we aim to describe the prevalence of disease combinations (i.e. disease clusters) in 
older patients with multimorbidity, as assessed in available studies. In addition, we 
intend to acquire information that can be supportive in the process of multimorbidity 
guideline development. 
 
Methods: We searched MEDLINE, Embase and the Cochrane Library for all types of 
studies published between January 2000 and September 2012. We included empirical 
studies focused on multimorbidity or comorbidity that reported prevalence rates of 
combinations of two or more diseases. 
 
Results: Our search yielded 3070 potentially eligible articles, of which 19 articles, 
representing 23 observational studies, turned out to meet all our quality and inclusion 
criteria after full text review. These studies provided prevalence rates of 165 
combinations of two diseases (i.e. disease pairs). Twenty disease pairs, concerning 12 
different diseases, were described in at least 3 studies. Depression was found to be the 
disease that was most commonly clustered, and was paired with 8 different diseases, in 
the available studies. Hypertension and diabetes mellitus were found to be the second 
most clustered diseases, both with 6 different diseases. Prevalence rates for each disease 
combination varied considerably per study, but were highest for the pairs that included 
hypertension, coronary artery disease, and diabetes mellitus. 
 
Conclusions: Twenty disease pairs were assessed most frequently in patients with 
multimorbidity. These disease combinations could serve as a first priority setting towards 
the development of multimorbidity guidelines, starting with the diseases with the highest 
observed prevalence rates and those with potential interacting treatment plans.  
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INTRODUCTION 
The growing interest in the concept of multimorbidity, which refers to the co-occurrence 
of multiple (often chronic) diseases or medical conditions within one person[1], is 
motivated by the rising prevalence of multimorbidity, its negative health consequences, 
and the challenge to manage multimorbid patients in health care settings, often family 
medicine practice[2-11]. Managing patients with multimorbidity is much more complicated 
than managing patients with a single condition[10]. Clinical evidence-based guidelines have 
been developed to provide recommendations for patient management, to define 
standards of care, and focus efforts to improve quality. However, most clinical guidelines 
address single diseases, and do not always provide guidance for patients with 
multimorbidity. Simply combining the current disease oriented guidelines might result in a 
complex, inconvenient or even conflicting treatment regime, in terms of interactions 
between drugs and diseases, conflicting management strategies, and 
polypharmacy[10-12]. To support health care providers in daily practice, guidelines for 
combinations of diseases are thus warranted, especially for the most prevalent 
combinations with complex or incompatible regimes. 
 
Despite the increasing body of research that has been conducted in the field of 
multimorbidity, there is still no clear, uniform operational definition for multimorbidity, 
and thus no clear picture of common multimorbidity combinations. Over the years, 
various methods have been developed and employed to measure multimorbidity. There 
are indices available that estimate a multimorbidity-score by weighting a range of 
diseases (e.g. Charlson Comorbidity Index[13] or Cumulative Illness Rating Scale[14]). 
Other applied multimorbidity measures are the Chronic Disease Score[15], RxRisk 
Model[16], or the Duke Severity of Illness Checklist[17]. Furthermore, multimorbidity can 
be assessed by simply counting the number of co-existing diseases within a person, using 
a predefined list of medical conditions. As disease counts are easy to use, it is presumably 
the most common approach to define multimorbidity. 
 
Two recent systematic reviews described the available measures of multimorbidity in 
more detail and pointed out that the choice of a measure depends on the outcome of 
interest and the type of data available[18, 19]. Overall, these methods are employed to 
predict health outcomes, for instance, disability, quality of life, health care utilization or 
mortality. Additionally, these methods are often applied to assess prevalence rates. 
Prevalence estimates vary widely depending on the study population, setting, data 
sources, the type of the diseases considered and the number of conditions included in 
the analysis[18, 20-23]. 
 
Although evidence for the overall prevalence of multimorbidity is accumulating, insight 
into the prevalence of specific disease combinations (i.e. disease clusters) is limited. A 
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few studies explored disease clusters of multimorbidity by conducting statistical cluster 
or factor analysis[24-26]. These studies identified several broad clusters of diseases, but 
it remained unclear which specific combinations of diseases were most frequently 
occurring, taken into account the variation in prevalence rates. To the best of our 
knowledge, there are no systematic reviews that have investigated multimorbidity 
clusters, and therefore, a complete overview is still lacking. 
With this current systematic review we aim to describe the prevalence of disease 
clusters in older patients with multimorbidity, as found in published studies. In addition, 
we intend to acquire information that can be supportive in the process of developing 
multimorbidity guidelines that could assist patient management and improve quality of 
health care. 
 
 
METHODS 
Search strategy 
To find eligible studies we consulted the electronic databases MEDLINE/PubMed, Embase 
and Cochrane Library. A search strategy was developed for each database, using a 
combination of key words and Medical Subject Headings (MEDLINE) or Emtree terms 
(EMBASE and Cochrane Library). Since the term multimorbidity does not have an 
equivalent in the database’s thesaurus, it was only searched as a key word. Until recently, 
the term comorbidity was used interchangeably with multimorbidity, as it also refers to 
the co-existence of multiple conditions[1, 27]. Hence, both terms and their spelling 
variations were included in our search algorithm. We combined search terms relating to 
multimorbidity (e.g. “multimorbid*”, “multiple chronic diseas*”, “multiple illness*”), 
comorbidity, chronic disease, and the definition or measurement (e.g. “index”, 
“definition”, “measurement”, “list”, “instrument”). The search strategy was developed 
iteratively to identify a combination of terms with an acceptable level of sensitivity and 
specificity. We restricted the search to articles with an available abstract, published in 
English or Dutch, and those published between January 2000 and September 2012. 
Before the year 2000, only a few articles had been published on the concept of 
multimorbidity. We did not restrict the search to a specific study type. To be complete, 
we also screened reference lists of all included articles. The final search strategy for 
MEDLINE is given in Appendix 2.1. 
 
Study selection 
The selection of studies followed several steps. First, different inclusion and exclusion 
criteria were specified for the selection of studies by title, abstract and full-text 
(Table 1). Second, a random sample of fifteen titles was screened by two authors (JS and 
JK) to control for unclear formulated inclusion and exclusion criteria, before screening all 
titles of the yielded articles; there was no disagreement or vagueness. Subsequently, one 
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author (JS) screened all titles for relevancy, based on the defined inclusion and exclusion 
criteria (Table 1). Third, two authors (JK and JS) independently appraised a sample of 
twenty abstracts. There was no disagreement between the two authors, after which all 
remaining abstracts were screened for eligibility by one author (JS) and, when necessary, 
by a second author (JK or JB). Last, full-text articles were independently screened for 
eligibility by at least two authors (JS screened all the full texts, and JK and JB both 
screened half of the full texts). To evaluate the full text articles on the inclusion and 
exclusion criteria, both authors appointed to screen the full text article filled out a self-
constructed checklist. Discrepancies and ambiguities were solved by discussion between 
the two authors and, when necessary, by a third author. 
 
Table 1. Inclusion and exclusion criteria of the screening process of the yielded articles. 
Inclusion criteria Exclusion criteria 
Titles 
 
 
 
 
 
 
Abstracts 
 
 
 
 
 
 
 
 
 
Full-texts 
- Included the words ‘multimorbidity’ or 
‘comorbidity’ or related words (see step 1 
and 2 in Appendix 2.1) 
 
Titles not including these words were 
excluded 
 
- Evidence that multimorbidity/comorbidity 
was the outcome variable, or the central 
independent variable 
 
- Availability of a list of diseases to account 
for multimorbidity/comorbidity, morbidity 
indices or measures.  
 
Abstracts not meeting these criteria were 
excluded. 
 
 
- Availability of prevalence rates of specific 
disease clusters*   
- No data of disease combinations (or impossible to 
calculate prevalence rates)* 
 
- Age of at least half of the study population was ≤ 55 
years 
 
- Diagnosis of a disease was based on medication 
prescription (ATC codes) only 
 
- Study size less than 500 persons† 
 
- Study conducted in a hospital setting‡ 
 
- Study examined solely two diseases§ 
 
- Study was focused on an index-disease with a 
prevalence < 0.5% in the total population in the 
Netherlands 
 
- Study with a non-empiric research type: ‘letter’, 
‘(narrative) review’, ‘editorial’, ‘case-study’, 
‘presentation’, ‘commentary’ 
* or results that allowed the calculation of a prevalence rate: Some studies reported odds ratios instead of 
prevalence rates. These data were converted into prevalence rates. If not possible, the article was excluded.   
† to include studies with results based on solid, robust data 
‡ our study is more focused on primary care as health professionals in primary care often see patients with 
multiple health conditions 
§ we assumed that studies solely focusing on two diseases would provide insufficient disease clusters with 
applicable prevalence rates 
 
 
Assessment of study quality 
After titles and abstracts had been screened, all remaining articles had an observational 
design. Therefore, quality assessment of the articles was based on several items of the 
Strengthening the Reporting of Observational studies in Epidemiology (STROBE) 
checklist[28], which we included in our checklist. The items that were required to be 
described in the articles were (1) the study design; (2) the setting; (3) the study size; (4) 
eligibility criteria of participants; (5) the type of diseases included to measure comorbidity 
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or multimorbidity; (6) the data collection method; and (7) outcome data related to the 
prevalence of combinations of diseases. These items, with specific conditions, were also 
considered as inclusion and exclusion criteria (see also Table 1). In addition, to be retained 
in our review, only those articles that met our inclusion and exclusion criteria, and thus 
our specified quality standard, were selected. 
 
Data extraction and synthesis 
For each included study, the following data were extracted: 
1. Study characteristics: First author, year of publication, country, study size, setting, 
population age; 
2. Information relating to the number and types of diseases examined; 
3. Information relating to (the prevalence of) the presented disease clusters. 
 
The checklist was employed to gather data about the study characteristics. These data 
were tabulated and ordered according to the population setting and the presence or 
absence of a specific index-disease. A mean age was given or calculated, but when 
impossible the age range was given. Subsequently, all possible diseases, and disease 
combinations as described in the included studies, were gathered, counted, and 
tabulated. In addition, the accompanying prevalence rates for each combination were 
collected and presented. When necessary, odds ratios were converted into prevalence 
rates. All given prevalence rates concerned the total study sample, and if not, prevalence 
rates were converted to relate to the total sample. 
 
 
RESULTS 
Included studies 
In total, 3070 potentially eligible articles were identified, of which 2410 remained after 
exclusion of duplicates, see Figure 1. After screening of titles and abstracts, 279 articles 
remained to be read completely. Of these articles, 212 were excluded because they did 
not meet our inclusion criteria, as shown in Figure 1. Additionally, 45 articles were found 
to be an abstract or supplement for a congress and were excluded, 1 article was excluded 
because of double publication of part of the results of the same research project, and of 
2 articles we had no access to the full-text. As a result, 19 articles remained. One of these 
articles focused on multimorbidity in different settings and described the data of these 
populations separately. These different settings were regarded as 5 individual studies 
and therefore, our final sample for analysis represented 23 studies. All 23 studies fulfilled 
our inclusion criteria and met our quality criteria. 
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Figure 1. PRISMA Flow chart outlining the study selection process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study characteristics 
All 23 studies had an observational design and were conducted in either the general 
population (n=13)[23, 29-38], primary care (n=7)[23, 39-43] or ambulatory care setting (n=1) 
[44]. Two studies were based on data of the Veterans Health Administration system 
(VHA)[6, 45] (Table 2). The population size of the studies varied from 599[23] to over one 
million[45] individuals. Except for two[44, 45], all studies reported clusters of two diseases. 
In five studies[37, 38, 42, 43, 45] patients were only included when diagnosed with a 
specific disease (i.e. index-disease). In 8 studies[29, 30, 32-34, 36, 39, 40] prevalence rates 
were converted to provide comparable prevalence rates of the disease clusters. In one 
study, odds ratios were converted into prevalence rates[35]. 
Records identified by searching MEDLINE/PubMed, EMBASE, and Cochrane Library 
(N=3070) 
Records screened by 
title 
(N=2410) 
Records screened by 
abstract 
(N=897) 
Records excluded 
(N=1513) 
Full-text articles 
assessed  
for eligibility 
(N=279) 
260 Full-text articles excluded:  
 
No disease-clustering (N=130) 
 
Different subject, not our focus (N=31) 
 
Low population age (N=18) 
 
Hospital or nursing home setting (N=13) 
 
Low prevalence index-disease or index 
disease concerned a risk factor (N=7) 
 
Study-protocol (N=4) 
 
Small study size (N=4) 
 
Missing info about age (N=4) 
 
Diagnosis with non-unique  
ATC code (N=1) 
 
Only a supplement/abstract (N=45) 
 
Reported duplicate results (N=1) 
 
Full-text not available (N=2) 19 articles, representing  
23 studies included  
Duplicates removed 
(N=660) 
Records excluded 
(N=618) 
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Type of diseases 
Sixty-three different diseases were found, of which some were defined rather broadly (e.g. 
heart disease, gastrointestinal disease), while others were described in more detail (e.g. 
cataract, atrial fibrillation). Diabetes mellitus was the most frequently measured disease 
(described in 19 out of 23 studies). Other commonly assessed diseases were 
hypertension, cancer, stroke, and depression (Figure 2). Besides the 63 diseases, 165 
combinations of two diseases (i.e. disease pairs) and 50 combinations of three diseases 
(i.e. disease triplets) were reported in the studies. Of the disease pairs, 20 were 
described rather frequently (≥ 3 studies), see Table 3. The disease triplets could not be 
replicated in any of the other studies and were therefore not further analyzed. 
The rank in frequency of diseases examined in the included studies depended on the 
definition of the diseases. As displayed in Figure 2, various diseases of the circulatory 
tract were examined frequently (6 diseases in the top 20). However, the definition of 
these diseases differed in level of detail. If heart failure, coronary artery disease and 
heart attack/angina were defined as heart disease (this broad definition could comprise 
the separate diseases), heart disease was examined in 17 studies instead of in 6 (in some 
studies coronary artery disease and heart failure were both examined), making it the 
third most commonly assessed disease. This also applied the category COPD/asthma and 
the separate diseases asthma and COPD. If the specific diseases were grouped into the 
broad combined category, then COPD/asthma was investigated in 14 studies, instead of in 
9 studies. 
 
Figure 2. Type  of diseases examined in the included studies (top 20).  
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Disease clusters 
The most frequently assessed combinations concerned 12 different diseases (Table 3). 
Regarding these diseases, several clusters were identified. Of the assessed diseases, 
depression was most frequently clustered, and was paired with 8 other diseases. 
Additionally, hypertension and diabetes mellitus were also found to be commonly 
clustered in the available studies (with 6 different diseases). Although depression was 
the disease most frequently assessed in pairs, the highest prevalence rates were found 
for disease pairs including hypertension, highest for its combination with osteoarthritis 
(20%). The top ten disease combinations with the highest prevalence rates all included 
the diseases hypertension, coronary artery disease, and diabetes mellitus. In the studies 
that focused on a specific index-disease, mainly studies concerning depression, even 
higher prevalence rates were identified; 57% of the patients with a major depression 
were also diagnosed with hypertension (see Table 4). 
Per study, varying prevalence rates for each disease combination were found. Especially 
for depression with hypertension (from 1.2% to 12.9%), and for cancer with hypertension 
(from 1.0% to 10.6%). Further, the highest prevalence values were often found in studies 
in which the morbidity data were collected via interviews or surveys. These studies 
almost always concerned the general population. Nearly all studies that applied 
electronic medical records (EMRs) to collect morbidity data were executed in a primary 
care setting. 
 
 
DISCUSSION 
While multimorbidity in older people seems to be the rule rather than the exception, 
evidence on the prevalence of specific disease clusters in patients with multimorbidity is 
limited. In this systematic review 19 articles were included, representing 23 studies, that 
described 63 diseases and 165 disease pairs. Twenty disease pairs, comprising 12 
different diseases, were examined rather frequently. Of the assessed diseases, 
depression was the disease most frequently clustered, and was paired with 8 different 
diseases. Hypertension and diabetes mellitus were found to be the second most 
commonly clustered diseases, and were combined with 6 different diseases. The 
combinations with the highest prevalence rates included hypertension, coronary artery 
disease and diabetes mellitus. 
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Table 3. Prevalence of clusters of two diseases. 
Disease Clustered with 
Prevalence per study 
(%; %; %), data 
gathered by an 
interview/survey* 
Prevalence per study 
(%; %; %), data 
collected by patients’ 
EMRs* 
No. of study* 
    
 
Depression Hypertension 1.2;  3.9;  7.6;  12.9  1, 12, 2, 8c 
 Arthritis  1.7;  2.8;  4.9  1, 2, 12 
 Diabetes Mellitus 1.7;  2.8 1.4 12, 2, 14 
 COPD/Asthma 0.9;  1.8  2, 12 
 Stroke 0.2;  0.9;  1.0;   0.8; 1.1 1, 2, 12, 14, 3 
 Cancer 1.1 0.9 12, 14 
 Heart failure 0.7;  0.8 0.7 12, 2, 14 
 Heart disease  0.6 1 
     
Hypertension Osteoarthritis 18.7;  20.1 3.2;  4.1;  9.1;   8c, 8a, 18, 8e, 8d 
 Coronary artery disease 9.8;  14.9 7.6   7, 8a, 3 
 Diabetes Mellitus 12.0;  14.0 2.5;  6.2;  6.4;  7.4   8b, 7, 3, 8e, 18, 8d 
 Cancer 5.5;  10.6 1.0;  3.4;   7, 8c, 18, 8e 
 Depression 1.2;  3.9;  7.6;  12.9  1, 12, 2, 8c 
 Dementia  2.9; 5.5 13, 3 
     
Diabetes Mellitus Hypertension 12.0;  14.0 2.5;  6.2;  6.4;  7.4 8b, 7, 3, 8e, 18, 8d 
  Coronary artery disease 4.1;  4.5 3.6   7, 6, 14 
 Stroke 0.6;  2.9 1.9 4, 7, 14 
 Depression 1.7;  2.8 1.4 12, 2, 14 
 Heart failure 1.8  1.8;  2.2 6, 3,14 
 Cancer 0.8;  2.2 1.9  4, 7, 14 
     
Cancer Hypertension 5.5;  10.6 1.0;  3.4 7, 8c, 18, 8e 
 Diabetes Mellitus 0.8;  2.2 1.9 4, 7, 14 
 Depression 1.1 0.9   12, 14 
 Stroke 0.5;  0.9   0.9 4, 7, 14 
     
Stroke Diabetes Mellitus 0.6;  2.9 1.9 4, 7, 14 
 Dementia  0.4; 2.7 13,3 
 Depression 0.2;  0.9;  1.0   0.8; 1.1 1, 2, 12, 14, 3 
 Cancer 0.5;  0.9   0.9 4, 7, 14 
     
Coronary artery disease Hypertension 9.8;  14.9 7.6   7, 8a, 3 
 Heart failure 2.8   2.8; 5.6 6, 14, 3 
 Diabetes Mellitus 4.1;  4.5 3.6   7, 6, 14 
     
Heart failure Coronary artery disease 2.8   2.8; 5.6 6, 14, 3 
 Diabetes Mellitus 1.8  1.8; 2.2 6, 3,14 
 Depression 0.7;  0.8 0.7 12, 2, 14 
     
Dementia Hypertension  2.9; 5.5 13, 3 
 Stroke  0.4; 2.7 13, 3 
     
Osteoarthritis Hypertension 18.7;  20.1 3.2;  4.1;  9.1 8c, 8a, 18, 8e, 8d 
  
 
  
Arthritis Depression 1.7;  2.8;  4.9  1, 2, 12 
     
COPD/Asthma Depression 0.9;  1.8  2, 12 
     
Heart disease Depression 0.6  1 
Prevalence of disease clusters found in at least three studies 
EMR: Electronic medical record 
* Not bold: studies conducted in a primary care setting, bold: studies conducted in the general population, 
underlined: study based on VHA (Veterans Health Administration system) data.  
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Table 4. Prevalence of clusters of two diseases, including an index-disease. 
Prevalence of disease clusters found in at least three studies 
EMR: Electronic medical record 
* Not bold: studies conducted in a primary care setting, bold: studies conducted in the general population, 
underlined: study based on VHA (Veterans Health Administration system) data.  
 
 
The prevalence estimates of disease clusters differed widely among studies, a result that 
is in line with findings reported in other reviews[20, 46]. We will discuss two main 
possible explanations. First, differences in the population under study may affect the 
prevalence of multimorbidity and related disease clusters, like age, income, or 
ethnicity[47-52]. Multimorbidity is strongly associated with age[47-50]. Although we 
focused on older adults, the population’s mean age still varied considerably (from 56 years 
to 85 years). Further, multimorbidity seems more common among people living in 
socioeconomically deprived areas or among people with a low income[47, 49, 50]. Second, 
variation in prevalence rates might be due to the applied definition of the diseases, the 
applied data collection method and the study setting[18-21, 53, 54]. In our review, some 
diseases were defined very broadly (e.g. cancer, heart disease) while other diseases were 
defined in more detail (e.g. osteoarthritis, atrial fibrillation). Studies executed in a primary 
care setting often applied medical records with information on a detailed level, yet they 
applied different classification codes with different definitions or based on different 
diagnostic methods (e.g. depression). In contrast, studies applied in the general 
population often used surveys or interviews, all inquiring about diseases differently. 
Other diseases, like obesity, are not always considered as a disease and therefore not 
included. As a consequence, few disease combinations and accompanying prevalence 
rates were identical. 
 
Index-disease Clustered with 
Prevalence per 
study, data gathered 
by an 
interview/survey* 
Prevalence per 
study, data collected 
by patients’ EMRs* No. of study* 
  
   
Depression Hypertension 57.9  15 
 Arthritis  55.6  15 
 Diabetes Mellitus 23.2  15 
 COPD/Asthma 23.3  15 
 Cancer 10.9  15 
 Heart disease  27.6  15 
     
     
Hypertension Depression  16.7 17 
     
Diabetes Mellitus Stroke  2.9 16 
  Depression  3.9; 17.6 16, 17 
 Cancer  2.7 16 
     
Dementia Hypertension 37.1  11 
 Stroke 16.4  11 
     
Osteoarthritis Hypertension 19.8  10 
 
Heart disease Depression  16.6 17 
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With our current results we have identified combinations of diseases that are likely to 
co-occur and thus, a suitable treatment plan needs to be developed. Existing clinical 
practice guidelines, however, do not often address multimorbidity, and following all 
guidelines for all individual diseases may lead to a considerable treatment burden and to 
contradictory drug and self-care regimes[10, 11, 55]. Indeed, Boyd et al[10] reported that 
several potential medication interactions were found for a pattern that consisted of the 
diseases hypertension, diabetes mellitus, osteoarthritis, osteoporosis, and COPD. 
Contradicting life-style recommendations were found for osteoporosis and diabetes 
mellitus. As it is reasonable that our identified disease pairs are highly common in 
(elderly) adults, it would be useful if guidelines address potential drug interactions and 
contradicting treatment recommendations (drug-disease interactions, and disease-
disease interactions) for these disease pairs. 
 
This systematic review has some limitations. We used the term multimorbidity in our 
search process. This term is not well indexed in literature databases, and we might have 
missed some studies. To compensate for this constraint, we combined an extended list of 
text words referring to the term multimorbidity and we included the term comorbidity 
(with its possible spelling variations) to our search strategy. Next, we developed a 
scoring method based on several items of the STROBE checklist[28], and added these 
items to our strict inclusion and exclusion criteria, in order to obtain a minimal quality 
standard of all included studies. As a result, we could not differentiate further between 
levels of quality. Last, with this type of study we were restricted to merely describe the 
most frequently explored disease pairs in patients with multimorbidity, and not 
necessarily the most occurring disease pairs. Yet, the 12 identified diseases do represent 
highly prevalent diseases internationally[56, 57], and the accompanying combinations of 
these diseases are also likely to be highly prevalent. 
 
Reflecting on our findings and limitations, more effort should be made to establish a 
multimorbidity disease list with uniformly defined diseases. Only by doing so, 
heterogeneity between study results can be diminished, and information about the 
prevalence and burden of multimorbidity will be more genuine and comparable. It seems 
also important to have a better understanding of specific treatment conflicts concerning 
certain disease clusters, and not merely by scrutinizing the existing guidelines, but by 
actually assessing daily practice according to guideline recommendations. In this regard, 
it seems practical to start with the most frequently occurring diseases. Furthermore, it is 
still valuable to gain more insight into (the prevalence of) specific co-occurring disease 
clusters, especially of clusters of three, and four diseases, as a large proportion of the 
elderly population is diagnosed with more than two chronic conditions[50]. For the 
development of a multimorbidity guideline, however, it might be easier to take into 
account rather small disease clusters instead of broad, comprehensive disease 
clusters[25, 26]. 
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Conclusion 
Management of care for (older) patients with multimorbidity can be challenging, or 
even burdensome. To be more concrete, health care professionals need to strike a 
balance between the various disease-specific guidelines before they can develop an 
appropriate treatment plan with feasible recommendations and advices, taking the 
patient’s personal abilities into account. The disease clusters that we have distinguished, 
could serve as a first priority setting towards the development of multimorbidity 
guidelines. A likely option is to start with the most frequently occurring disease 
combinations, as regards the evaluation of potential treatment conflicts, the adjustment 
of existing clinical guidelines, or even the development of new guidelines. 
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ABSTRACT 
 
Background: To support the management of multimorbid patients in primary care, 
evidence is needed on prevalent multimorbidity patterns. 
 
Objective: To identify the common and distinctive multimorbidity patterns. 
 
Methods: Clinical data of 120,480 patients (≥55 years) were extracted from 158 general 
practices in 2002–2011. Prevalence rates of multimorbidity were analyzed (overall, and for 
24 chronic diseases), adjusted for practice, number of diseases and patients’ registration 
period; differentiated between patients 55–69 and ≥70 years. To investigate 
multimorbidity patterns, prevalence ratios (prevalence rate index-disease group divided by 
that in the non-index-disease group) were calculated for patients with heart failure, 
diabetes mellitus, migraine or dementia. 
 
Results: Multiple membership multilevel models showed that the overall adjusted 
multimorbidity rate was 86% in patients with ≥1 chronic condition, varying from 70% 
(migraine) to 98% (heart failure), 38% had ≥4 chronic diseases. In patients 55–69 years, 83% 
had multimorbidity. Numerous significant prevalence ratios were found for disease 
patterns in heart failure patients, ranging from 1.2 to 7.7, highest ratio for chronic 
obstructive pulmonary disease-cardiac dysrhythmia. For diabetes mellitus, dementia or 
migraine patients highest ratios were found for heart failure-visual disorder (2.1), heart 
failure- depression (3.9) and depression-back/neck disorder (2.1), respectively (all P-values 
<0.001). 
 
Conclusions: Multimorbidity management in general practice can be reinforced by 
knowledge on the clinical implications of the presence of the comprehensive disease 
patterns among the elderly patients, and those between 55 and 69 years. Guideline 
developers should be aware of the complexity of multimorbidity. As a consequence of this 
complexity, it is even more important to focus on what matters to a patient with 
multimorbidity in general practice. 
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INTRODUCTION 
Due to the aging of the population and improvements in medical care, a growing number 
of people are confronted with having one, and often multiple chronic conditions 
(i.e. multimorbidity)[1]. Prevalence estimates of multimorbidity ranged from 20–30% in 
persons of all ages, to 55–98% in persons 60 years and older, although these estimates are 
highly dependent on the measurement methods[2, 3]. Multimorbidity is related to negative 
health consequences, such as a poorer quality of life and functional status, higher rates of 
hospital admission and avoidable readmissions[4, 5]. 
 
Next to the negative effects on the patient, multimorbidity provides challenges to health 
care professionals, such as the GP, since traditional clinical practice guidelines focus on 
patients with a single disease. The question rises whether these guidelines support 
multimorbidity management[6-8]. Although studies have shown that the majority of the 
(reviewed) guidelines addressed the issue of comorbidity[7, 9], few guidelines gave 
management guidance in the presence of two or more conditions, and far less addressed 
the issue specific for older patients. As a result, experts in the field state that future 
guidelines should become more patient centered, integrate similar disease processes, and 
incorporate quality of life, risks, benefits and burden of recommended treatments for 
patients with multimorbidity[7, 10]. 
 
More insight into commonly occurring disease combinations (i.e. disease patterns) in the 
elderly could serve as a starting point for the development and formulation of evidence-
based management plans for multimorbidity. Currently, consistent evidence about 
prevalence rates of multimorbidity patterns is lacking as available studies on the 
prevalence of disease combinations in (older) people[11] often have limitations. Most 
studies focus solely on disease pairs[12, 13] which might not reflect the true situation, as 
elderly patients often have more than two diseases. Another issue is the age group under 
study. Some studies underline that multimorbidity is also prevalent among patients of 
younger age[12], but little is known about the multimorbidity patterns. Finally, the 
classification of disease patterns is described by using statistical techniques (e.g. factor or 
cluster analysis[11]) that require specific assumptions of the data which cannot always be 
met. 
The objective of this study is therefore, to identify highly prevalent, or prominent 
multimorbidity patterns in the elderly population. More specifically, two research 
questions are formulated: 
1. What is the multimorbidity level for common chronic diseases in a primary care 
population aged 55 years and older, and the multimorbidity level in two distinct age 
groups? 
2. Are there disease patterns that are significantly more or less prevalent in patients 
with a specific chronic disease compared to the population without that disease? 
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METHODS 
Study population 
We selected patients aged 55 years and older from general practices that participated in 
NIVEL Primary Care Database (formerly known as National Information Network of General 
practice (LINH)). This nationally representative database holds longitudinal data derived 
from patients’ electronic medical records (EMRs) on for instance consultations, and 
morbidity, from about 90 Dutch general practices. The database includes a dynamic pool 
of practices and annually changes in composition[14]. In the Netherlands, all citizens are 
required to be registered with a general practice, and the GP has a gatekeeper role for 
access to specialized care. As records from the GP are likely to be most complete and 
reflect the total population, these are especially suitable for estimating prevalence rates of 
multimorbidity. 
 
We selected practices that provided morbidity data for at least two complete consecutive 
years in the period 2002–2011. Quality checks on the data are part of the database protocol. 
Patients were required to be registered at the same practice for at least two full 
uninterrupted years. Diagnostic data were more accurate by using this minimum follow-up 
period, as for some chronic diseases patients do not necessarily visit their GP annually. Age 
of the patients was determined at start of their follow-up period. We only included patients 
diagnosed with at least one chronic condition, as we were interested in the prevalence and 
patterns of multimorbidity. This study was executed according to the precepts of the Dutch 
legislation on privacy and the regulations of the Dutch Data Protection Authority. 
According to Dutch legislation, studies using this type of observational data do not require 
medical ethical approval, or informed consent. 
 
Selection of chronic diseases 
In the Netherlands, diagnostic codes for diseases are recorded according to the 
International Classification of Primary Care (ICPC-1)[14], and GPs are expected to structure 
their EMR around disease episodes[16]. All patient contacts related to one health problem 
were clustered into a disease episode, constructed by using an algorithm to group ICPC-
coded contact records from EMRs into episodes of care[17]. We used these disease 
episodes for the selection of chronic diseases. We chose 28 common chronic diseases[18], 
and added hypertension to the list due to its high prevalence rate in the elderly (although 
a risk factor rather than a disease). This resulted in 29 diseases listed with their ICPC codes 
in Appendix 3.1. A condition was included or present if there was a ICPC code 
corresponding to one of the selected diseases recorded in the patient’s EMR during the 
complete follow-up period. 
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Statistical analysis 
Multimorbidity level 
The focus of this study was to determine the impact of diseases on the outcome per patient 
(i.e. multimorbidity yes/no). As a consequence, patients with multiple diseases were 
counted more than once, i.e. as often as their number of diseases. This would introduce 
bias; the disease specific multimorbidity proportions were biased towards the mean. To 
adjust for this phenomenon, we applied multilevel logistic regression analyses with a 
multiple membership structure[19]. With this technique, each patient is weighted by means 
of their diagnosed number of diseases. Further, patients (level 1) were nested within 
general practices, and practices and diseases were cross-classified at level 2. Based on the 
fact that not all patients had a full practice registration period, a correction factor was 
added to the models, accounting for the size of deviation from complete 10 years of 
registration. As a result, the intercept of the model was estimated as if all patients were 
considered to have a complete follow up of 10 years. The overall mean multimorbidity level 
(dependent variable) was estimated, and that for each of the chronic diseases included. 
The disease specific proportion was calculated as the sum of the overall adjusted rate, and 
the disease specific residual estimated from the disease level random effect[19]. Multilevel 
linear regression analyses were conducted with a similar model structure to analyze the 
overall adjusted mean number of diseases, and that for each chronic disease. All analyses 
were conducted for the total population, and separately for patients between 55 and 69 
years, and ≥70 years. Diseases with a prevalence rate below 0.5% were excluded from these 
analyses. This since the number of patients diagnosed with one of the diseases was too 
minimal to ensure reliable prevalence rates assessed in the analyses. See Appendix 3.2 for 
more information about the multiple membership analysis technique. 
 
Multimorbidity patterns 
Four chronic diseases were selected to examine their most prevalent disease patterns, and 
the degree of association between these patterns. The selection of these index-diseases 
was based on two criteria, namely (i) to cover the full range of multimorbidity levels (low 
versus high level of multimorbidity), and (ii) diseases that especially affected the elderly, 
since this patient group is most likely to be the target group with problems regarding 
treatment of multimorbidity. For each of the index-diseases, the most frequently co-
occurring diseases were assessed, and those with a minimum prevalence rate of 10% were 
presented. Subsequently, prevalence ratios were calculated (i.e. prevalence rate of the 
disease pair within patients with the index-disease divided by the prevalence rate of the 
disease pair in patients without the index-disease). The ratios indicated whether the 
occurrence of a disease pair was higher or lower in patients with compared to patients 
without the index disease. The ratio’s magnitude equals the strength of the relationship of 
that disease pair. Since the focus was on disease patterns within a specific patient group, 
crude data and descriptive statistics were used. Statistical significance of the ratios was 
assessed using chi-square tests. Descriptive statistics were performed to define the main 
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characteristics of the study population, by using STATA SE version 12.1, and the multilevel 
analyses were performed by using MLwiN version 2.30. 
 
 
RESULTS 
Initially, 170,583 persons aged 55 years and older were included. Prevalence numbers of 
five chronic diseases (i.e. HIV/aids, congenital cardiovascular anomaly, intellectual 
disability, schizophrenia and personality disorder) were less than 0.5%, and these diseases 
were therefore not included in the analyses. Further, 50,103 persons were not diagnosed 
with any of the 24 (i.e. 29 minus the five excluded diseases) diseases, and were therefore 
excluded. This resulted in a list of 24 chronic diseases among 120,480 patients, registered 
at 158 general practices. Patients’ mean age was 67 years (SD 9.8), 45% were men, and 62% 
had multimorbidity (Table 1). Of the patients 55–69 years, and 70 years and older, 61% and 
75% had multimorbidity, respectively. 
 
 
Table 1. Demographic characteristics of the study population (patients aged ≥ 55 years 
diagnosed with at least one chronic disease in 2002-2011*). 
 
Total Men Women P value† 
Number of patients, (%)     
Total 120,480 (100.0) 54,375 (100.0) 66,105 (100.0)  
Multimorbidity (≥2 diseases) 74,733 (62.0) 32,420 (59.6) 42,313 (64.0) <0.001 
Mean age in years, (SD) ‡     
Total 66.9 (9.8) 65.7 (9.1) 67.9 (10.2) <0.001 
Multimorbidity  68.3 (9.8) 67.1 (9.3) 69.3 (10.2) <0.001 
Mean number of years follow up, (SD)     
Total 4.6 (2.3) 4.6 (2.3) 4.5 (2.3) 0.05 
Multimorbidity 4.9 (2.4) 4.9 (2.4) 4.9 (2.4) 0.01 
 
 
Patients 55-69 years Patients ≥70 year P value† 
Number of patients, (%)    
Total 75,310 (100.0) 45,170 (100.0)  
Multimorbidity (≥2 diseases) 41,866 (55.6) 32,867 (72.8) <0.001 
Mean age in years, (SD) ‡    
Total 60.4 (4.6) 77.6 (5.8) <0.001 
Multimorbidity  60.9 (4.7) 77.8 (5.7) <0.001 
Mean number of years follow up, (SD)    
Total 4.7 (2.4) 4.2 (2.2) <0.001 
Multimorbidity 5.2 (2.5) 4.5 (2.2) <0.001 
In this table, crude frequencies, percentages, and standard deviations (SD) are reported 
*
 Minimum follow up period 2 years, maximum follow up 10 years 
† Statistical significance between men and women, and between patients 55-69 years and ≥70 years. Number of 
patients tested with Chi square tests, mean age, and mean follow up with T tests 
‡ Patient’s age at the year of inclusion 
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Multimorbidity level 
The majority of the patients were diagnosed with more than one chronic disease (overall 
adjusted mean: 86%) (Table 2). The multimorbidity level ranged from 70% 
(migraine/hypertension) up to 98% (heart failure). In total, heart failure, heart valve 
disorder and a history of stroke were diseases that were significantly more often 
associated with multimorbidity (98%, 95% and 94%, respectively) compared to other 
diseases. On average, 83% of the patients aged 55–69 years and 94% of the patients 70 years 
and older were diagnosed with multiple chronic diseases. The highest multimorbidity level 
was found for heart failure, and the lowest for hypertension. Notably, in the oldest patients 
(i.e. 70 years and older) migraine had a relative high multimorbidity rate (97%), though it 
had nearly the lowest rate in patients 55–69 years (71%). Furthermore, dementia, 
Parkinson’s disease and alcohol abuse turned out to be diseases with a relatively lower 
multimorbidity rate in patients aged 70 years and older. Results of the mean number of co-
occurring diseases can be found in Table 2).  
 
Disease patterns 
Heart failure (high multimorbidity level), migraine (low multimorbidity level), diabetes 
mellitus (highly prevalent in the elderly) and dementia (specifically related to older age) 
were examined in more depth. Cluster diagrams (Figures 1–4) illustrate the associations 
between the most frequently co-occurring disease triplets. 
 
Heart failure 
Thirteen chronic diseases were highly common within heart failure patients, with 
prevalence rates varying from 10% (asthma) to 49% (hypertension) (Figure 1). Focusing on 
disease triplets, all prevalence ratios were statistically significant above 1.0, and 75% even 
above 2.0 (see Appendix 3.3). Prevalence ratios of the triplets including cardiac 
dysrhythmia were high; they were at least 6.0 for the combination with coronary artery 
disease (CAD), chronic obstructive pulmonary disease (COPD) and osteoporosis. The same 
holds for the prevalence ratio of CAD-COPD (ratio 5.4), which was much higher in heart 
failure patients in comparison to patients without it. Focusing on some remarkable 
quartets (data not shown), almost 3% of the patients were diagnosed with both cardiac 
dysrhythmia, COPD and CAD. This prevalence rate was 14.2 times higher than that in the 
population without heart failure. The combination cardiac dysrhythmia-COPD-
osteoporosis within heart failure had a ratio of 13.6. 
 
Migraine 
Prevalence ratios of many of the disease triplets were around 1.0 (Figure 2), indicating that 
the combinations for migraine were equally prevalent in patients with other chronic 
diseases (with the exception of chronic back or neck disorder with depression (ratio 2.1)). 
Seven combinations were less frequent in patients with migraine in comparison to those 
without migraine (ratio <0.8). In line with the frequently occurring triplet chronic back or 
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neck disorder-depression-migraine, the quartet that also included osteoarthritis had a ratio 
of 2.4 (prevalence rate 0.9%). 
 
Diabetes mellitus 
Regarding the disease triplets, heart failure was highly associated with visual disorder and 
with hypertension in patients with diabetes mellitus (ratios 2.1 and 2.0, respectively) 
(Figure 3). Other prevalence ratios of triplets that included diabetes mellitus and heart 
failure ranged between 1.5 and 2.0. More particularly common disease triplets were 
diabetes mellitus-CAD and COPD, or visual disorder, or hypertension, and diabetes mellitus-
hypertension-visual disorder (see Appendix 3.3). Some distinct disease quartets were 
found (data not shown), especially the combination heart failure-visual disorder-
hypertension (prevalence ratio 2.6). Further, the quartet chronic back or neck disorder-
heart failure-visual disorder had a ratio of 2.4 within diabetes mellitus patients. 
 
Dementia 
Patients with dementia were more often diagnosed with heart failure and depression, 
heart failure and stroke and depression and stroke (ratios 3.9, 3.5 and 3.3, respectively) 
(Figure 4). There were four disease triplets with ratios between 2.5 and 3.0. Most quartets 
including stroke and depression plus one additional disease had prevalence ratios around 
3.5. The quartet depression-stroke-diabetes-dementia, had a ratio of 6.2 (prevalence rate 
0.9%). 
 
When focusing on the patients aged 55–69 years, all ratios were higher for the patterns 
including heart failure, or diabetes mellitus, indicating that the identified disease 
combinations were even more specific for the index-disease patients (data not shown). For 
migraine, similar ratios were found since nearly all patients with migraine were younger 
than 70 years. For dementia, ratios were not calculated as almost all patients were older 
than 70 years. 
 
 
DISCUSSION 
This study showed that multimorbidity is the rule rather than the exception in primary care; 
not only for patients of 70 years and older, but also for patients of 55–69 years, as 83% (of 
those diagnosed with a chronic disease) presented multimorbid problems in the general 
practice. Multimorbidity is not restricted to disease pairs, but often consists of more 
extensive patterns (i.e. triplets, quartets) of chronic diseases. These patterns relate to 
complicated care needs that require change in general practice management. 
 
Other studies confirm the high multimorbidity rate for many chronic diseases, for instance 
for heart failure or diabetes mellitus[11, 13], or confirm the finding that multimorbidity is 
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not just a problem of the elderly[12]. Yet, these studies did not focus on the complexity of 
multimorbidity (i.e. extensive disease patterns), especially not for patients younger than 
70 years.  
 
For four index-diseases, we identified the most common disease patterns of which some 
were specifically related to the index-disease and others were more common among the 
total population. Besides age as an explanation for the identified patterns, additional 
explanations for the co-occurrence of diseases are possible, as stated by van Weel and 
Schellevis[8]. They divided the co-occurrence of diseases into four categories namely, 
(i) diseases with a common pathophysiology, (ii) diseases that have developed due to 
complications of another disease, (iii) intercurrent multimorbidity which considers acute 
diseases in patients diagnosed with a chronic disease and (iv) concurrent diseases without 
any known causal relation between the diseases. Most of the diseases presented in our 
cluster diagrams have a common pathophysiology. For instance, cardiac dysrhythmia and 
CAD are both common causes of heart failure, and diabetes and hypertension are risk 
factors for heart failure[20]. Furthermore, the identified disease pattern diabetes mellitus-
cardiac disease-COPD could be explained by shared cardiovascular and metabolic risk 
factors, such as hypertension and smoking. Visual disorder (e.g. retinopathy) as a common 
disease in diabetes mellitus patients can be considered as a complication of the presence 
of diabetes, and the same applies for dementia after stroke[21]. Some identified disease 
combinations have similar symptoms, leading to intensive diagnostic tests that could result 
in both diagnoses (e.g. COPD and heart failure)[20]. We found that COPD strongly 
clustered with CAD and cardiac dysrhythmia in heart failure patients. The intercurrence of 
multiple diseases could not be confirmed since our study did not focus on acute diseases. 
For some combinations, it is unclear how they are related, and if there is a causal 
relationship. These combinations could indicate concurrent co-occurring diseases, for 
instance cardiac dysrhythmia and osteoporosis in heart failure patients. Remarkably, 
disease patterns that included diabetes mellitus were less prevalent in migraine patients 
than in patients with other chronic diseases. A few studies do confirm the ‘protective’ 
effect of diabetes on migraine[22]. Considering the variation within the disease patterns, it 
may be useful to explore the patterns of disease for other common index-diseases. 
The cluster diagrams showed that hypertension was highly prevalent in all four chosen 
index-diseases. This is also confirmed in other studies exploring disease pairs and 
triplets[11, 13]. The current study, moreover, showed that the ratios for hypertension and 
other diseases were not quite prominent, underlining that hypertension is not specifically 
related to one certain type of disease. Only in the cluster diagram for diabetes mellitus 
some distinct combinations were found that included hypertension. In a study by Islam et 
al[11], it was found that diabetes and hypertension were always classified in the same 
cluster or group, using several analytic techniques. In a study by Marengoni et al[13], cluster 
analysis revealed a cluster consisting of heart failure-hypertension-atrial fibrillation-CAD. 
These diseases are also highly prevalent, and strongly clustered (i.e. high prevalence 
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ratios), in our cluster diagram of heart failure. A second cluster found by Marengoni et al 
was dementia, depression and hip fracture[13]. Our study showed that depression was 
highly prevalent in dementia patients, and it clustered strongly with most cardiac diseases, 
and with osteoarthritis. 
 
With the applied study design, we were able to provide reliable prevalence rates of 
common disease patterns in an elderly population. Data of a large sample of patients were 
available and minimal selection bias exists as the practices included are representative for 
the Netherlands. Furthermore, information related to chronic diseases is most likely 
complete in general practice registries since the GP acts as gatekeeper for secondary care. 
Recording in EMRs is most likely accurate as practices also used their files for 
reimbursements. Possible bias due to patients’ perception of the presence of a chronic 
illness, or other factors that are related to the accuracy of self-reported disease 
diagnosis[3], is excluded when using EMR data. Another major strength of this study is the 
use of the multiple membership technique. Most studies do not account for the fact that 
older patients often are diagnosed with multiple diseases and thus are counted several 
times in multimorbidity prevalence estimations. With the multiple membership technique, 
this bias is eliminated by weighting each patient by means of their number of diseases.  
This study also has some limitations. Although quality requirements regarding data 
recordings exist, possible mistakes in ICPC recording could have been made, for instance 
due to typing errors or incorrect coding. Though, it is not likely that errors occurred 
systematic differently for the index-disease and non-index-disease group. Further, it may 
be possible that GPs differ in their decision of reporting a chronic disease diagnosis, for 
instance for diagnoses that rely on more subjective criteria (e.g. depression). However, we 
have taken this into account by the correction for practice in the statistical model. In 
addition, one can argue whether the disease depression reflects a chronic depression. 
Although no information about the diagnostic method was available, the ICPC-1 codes for 
depression were classified in the ‘diagnosis section’ of the ICPC-1 classification system. This 
considers a more definitive diagnosis than a registration in the ‘symptoms/and complaints 
section’. Another limitation relates to the data sample. We consider the large data sample 
of patients as a strength of this study, but to account for the variance in follow-up period 
of the patients we adjusted for the years of registration. As a result, the overall adjusted 
mean is somewhat overestimated since it considers the mean multimorbidity level as if all 
patients were registered for the complete follow-up period of 10 years. Further, although 
the data were collected within a 10-year period, we could not determine the direction of 
the identified associations. This since we determined whether a disease was present 
(yes/no) after the follow-up period, but did not determine which disease was diagnosed 
first, or second, or last. Another issue for consideration is that we have determined 
patients’ age at moment of inclusion. This means that some patients, that were classified 
to the 55–69 years group, turned 70 years during their follow-up period. If other age 
categories were chosen, some of the patients moved from the ‘younger’ category to the 
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‘older’ category, which could have altered the results. Yet, the overall findings, including 
the cluster diagrams, would have been unchanged and still demonstrate that 
multimorbidity is most often characterized by the presence of complex disease patterns. 
 
As older people frequently visit their GP, findings from this study seem particularly relevant 
to GPs. The multimorbidity patterns displayed in this study illustrate the heterogeneous 
nature of this patient group[10]. Patients with multimorbidity differ widely as regards the 
possible diagnosed diseases. Since they are also heterogeneous in terms of their disease 
severity, functional status, or prognosis this may lead to a great variety in different 
treatments considered by the GP. GPs should be aware of the fact that not only patients of 
70 years and older, but also those between 55 and 70 years have complex health care needs 
and require complex management. Further, they should keep in mind that the proportion 
of patients, for which recommendations reported in current practice guidelines are limited 
applicable, might be even larger than one expects, and that this is already true for younger 
elderly. As a consequence, the workload for the GP might be higher than expected due to 
more time consuming consultations. Due to the large extent of all possible disease 
combinations, it seems unrealistic to develop new guidelines for all possible combinations. 
Therefore, GPs may need other information, skills and tools to provide optimal care for this 
patient group. For instance, to inquire about patient preferences during a consultation, and 
to integrate these preferences into medical decision making. This requires patient’s ability 
to prioritize their preferences for care, and to weigh risks and benefits of the treatment 
and the various decision options given by the GP. In turn, it requires skills and time from 
the GP to discuss all options with the patient. 
 
Conclusions 
This study stresses the complexity of multimorbidity, and the challenges to provide (high 
quality) care for patients with multimorbidity by GPs. Guideline developers should be 
aware of this complexity, and GPs should focus on what matters to the patient, rather than 
on what is the matter in this patient group. 
 
Chapter 3  
54 
 
Ta
bl
e 
2.
 
M
u
lti
m
o
rb
id
ity
 
le
v
el
 
an
d 
n
u
m
be
r 
o
f c
o
-
o
c
c
u
rr
in
g 
di
s
ea
s
es
 
in
 
pa
tie
n
ts
 
di
ag
n
o
se
d 
w
ith
 
at
 
le
a
st
 
o
n
e 
o
u
t o
f 2
4 
ch
ro
n
ic
 
di
s
ea
se
s,
 
20
02
-
20
11
.
 
 
To
ta
l 
Pa
tie
n
ts
 
ag
ed
 
55
-
69
 
ye
ar
s
 
Pa
tie
n
ts
 
ag
ed
 
≥
70
 
ye
ar
s†
 
 
%
 
m
u
lti
m
o
rb
id
ity
 
(95
%
 
CI
)* 
M
ea
n
 
n
o
.
 
o
f d
is
ea
se
s 
 
(95
%
 
CI
)*,‡
 
N 
%
 
m
u
lti
m
o
rb
id
ity
 
(95
%
 
CI
) *
 
M
ea
n
 
n
o
.
 
o
f d
is
ea
se
s 
 
(95
%
 
CI
) *
,‡ 
N 
%
 
m
u
lti
m
o
rb
id
ity
 
(95
%
 
CI
)* 
M
ea
n
 
n
o
.
 
o
f d
is
ea
se
s 
(95
%
 
CI
) *
,‡  
O
v
er
al
l m
ea
n
 
85
.
6 
(82
.
9−
88
.
0) 
3.
25
 
(3.
11
−
3.
40
) 
75
31
0 
83
.
4 
(80
.
2−
86
.
1) 
3.
04
 
(2.
89
-
3.
18
) 
45
17
0 
93
.
5 
(92
.
2−
94
.
6) 
3.
96
 
(3.
83
-
4.
10
) 
He
ar
t f
ai
lu
re
 
98
.
4 
(96
.
0−
99
.
4) 
+
 
4.
97
 
(4.
31
−
5.
63
) +
 
23
23
 
98
.
5 
(96
.
2−
99
.
4) 
+
 
5.
06
 
(4.
39
-
5.
73
) +
 
71
97
 
97
.
4 
(94
.
6−
98
.
8) 
+
 
4.
71
 
(4.
14
-
5.
28
) +
 
He
ar
t v
al
ve
 
di
se
as
e 
94
.
5 
(87
.
1−
97
.
8) 
+
 
3.
99
 
(3.
34
−
4.
65
) +
 
10
31
 
93
.
7 
(85
.
3−
97
.
4) 
+
 
3.
60
 
(2.
94
-
4.
27
) 
12
66
 
95
.
4 
(90
.
9−
97
.
7) 
4.
43
 
(3.
87
-
4.
98
) 
St
ro
ke
 
94
.
0 
(86
.
0−
97
.
6) 
+
 
3.
74
 
(3.
08
−
4.
40
) 
30
08
 
92
.
7 
(83
.
0−
97
.
1) 
3.
48
 
(2.
81
-
4.
15
) 
40
76
 
94
.
8 
(89
.
5−
97
.
5) 
3.
96
 
(3.
39
-
4.
53
) 
Ca
rd
ia
c 
dy
sr
hy
th
m
ia
 
91
.
0 
(79
.
8−
96
.
3) 
3.
66
 
(3.
00
−
4.
32
) 
49
83
 
85
.
8 
(69
.
8−
94
.
0) 
3.
17
 
(2.
50
-
3.
85
) 
57
97
 
96
.
7 
(93
.
2−
98
.
4) 
4.
41
 
(3.
85
-
4.
98
) 
Co
ro
n
ar
y 
ar
te
ry
 
di
se
as
e 
88
.
8 
(75
.
5−
95
.
3) 
3.
39
 
(2.
73
−
4.
05
) 
10
10
8 
85
.
9 
(69
.
9−
94
.
1) 
3.
09
 
(2.
41
-
3.
76
) 
90
37
 
94
.
1 
(88
.
1−
97
.
2) 
4.
01
 
(3.
44
-
4.
58
) 
Di
ab
et
es
 
M
el
litu
s 
88
.
5 
(75
.
0−
95
.
2) 
3.
23
 
(2.
57
−
3.
89
) 
15
78
1 
87
.
4 
(72
.
7−
94
.
8) 
3.
06
 
(2.
38
-
3.
73
) 
11
22
6 
93
.
1 
(86
.
1−
96
.
7) 
3.
77
 
(3.
20
-
4.
34
) 
CO
PD
 
88
.
1 
(74
.
1−
95
.
0) 
3.
40
 
(2.
74
−
4.
06
) 
80
73
 
86
.
1 
(70
.
4−
94
.
2) 
3.
17
 
(2.
49
-
3.
84
) 
66
23
 
93
.
1 
(86
.
2−
96
.
7) 
3.
97
 
(3.
40
-
4.
54
) 
Vi
su
al
 
di
so
rd
er
 
88
.
0 
(74
.
1−
95
.
0) 
3.
38
 
(2.
72
−
4.
04
) 
59
64
 
82
.
6 
(64
.
5−
92
.
5) 
2.
98
 
(2.
31
-
3.
66
) 
74
20
 
92
.
7 
(85
.
5−
96
.
5) 
3.
79
 
(3.
22
-
4.
35
) 
De
m
en
tia
 
85
.
4 
(69
.
5−
93
.
8) 
3.
26
 
(2.
60
−
3.
92
) 
42
2 
85
.
0 
(69
.
3−
93
.
5) 
3.
13
 
(2.
47
-
3.
79
) 
31
27
 
84
.
1 
(71
.
0−
91
.
9) 
-
 
3.
25
 
(2.
68
-
3.
82
) +
 
Rh
eu
m
at
oi
d 
ar
th
rit
is 
85
.
4 
(69
.
5−
93
.
7) 
3.
28
 
(2.
62
−
3.
94
) 
21
38
 
81
.
6 
(62
.
9−
92
.
0) 
2.
95
 
(2.
28
-
3.
62
) 
15
40
 
95
.
1 
(90
.
1−
97
.
6) 
4.
26
 
(3.
70
-
4.
82
) 
Pa
rk
in
so
n
's
 
di
se
as
e 
84
.
5 
(68
.
1−
93
.
3) 
3.
23
 
(2.
57
−
3.
88
) 
45
0 
81
.
6 
(63
.
5−
91
.
8) 
2.
94
 
(2.
28
-
3.
60
) 
96
3 
86
.
6 
(75
.
3−
93
.
2) 
-
 
3.
45
 
(2.
89
-
4.
01
) 
As
th
m
a 
84
.
4 
(67
.
8−
93
.
3) 
3.
24
 
(2.
57
−
3.
90
) 
63
03
 
83
.
4 
(65
.
7−
92
.
9) 
3.
05
 
(2.
38
-
3.
72
) 
24
71
 
96
.
7 
(93
.
3−
98
.
4) 
4.
70
 
(4.
13
-
5.
26
) +
 
An
xie
ty
 
di
so
rd
er
 
83
.
9 
(67
.
0−
93
.
0) 
3.
21
 
(2.
55
−
3.
87
) 
24
62
 
81
.
9 
(63
.
5−
92
.
2) 
3.
03
 
(2.
36
-
3.
70
) 
10
84
 
96
.
2 
(92
.
4−
98
.
1) 
4.
40
 
(3.
85
-
4.
96
) 
O
st
eo
po
ro
sis
 
83
.
3 
(66
.
0−
92
.
8) 
3.
22
 
(2.
56
−
3.
88
) 
40
17
 
77
.
5 
(56
.
9−
90
.
0) 
2.
86
 
(2.
18
-
3.
53
) 
39
64
 
92
.
6 
(85
.
4−
96
.
4) 
3.
91
 
(3.
35
-
4.
48
) 
He
ar
in
g 
di
so
rd
er
 
83
.
3 
(66
.
0−
92
.
8) 
3.
15
 
(2.
49
−
3.
81
) 
37
50
 
76
.
3 
(55
.
2−
89
.
3) 
2.
74
 
(2.
07
-
3.
41
) 
43
26
 
92
.
3 
(84
.
7−
96
.
2) 
3.
78
 
(3.
21
-
4.
35
) 
O
st
eo
ar
th
rit
is 
 
82
.
3 
(64
.
3−
92
.
3) 
3.
03
 
(2.
37
−
3.
69
) 
11
27
5 
77
.
3 
(56
.
5−
89
.
9) 
2.
75
 
(2.
08
-
3.
43
) 
92
12
 
92
.
3 
(84
.
8−
96
.
3) 
3.
72
 
(3.
15
-
4.
29
) 
De
pr
es
si
o
n 
82
.
0 
(63
.
9−
92
.
2) 
3.
10
 
(2.
44
−
3.
76
) 
62
89
 
79
.
3 
(59
.
4−
90
.
9) 
2.
88
 
(2.
20
-
3.
55
) 
34
69
 
94
.
4 
(88
.
8−
97
.
3) 
4.
18
 
(3.
62
-
4.
75
) 
Ch
r.
 
ba
ck
 
o
r 
n
ec
k 
di
so
rd
er
 
79
.
0 
(59
.
3−
90
.
6) 
2.
95
 
(2.
29
−
3.
61
) 
12
16
6 
76
.
4 
(55
.
3−
89
.
5) 
2.
75
 
(2.
08
-
3.
43
) 
54
39
 
94
.
7 
(89
.
3−
97
.
5) 
4.
17
 
(3.
60
-
4.
74
) 
Al
co
ho
l a
bu
se
 
78
.
5 
(58
.
8−
90
.
3) 
2.
89
 
(2.
23
−
3.
55
) 
12
94
 
81
.
2 
(62
.
5−
91
.
8) 
2.
93
 
(2.
26
-
3.
60
) 
23
4 
87
.
8 
(78
.
5−
93
.
4) 
-
 
3.
65
 
(3.
13
-
4.
17
) 
Ca
n
ce
r 
77
.
3 
(57
.
0−
89
.
8) 
2.
85
 
(2.
19
−
3.
51
) 
10
22
2 
72
.
7 
(50
.
5−
87
.
5) 
2.
62
 
(1.
95
-
3.
30
) 
82
57
 
88
.
8 
(78
.
5−
94
.
5) 
3.
48
 
(2.
91
-
4.
05
) 
Ep
ile
ps
y 
76
.
8 
(56
.
6−
89
.
4) 
2.
98
 
(2.
33
−
3.
64
) 
87
4 
73
.
5 
(51
.
8−
87
.
8) 
2.
77
 
(2.
10
-
3.
44
) 
49
0 
93
.
2 
(87
.
1−
96
.
5) 
4.
03
 
(3.
50
-
4.
57
) 
Bu
rn
o
u
t 
75
.
9 
(55
.
1−
89
.
0) 
2.
74
 
(2.
08
−
3.
40
) 
19
38
 
77
.
5 
(57
.
0−
90
.
0) 
2.
73
 
(2.
06
-
3.
40
) 
35
0 
93
.
6 
(88
.
1−
96
.
6) 
4.
05
 
(3.
53
-
4.
58
) 
Hy
pe
rte
n
si
o
n
 
69
.
9 
(47
.
4−
85
.
7) 
2.
57
 
(1.
91
−
3.
23
) - 
35
72
6 
68
.
1 
(44
.
9−
84
.
8) 
2.
46
 
(1.
79
-
3.
14
) 
22
93
2 
81
.
0 
(66
.
3−
90
.
2) 
-
 
3.
04
 
(2.
46
-
3.
61
) - 
M
ig
ra
in
e
 
69
.
9 
(47
.
5−
85
.
6) 
2.
62
 
(1.
96
−
3.
28
) 
23
16
 
71
.
2 
(48
.
6−
86
.
6) 
2.
62
 
(1.
95
-
3.
30
) 
34
8 
96
.
7 
(93
.
9−
98
.
2) 
-
 
4.
02
 
(3.
50
-
4.
55
) 
N=
n
u
m
be
r 
o
f p
a
tie
n
ts
; C
I=
co
n
fid
e
n
ce
 
in
te
rv
a
l; 
Si
gn
=
si
gn
ific
an
ce
; c
hr
=
ch
ro
n
ic
.
 
Pe
rc
e
n
ta
ge
s 
(95
%
 
CI
), a
n
d 
m
e
a
n
 
n
u
m
be
r 
o
f d
is
e
as
es
 
a
re
 
a
dju
st
e
d 
fo
r 
th
e
 
pr
ac
tic
e
 
le
ve
l, 
di
se
a
se
 
le
ve
l (n
u
m
be
r 
o
f d
is
e
as
e
s),
 
a
n
d 
th
e
 
re
gi
st
ra
tio
n
 
pe
rio
d 
at
 
th
e 
pr
a
ct
ic
e 
(i.e
.
 
ye
a
rs
 
o
f f
ol
lo
w
 
u
p 
w
ith
 
a
 
m
in
im
u
m
 
pe
rio
d 
o
f 2
 
ye
a
rs
 
an
d 
a
 
m
ax
im
u
m
 
pe
rio
d 
of
 
10
 
ye
a
rs
). 
*
 
D
is
e
as
e
 
ou
tc
o
m
e
 
(i.e
.
 
m
u
lti
m
o
rb
id
ity
 
le
ve
l, 
m
ea
n
 
n
o
.
 
o
f d
is
ea
se
s) 
w
a
s 
st
at
is
tic
a
lly
 
si
gn
ific
an
t h
ig
he
r(+
) o
r 
lo
w
e
r(-
) (
p<
0.
05
) th
a
n
 
th
e 
o
ve
ra
ll 
m
e
a
n
 
o
u
tc
om
e
.
 
† B
e
tw
e
en
 
pa
tie
n
ts
 
55
-
69
 
ye
a
rs
 
a
n
d 
pa
tie
n
ts
 
≥
 
70
 
ye
a
rs
,
 
th
e
re
 
w
a
s 
a
 
st
a
tis
tic
a
lly
 
si
gn
ific
an
t d
iff
e
re
n
ce
 
(p<
0.
05
) in
 
th
e
 
pr
o
po
rti
o
n
 
o
f p
a
tie
n
ts
 
w
ith
 
m
u
lti
m
o
rb
id
ity
 
(ex
ce
pt
 
fo
r 
he
a
rt 
va
lv
e
 
di
so
rd
e
r 
a
n
d 
vi
su
a
l d
is
o
rd
e
r). 
‡ M
e
a
n
 
n
o
.
 
co
-
o
cc
u
rr
in
g 
di
se
as
e
s 
in
cl
u
di
n
g 
th
e
 
co
n
ce
rn
in
g 
di
se
as
e 
Multimorbidity patterns in primary care 
55 
Figure 1. Cluster diagram of the most common disease patterns in patients with heart failure. 
 
CAD = coronary artery disease; Card. = cardiac; dis. = disorder; DM = diabetes mellitus; HBP = high blood pressure; 
HF = heart failure; OA = osteoarthritis. Cluster diagrams of the most common chronic diseases (with a prevalence 
rate of ≥10%) and disease patterns in patients with the index diseases heart failure (i), migraine (ii), diabetes mellitus 
(iii) or dementia (iv). Size of the circles is proportional to the number of patients diagnosed with that disease; the n 
in the circle refers to the number of patients with both the index-disease and a co-occurring disease (e.g. in this 
figure, 3022 patients were diagnosed with both heart failure and diabetes mellitus). Lines display statistically 
significant prevalence ratios of the observed prevalence rate of that combination within patients with the index-
disease divided by the prevalence rate of that combination in the population without the index-disease (i.e. the non-
index-disease population). Width of the lines reflects the magnitude of the ratio. Percentages refer to the percentage 
of that combination within the index-disease population (e.g. in this figure, of the heart failure patients 5% were also 
diagnosed with COPD and osteoarthritis). In this figure, crude prevalence rates were presented. To increase the 
visibility of this diagram, ratios with a minimum of 3.00 were presented (see Appendix 3.3 for all ratios). 
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Figure 2. Cluster diagram of the most common disease patterns in patients with migraine  
(see Figure 1 legend for more details). 
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Figure 3. Cluster diagram of the most common disease patterns in patients with diabetes 
mellitus (see Figure 1 legend for more details). 
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Figure 4. Cluster diagram of the most common disease patterns in patients with dementia (see 
Figure 1 legend for more details). 
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ABSTRACT 
 
Purpose: Complex medication management in older people with multiple chronic 
conditions can introduce practice variation in polypharmacy prevalence. This study aimed 
to determine the inter-practice variation in polypharmacy prevalence and examine how 
this variation was inﬂuenced by patient and practice characteristics. 
 
Methods: This cohort study included 45,731 patients aged 55 years and older with at least 
one prescribed medication from 126 general practices that participated in NIVEL Primary 
Care Database in the Netherlands. Medication dispensing data of the year 2012 were used 
to determine polypharmacy. Polypharmacy was deﬁned as the chronic and simultaneous 
use of at least ﬁve different medications. Multilevel logistic regression models were 
constructed to quantify the polypharmacy prevalence variation between practices. Patient 
characteristics (age, gender, socioeconomic status, number, and type of chronic 
conditions) and practice characteristics (practice location and practice population) were 
added to the models. 
 
Results: After accounting for differences in patient and practice characteristics, 
polypharmacy rates varied with a factor of 2.4 between practices (from 12.4% to 30.1%) and 
an overall mean of 19.8%. Age and type of conditions were highly positively associated with 
polypharmacy, and to a lesser extent a lower socioeconomic status. 
 
Conclusions: Considerable variation in polypharmacy rates existed between general 
practices, even after accounting for patient and practice characteristics, which suggests 
that there is not much agreement concerning medication management in this complex 
patient group. Initiatives that could reduce inappropriate heterogeneity in medication 
management can add value to the care delivered to these patients. 
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INTRODUCTION 
In older people, who are frequently diagnosed with multiple (chronic) conditions[1], 
regular use of multiple different medications is common[2]. As a consequence, appropriate 
prescribing is often not that simple or apparent for physicians[3-5]. On the one hand, 
prescribing according to recommendations stated in practice guidelines may result in an 
excessive amount of medications which, in turn, may lead to poor adherence and adverse 
effects[6-8]. On the other hand, when deciding not to prescribe an additional medication, 
uncertainty remains about potential beneﬁts of the omitted medication to the 
patient[9, 10]. Overall, for patients with multiple chronic conditions, who are usually 
treated in primary care, several pharmaceutical treatment options seem possible and 
adequate, inﬂuenced by the physician’s and the patient’s perspective, which may lead to 
variation in medical behavior and practice variation[11, 12]. More focused on the number of 
medications prescribed for a patient, complex medication management might result into 
practice variation as regards the number of patients with multiple medications or 
polypharmacy. 
 
Polypharmacy is the simultaneous use of several medications and is often deﬁned as the 
chronic use of at least ﬁve different medications[2, 13, 14]. Polypharmacy has been 
associated with reduced medication adherence, an increased risk for potentially 
inappropriate medication use, adverse drug reactions, and unplanned 
hospitalizations[6-8]. Studies have demonstrated that a higher age, lower socioeconomic 
status (SES), a higher number, and the type of diagnosed conditions are suggested to be 
positively associated with polypharmacy. Findings of a gender effect are 
inconsistent[2, 6, 15]. 
 
When variation in medication prescribing, and polypharmacy, cannot be justiﬁed or 
explained by differences in the patient population and their clinical characteristics[16-18], 
this points towards other factors involved in decision-making on a higher level (practice 
level), for instance, contextual factors, or a lack of consensus about the chosen 
pharmaceutical treatment[11, 12]. Available studies on practice variation and medication 
prescribing focused on the use of potentially inappropriate medications in older 
patients[8, 19, 20], and to our knowledge, only one study examined the broader concept 
of polypharmacy in relation to practice variation[21]. They found a six fold variation 
between practices in the prevalence rate of polypharmacy; part of this variation could be 
explained by practice structure, workload, and prescribing proﬁle. Although they adjusted 
for age and gender, other assuming relevant patient characteristics were not included in 
this study[21]. 
 
Quantifying and understanding practice variation as regards polypharmacy prevalence is 
relevant, as it can highlight the complexity in managing these patients and may provide 
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clues to facilitate prescribing medications in this patient group. Therefore, the aim of this 
study was to examine the inter-practice variation of the prevalence of polypharmacy 
amongst older patients in primary care and how this is inﬂuenced by patient and practice 
characteristics. Based on previous studies[2, 6, 15, 17, 22, 23] our hypothesis was that 
patient characteristics (age, gender, SES, and chronic conditions) were associated with 
polypharmacy and could explain part of the variation between practices, and we 
hypothesized that some of the practice variation could be explained by differences in 
practice population. In some general practices, physicians might be more experienced with 
managing older complex patients with polypharmacy, which could result in less uncertainty 
in management. In previous studies[8, 17, 20], it was found that the type of practice or 
practice size and the practice location were associated with (high risk) prescribing. Our 
hypothesis was that practice size could explain some practice variation because in larger 
practices, several physicians share work environment and cultural aspects and can 
therefore have a more similar prescribing behavior than physicians from different 
practices[12]. 
 
 
METHODS 
Database and study population 
In this cohort study, we used linked data from routine electronic medical records (EMR) of 
general practices that participate in a network of a representative sample of practices in 
the Netherlands, the NIVEL Primary Care Database (NIVEL-PCD)[24], and from dispensing 
data of a sample of public pharmacies that supplied data to a pharmacy-dispensing 
registration database (i.e. the Foundation for Pharmaceutical Statistics, SFK)[25]. The 
general practitioner (GP) in the Netherlands, and several other countries, has a gatekeeper 
role for access to specialized care[26]. As a result, EMR records from the GP are likely to be 
most complete, hold information from other health care professionals like medical 
specialists, who manage the patient as well, and include the total population as all Dutch 
inhabitants are obligatory listed to a GP. The sample of participating pharmacies in NIVEL-
PCD is representative as regards age and gender, compared with the total sample of 
pharmacies in the Netherlands[27]. Linkage was based on matching records from variables 
available in both data sources, namely, gender, year of birth, four-digit postal code, date of 
dispensing/prescribing, and the Anatomic Therapeutic Classiﬁcation code (ATC) of a 
medication (i.e. A10BA02 metformin). Linkage was accepted if at least half of the 
prescriptions (NIVEL-PCD) matched with the dispensed medications (SFK) within a lag 
period of 0–6 days[28]. We included older patients, speciﬁed as those aged 55 years and 
older, who were registered on the full calendar year of 2012 in a participating general 
practice. From NIVEL-PCD, we extracted demographic information and morbidity data 
from patients’ EMRs. To determine polypharmacy, information about the chronic usage of 
patients’ prescribed medications was needed. Accurate information about the duration of 
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a prescription and its daily dosage was available in the SFK database. Dispensed data from 
SFK was also considered more complete as regards the medications prescribed in 
specialized care, rather than prescription data from NIVEL-PCD. Moreover, dispensed data 
represent actual usage of medications more closely than prescription data as the 
medications were actually distributed from the pharmacy to the patient. Therefore, from 
SFK, we extracted data of patients’ dispensed medications. Of the population aged 55 
years and older with at least one prescription (117,232 patients) 45,731 patients from 126 
general practices participating in NIVEL-PCD were identiﬁed in 120 pharmacies that 
supplied data to SFK (mean number of prescriptions linked population vs. non-linked 
population 22.3 and 22.8, respectively). 
 
Measures 
Polypharmacy  
The deﬁnition of polypharmacy (no/ yes) was derived from the Dutch multidisciplinary 
guideline of Polypharmacy in the elderly[29]; ﬁve or more chronically used medications 
with different ATC codes at the third level (e.g., R03B), which were used simultaneously 
for at least 1 day in 2012. Chronic usage was deﬁned as four or more prescriptions of a 
medication (i.e. similar ATC codes at the third level) or a medication prescribed for at least 
90 days[29]. See Box 1 for more information. 
 
 
Box 1. Additional information related to the operationalization of the outcome 
variable polypharmacy.  
For the prescription duration period, recorded information about the amount of doses 
dispensed by the pharmacist and about the daily deﬁned dose for the patient was 
applied. The prescribed periods of all chronically used medications determined whether 
ﬁve or more different medications were used simultaneously for at least 1 day in 2012 (i.e. 
polypharmacy). Dermatologicals for topical usage were excluded of the count because 
these medications usually do not interact with other (systemic) medications[29]. 
Antibiotics (i.e. ATC codes “J01”) were also not taken into account because they are 
almost exclusively prescribed for acute infections. For some dispensed prescriptions, 
there was no or incorrect information about the dispensed dosage or daily prescribed 
dosage. For these prescriptions (11% of all prescriptions in the dataset), the prescribed 
period was considered the period between the ﬁrst and last dispensing date of that 
medication. We have set 120 days between two dates as the maximum number of days 
to be considered as a consecutive period. If there were more than 120 days between two 
dates, this was considered as a gap in using. 
 
 
Patient characteristics 
We included age, gender, SES, the number of chronic diseases, and the type of chronic 
diseases in the analyses. Age was divided in seven 5-year categories (55 to ≥85 years). For 
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SES, a ‘status score’ was applied, based on patients’ four-digit postal codes (neighborhood 
level), developed by the Netherlands Institute for Social Research[30]. It was established 
in 2010 with four indicators (mean income, the proportion of people with a low education 
level, low income, and unemployed). Similar to previous studies[30, 31], we divided the 
scores into quintiles, and patients with a score in the highest and lowest quintile indicated 
patients living in a neighborhood with a high and low SES, respectively. Scores of patients 
within the middle three quintiles indicated patients living in a neighborhood with a medium 
SES. Based on previous studies, we selected 29 chronic diseases using constructed disease 
episodes of recorded morbidity data from GPs’ EMRs[32, 33]. The number of chronic 
diseases was divided into three categories (0–1 chronic disease, 2–4 diseases, and 
≥5 diseases). Multimorbidity was deﬁned as two or more chronic diseases (no/yes). 
 
Practice characteristics  
Three measures on GPs’ experience with managing complex patients were studied. The 
measures were “proportion elderly patients” operationalized as the proportion patients 
of ≥70 years in a practice from the total practice population, “proportion patients from a 
low SES neighborhood” and “proportion multimorbid patients”. The variable “proportion 
patients from a low SES neighborhood” was divided in three categories (i.e. 0–10%, 10–50%, 
and ≥50%) because of the skewness of the data. We also analyzed the practice type 
(i.e. solo, duo, and group), the practice’s degree of urbanization in three categories (highly, 
moderate, and not urbanized) and practice size (i.e. small, medium, and large), based on 
the practices’ number of listed patients divided into tertiles. 
 
Statistical analysis 
Descriptive statistics described the study population. To examine inter-practice variation in 
polypharmacy prevalence, we constructed multilevel logistic multivariate regression 
models with patients (level 1) clustered within general practices (level 2), polypharmacy as 
the dependent variable, the patient and practice variables as determinants, and the 
practice level as random effect. In order to test our hypotheses, the ﬁrst model included 
the patient-related variables gender, age, SES, and number of chronic conditions as 
determinants. In model 2, we added 29 types of chronic conditions, and it considered the 
full model as regards the patient-related variables. In model 3, the practice population 
variable “proportion patients with multimorbidity” was added, as well as the variable 
concerning the practices’ degree of urbanization. The other variables on practice level 
were not included into the multivariate model because their p-values were ≥0.20 when 
adding them to model 2 separately. All determinants were centered on their mean to make 
the results more interpretable. In all models, we adjusted for the practice’s type of 
electronic medical record software system to account for possible differences in 
registration methods. Only patients with complete data were included in the multilevel 
analysis, and practices with a minimum number of 50 patients to estimate robust models. 
Besides the odds ratio (OR), 95% conﬁdence interval (CI), and p-value indicating the 
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association between polypharmacy and the determinants, we reported the practice 
variance component as an estimation of the variance of the polypharmacy rate between 
practices (i.e. a decrease in value between the models indicated a decrease in the inter-
practice variation). Further, we reported the proportion change in variance, indicating the 
proportion of variance explained by adding explanatory variables. The 95% coverage 
interval of the practice variance components indicated the range in the practices’ 
difference in the proportion polypharmacy patients that cannot be explained by the 
covariates. This coverage interval was calculated in the following way: Intercept ± 1.97 sqrt 
(between practice variance), which was transformed back to the probability scale. The 
average polypharmacy prevalence per general practice was also estimated by using an 
empirical Bayes estimator[34]. All analyses were performed using STATA SE version 13.0 
and MLwiN version 2.30. A p-value below 0.05 was considered statistically signiﬁcant. 
 
 
RESULTS 
Population characteristics 
Of the patients, 27% had polypharmacy, and they were on average 5 years older than those 
without polypharmacy (72 vs. 67 years), lived more often in a neighborhood with a low SES 
(20% compared with 16%), and showed more multimorbidity (90% vs. 46%; Table 1). The 
number of medications used in the polypharmacy group was on average 11.2 of which 6.9 
was used chronically. Information about the practice characteristics is shown in Table 2. 
 
Inter-practice variation 
For the multilevel analyses, data of 44,917 patients from 86 practices (mean no. of patients 
per practice (SD); 525 (464)) were studied because for 235 patients data on SES was missing 
and 40 practices (with 579 patients) had less than the required number of patients. In 
model 1 (Table 3), the overall mean polypharmacy rate was 21.4%. The practice variance 
component was 0.07 (SE= 0.01), which corresponds to a 95% coverage interval of 14.1–31.0, 
meaning that the polypharmacy prevalence ranged from 14% to 31% between practices. The 
number of chronic conditions was most strongly positively associated with polypharmacy 
(OR 36.4, 95%CI 32.8-40.3, for ≥5 chronic conditions). After including the type of chronic 
conditions into the model (model 2), only having 2–4 conditions compared with 0 or 1 
condition was still signiﬁcantly associated with polypharmacy. Nearly all chronic conditions 
were positively associated with polypharmacy, most strongly cardiac conditions (heart 
failure: OR 5.25, 95%CI 4.59-6.00; coronary artery disease: OR 6.50, 95%CI 6.02-7.02). The 
practices’ difference (95% coverage interval) in adjusted polypharmacy prevalence ranged 
from 12.1% to 31.6%. For model 2, the average proportion of patients with polypharmacy in 
each practice separately is presented in Figure 1. 
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Table 1. Descriptive characteristics of the study population: patients aged ≥ 55 years with at 
least one prescribed medication in 2012, divided by patients with and without polypharmacy. 
 
No polypharmacy 
(N= 33,449) 
Polypharmacy 
(N= 12,282) P-value* 
 N % N %  
Male 15,279 45.7 5,702 46.4 0.155 
Female 18,170 54.3 6,580 53.6  
Age, mean (SD) 66.6 (8.7)  72.4 (9.5)  <0.001 
Age groups:     <0.001 
   55-59 years 8,220 24.6 1,214 9.9  
   60-64 years 7,859 23.5 1,664 13.5  
   65-69 years 6,583 19.7 2,134 17.4  
   70-74 years 4,467 13.3 2,088 17.0  
   75-79 years 3,105 9.3 2,108 17.2  
   80-84 years 1,900 5.7 1,677 13.6  
   ≥ 85 years 1,315 3.9 1,397 11.4  
SES categories†     <0.001 
   High 5,044 15.2 1,477 12.1  
   Medium 22,772 68.4 8,275 67.8  
   Low 5,472 16.4 2,456 20.1  
Mean no. of chronic conditions (SD) ‡ 1.6 (1.3)  3.4 (1.6)  <0.001 
Number of chronic conditions:      
   0 6,916 20.7 133 1.1 <0.001 
   1 11,054 33.0 1,118 9.1  
   2 8,516 25.5 2,738 22.3  
   3 4,341 13.0 3,166 25.8  
   4 1,770 5.3 2,468 20.1  
   5 636 1.9 1,459 11.9  
   ≥ 6 216 0.6 1,200 9.7  
Multimorbidity § 15,479 46.3 11,031 89.8 <0.001 
Mean no. of medications (SD) ¶ 4.5 (2.9)  11.2 (4.2)  <0.001 
Mean no. chronically used medications (SD) || 1.7 (1.4)  6.9 (2.1)  <0.001 
Number of chronically used medications:      
   0  8,424 25.2 0 0.0 <0.001 
   1-4  24,715 73.9 0 0.0  
   5-9  310 0.9 10,838 88.2  
   10-14  0 0.0 1,377 11.2  
   ≥ 15  0 0.0 67 0.6  
Note: Total N=45,731 patients, 126 practices. SD= standard deviation. 
* Statistical significance tested with Chi-squared tests (binary variables) or T-tests (continuous variables). 
† Socioeconomic status (SES) on neighborhood level (i.e. four-digit postal code). 
‡ Based on a list of 29 chronic conditions[32]. 
§ ≥ 2 chronic conditions out of the list of 29 chronic conditions[32]. 
¶ Medication on the third Anatomic Therapeutic Classification level. 
|| Medication on the third Anatomic Therapeutic Classification level, with at least four prescriptions, or those used 
for minimal 90 days (excluding the dermatologicals and antibiotics).  
 
 
After accounting for the patient population, in some practices, there were still at least 
twice as many patients with polypharmacy than in other practices (a factor 2.6 difference). 
In model 3, including the practice variables, the practices’ range (95% coverage interval) in 
polypharmacy prevalence varied from 12.4% to 30.1% indicating that there was a factor 2.4 
difference as regards the polypharmacy prevalence between practices after including all 
explanatory variables, with an overall mean of 19.8%. Practices located in moderately and 
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low urbanized areas had a signiﬁcantly lower odds ratio of polypharmacy than practices 
located in very strong or strong urbanized areas. 
 
 
Table 2. Characteristics of the general practices, and the number of patients per practice 
variable. 
 
Practices 
(N=126) 
Patients 
(N=45,731) 
 N % N % 
Type of practice     
   Single-handed practices 69 54.8 20,174 44.1 
   Duo practices  40 31.7 14,803 32.4 
   Group practices 17 13.5 10,754 23.5 
Practice size *     
   Small 76 60.3 15,336 33.5 
   Medium 33 26.2 16,698 36.5 
   Large 17 13.5 13,697 30.0 
Degree of urbanization (location of the practice):     
   (Very) strong 67 53.2 19,185 41.9 
   Moderate 28 22.2 10,176 22.3 
   Little or not 31 24.6 16,370 35.8 
     
Practice population characteristics 
    
Mean % patients ≥70 years (SD) 11.4  (3.92) -  
Mean % patients living in a low SES neighborhood (SD) 
† 26.4  (28.8) -  
Mean % patients with multimorbidity (SD) 20.1  (4.18) -  
Mean no. of pharmacies per practice (SD) ‡ 2.28  (1.20) -  
Electronic medical record software type:     
   A 63 50.0 22,047 48.2 
   B 9 7.1 2,783 6.1 
   C 12 9.5 3,630 7.9 
   D 34 27.0 12,207 26.7 
   E 7 5.6 5,063 11.1 
   F § 1 0.8 1 <0.01 
SD= standard deviation 
* Number of registered patients; small:1819-3408, medium: 3433-6056, large: 6059-15300 
† Estimated by counting the number of patients living in a low socioeconomic status (SES) neighborhood divided 
by the total practice population for whom SES information was available 
‡ The pharmacies that supplied data to Foundation for Pharmaceutical Statistics (SFK) and Netherlands Institute 
for Health Services Research ( NIVEL)  
§ Type F electronic medical record software type was not included in the multilevel models since only one practice 
with one patient of the study population used this type. 
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Figure 1. The adjusted average polypharmacy prevalence per practice after accounting for 
differences in patient characteristics (model 2). 
 
 
Note: N=44,917 patients in 86 general practices. The thick horizontal grey line at 20.1% represents the overall 
adjusted proportion of patients with polypharmacy. The black dotted line represents the estimated average 
proportions of patients with polypharmacy in each practice. The error bars represent the 95% confidence interval 
around the estimate of that practice.
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DISCUSSION 
Although polypharmacy is common in primary care, this is one of the ﬁrst studies 
examining the variation in polypharmacy prevalence between general practices. It was 
shown that after accounting for differences in patient and practice characteristics, practice 
variation existed in the polypharmacy rate between practices (factor 2.4). Higher age and 
most prevalent chronic conditions were highly positively associated with polypharmacy, 
and to a lesser extent, a lower SES. Further, practices located in lower urbanized areas had 
a lower odds ratio of polypharmacy than (very) strong urbanized located practices. 
 
One study from 1995 examined inter-practice variation in relation to polypharmacy rates in 
general practices[21]. They showed lower rates of polypharmacy and more inter-practice 
variation, that is, a six fold variation. The discrepancy in ﬁndings might be due to the 
increasing prevalence of polypharmacy in recent years[13] or to changes in regulation and 
the rise in the development of disease guidelines[35, 36]. Furthermore, the introduction of 
electronic health record systems, electronic prescription systems, and guidelines that 
recommend uniformity in recording are also likely to contribute to reduced variation 
between practices[37]. 
Recently conducted studies on polypharmacy found prevalence rates comparable with our 
ﬁndings[2, 14]. In accordance with our hypothesis, and similar with other studies, we found 
that higher age and number of chronic conditions were highly positively associated with 
polypharmacy[2, 6, 13-15, 38]. It was also found that the type of chronic conditions was 
associated with the number of medications[2, 38]. Our current study underlined that 
especially the type of diseases, rather than the number of diseases, was related to the 
number of medications prescribed. The strong association between the number of 
conditions and polypharmacy decreased when including the type of chronic conditions. 
Remarkably, an increase in the number of prevalent chronic conditions is not directly 
accompanied by an increase in prescribed medications. In patients with ﬁve or more 
conditions, it seems that other factors start to play an important role, for instance, 
interactions between medications, other treatment options like surgery, or perhaps 
maintaining the status quo[9]. Some diseases are associated with a high number of 
prescribed medications[2, 38], and especially as -not unlikely in this age group- other 
diseases are involved as well, this could lead to several eligible treatment options and 
practice variation in the number of prescribed medications. Nevertheless, after accounting 
for the type of chronic conditions, still considerable variation between practices remained. 
The ﬁnding that practices located in the lowest and moderately urbanized areas had a 
signiﬁcantly lower odds ratio of polypharmacy than very strong urbanized located 
practices cannot be conﬁrmed in literature. Guthrie et al[20] found that practices located 
in moderately urbanized areas were more likely to have patients with a high-risk 
prescription than practices in primary cities; however, the clinical signiﬁcance of the 
associations were marginal[20]. In contrary to our hypothesis, practice size did not 
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signiﬁcantly affect polypharmacy prevalence as had been shown in other studies. Yet, in 
these studies, those factors could hardly explain any variance in prescribing (high risk) 
medication[18, 20].  
 
Strengths of the study are the number of data; 86 practices with, on average, 500 older 
patients, which contributes to stable and robust multilevel models. A second strength 
concerned the analyses of actually distributed medications from the pharmacist to the 
patient instead of just prescription data. A possible limitation is that due to the fact that 
not all pharmacies agreed to share their data with the NIVEL-PCD, the study population 
covered a subpopulation of the total general practice sample. Nevertheless, it was found 
that the studied patients were comparable as regards the mean age and gender with a 
larger sample of eligible patients only available in NIVEL-PCD. Further, the proportion of 
patients with polypharmacy may be slightly overestimated as patients with one or two 
prescriptions were less likely to be included in the analyses because of the applied linkage 
method. Yet, the majority of the study population (90%) did receive more than two 
prescriptions, and as it applies to all practices in the same order, it is not likely to affect the 
results of our main question, namely, practice variation. The identiﬁed variation in 
polypharmacy prevalence might not only be due to the GPs, or physicians working in the 
general practice. Our dispensed medication data could also hold medications prescribed by 
medical specialists. Besides, also the pharmacist could have a role in the medications 
dispensed as he or she checks whether the patients’ prescribed medications can be 
combined. 
 
Because evidence for effective treatment is mostly gathered in younger adults without 
multimorbidity, it seems logical that for older patients with multiple chronic conditions, 
physicians more often rely on their own experiences and reasoning when prescribing 
medications. This is not necessarily worrisome if it is justiﬁed, for instance, when 
accounting for the patient’s preferences and priorities[39]. However, because 
considerable variation between practices existed after accounting for differences in 
patient and practice characteristics, the results indicate that physicians from different 
practices have different prescribing behaviors, and it suggests that there might be 
professional uncertainty about the best treatment. However, next to the GP, also the 
medical specialist and pharmacist play an important role in medication therapy 
management. It is likely that part of the unexplained variation is due to pharmacy-related 
factors or by factors that indicate the level of cooperation between the GP and pharmacist. 
Several strategies and activities exist to reduce unnecessary medication use, involving 
different health care professionals such as the GP and pharmacist[29, 40-46]. For instance, 
when contemplating on complex patients and medication combinations, this could turn 
differences in management views into a common view. It seems valuable to further 
investigate possible explanations for the variance in polypharmacy prevalence, such as 
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differences in physician-related characteristics, such as their clinical experience, and in the 
level of cooperation between the various professionals involved in medication prescribing. 
 
In conclusion, because numerous inter-practice variation in polypharmacy prevalence exist, 
attention for medication management is important, especially in complex older patients 
with multiple chronic conditions. Physician initiatives to achieve a more shared vision about 
the best therapeutic treatment add to the patient’s value of care. 
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ABSTRACT 
 
Background: For older patients with polypharmacy, medication management is a process 
of careful deliberation that needs periodic adjustment based on treatment effects and 
changing conditions. Because of the heterogeneity of the patient group, and limited 
applicability of current guidelines, it is difficult for GPs to build up a routine. 
 
Aim: To gain insight into GPs’ medication management strategies for patients with 
polypharmacy, and to explore the GPs’ perspectives and needs on decision-making 
support to facilitate this medication management. 
 
Design and setting: Two focus group meetings with Dutch GPs, discussing four clinical 
vignettes of patients with multimorbidity and polypharmacy. 
 
Method: Questions about medication management of the vignettes were answered 
individually; the strategy chosen in each case was discussed in a plenary session. Analysis 
followed a Framework approach. 
 
Results: In total, 12 GPs described a similar strategy regarding the patients’ medication 
management: Defining treatment goals; determining primary goals; and adjusting 
medications based on the treatment effect, GPs’ and patients’ preferences, and patient 
characteristics. There was variation in the execution of this strategy between the GPs. 
The GPs would like to discuss their choices with other professionals and they valued 
structured medication reviews with the patient, as well as quick and practical support 
tools that work on demand. 
 
Conclusions: To facilitate decision making, a more extensive and structured collaboration 
between health care professionals is desired, as well as support to execute structured 
medication reviews with eligible patients, and some on-demand tools for individual 
consultations. 
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INTRODUCTION 
An ageing population means GPs increasingly manage older patients with multiple 
chronic conditions (that is, multimorbidity)[1-3]. These patients are often recommended 
to use multiple different medications at several times of the day. The chronic use of at 
least five medications is also called ‘polypharmacy’[4, 5]. In a recent study, it was found 
that the proportion of older patients with polypharmacy varied, by a factor of 2.4, 
between general practices after accounting for differences in the patient and practice 
population[6]. This suggests that medication management, the process of monitoring 
and evaluating the patient’s prescribed medications, differs between GPs. Both 
multimorbidity and polypharmacy are associated with a range of adverse health 
outcomes, for instance, a lower quality of life, more adverse drug reactions, and higher 
rates of unplanned hospitalization[5, 7, 8]. Therefore, in older patients with 
polypharmacy, attention to appropriate medication prescribing is of major importance. 
 
GPs in the Netherlands are searching for appropriate polypharmacy for older patients to 
help optimize prescriptions[9], while taking into account the best evidence along with 
patient perspectives; but this is often complex. It concerns a heterogeneous patient 
group as regards the combination in types and severity of diseases[10]. Each patient also 
has their own characteristics (age, prognosis, cognitive ability, and preferences) to be 
taken into account[11, 12]. Due to changes in conditions of life and treatment effects, 
which are likely in this patient group, periodic adjustment of the prescribed medications is 
necessary. Unfortunately, due to the single-disease focus of most clinical practice 
guidelines (CPGs), it is not always possible to adopt the recommendations on medication 
prescribing in patients with multimorbidity[13-16]. GPs have to find a balance between the 
risks and benefits of adhering to the CPGs and providing patient-centered care[12, 15]. In 
daily practice, GPs and patients often decide together which prescribing option to start 
with, and GPs often rely on their own experience when changing or stopping a 
medication prescription[17, 18]. 
 
Considering the limited applicability of CPGs and the heterogeneous patient group, little 
is known of how GPs assess the benefits and harms of the available treatment options. 
Furthermore, it remains unclear how GPs make decisions in medication management, and 
by what kind of factors this management is influenced. Therefore, this study aims to gain 
insight into the GPs’ medication management strategy for older patients with 
polypharmacy, and to explore the GPs’ perspectives, needs, and ideas on decision-making 
support to facilitate medication management for these patients. 
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METHODS 
Design 
Two focus groups meetings with experienced GPs were organized. Local trainers were 
motivated to create more awareness among the trainees on polypharmacy and two 
meetings were organized within their training program. All GPs participated voluntarily, 
being informed that anonymity and confidentiality were ensured; the discussion was 
audio-recorded. The meeting started with an individual written medication review of 
clinical case vignettes. A senior GP who lectured the GP-trainers moderated the meetings 
assisted by two researchers. The topic guide covered items on the medication 
management strategy, the accomplishment of the strategy, impact factors (sex, age, 
lifestyle, social context), and support tools. 
 
Clinical case vignettes 
Each focus group meeting started with an individual assignment for the GPs; reviewing 
medication management of four clinical case vignettes covered in a survey. The vignettes 
are described in Appendices 5.1–5.4, accompanied with possible treatment 
considerations, based on Dutch CPGs. The vignettes described patients (aged 68–84 
years) diagnosed with multiple, highly prevalent chronic diseases, often part of a cluster 
of diseases[10]. The patients used multiple medications, some of which can influence 
clinical functions, such as impaired renal function due to NSAIDs, or furosemide and 
hyponatremia[19, 20], or can induce symptoms (for example, dipyridamole and 
headache). The vignettes varied as regards to the safety of the combination of the 
medications, patient’s sex, age, lifestyle, and social context. The questions accompanying 
the vignettes covered treatment goals, an appraisal of the patient’s prescribed 
medications, and the possibility of consulting another health care professional. The 
vignettes were developed by two of the authors and were validated by two additional 
practicing GP-researchers. 
 
Analysis 
A Framework approach[21] was used by defining themes a priori, in order to facilitate the 
plenary session and to focus on the research aims. The themes were integrated into the 
clinical vignette survey, and concerned ‘patient complexity’ and ‘treatment 
goals/strategy’, as these concepts were both considered as influencing GPs’ 
management[12, 18, 22]. Concerning decision support, no a priori themes were defined. 
After the first meeting, the audio-tape was transcribed verbatim. The transcript was case 
and thematically coded by one researcher and quotes were classified into the two 
themes, if possible, or new themes were reported. If new themes emerged, they were 
discussed during the second meeting. The second meeting added no new themes and the 
course was comparable with the first meeting. The data indexed into the themes were 
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checked by a second researcher and, in any case of disagreement, the two researchers 
were in discussion until consensus was reached. 
 
 
RESULTS 
Participants and group dynamics 
A total of 12 GPs participated in two focus groups, each lasting around 75 minutes. All the 
GPs worked in the eastern or southern part of the Netherlands, and had, on average, 24.8 
years of work experience (Table 1). The plenary sessions were dynamic. The GPs were 
enthusiastic, eager to hear about the considerations made by their peers, and the 
meeting was considered useful: 
 
 
 
 
Table 1. Characteristics of the GPs participating in the focus groups (total N=12). 
 
 
 N* 
Sex  12 
    Male, % 66.7 8 
Mean age, years [range] 56.3 [46-63] 12 
Mean years of work experience as a GP [range] 24.8 [10-35] 12 
Mean days working as a GP [range]† 4.1 [3-5] 11 
Practice holder†  11 
    Yes, % 100.0 11 
Practice type†  11 
    Solo 18.2 2 
    Duo 36.4 4 
    Group 45.5 5 
Practice with above average number of older patients (≥65 years)†‡  10 
    Yes 30.0 3 
    No 70.0 7 
Practice including a pharmacy†  11 
    Yes 18.2 2 
    No 81.8 9 
Mean no. of cooperating pharmacies [range]† 3.2 [1-5] 9 
Frequency of organized meetings with pharmacists† 
    Monthly 
    Bimonthly 
    1-2 times a year  
    Never   
 
44.5 
22.2 
22.2 
11.1 
9 
4 
2 
2 
1 
* For some questions, there was missing data 
† The moderator also participated in one meeting (and completed the clinical vignette survey) but was not active 
as a GP in a practice any more (since 1 year). Therefore, for applying the background questions the total N is 11.  
‡ Based on the question, ‘On average around 16% of the Dutch population is 65 years and older. Do you think 
that more than 16% of your practice population is 65 years or older?’ 
 
 
‘It turns out (again) that we should discuss these patients not on our own, but in a 
team, as it yields more [information] than you anticipate.’ (GP5) 
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GPs’ medication management strategy   
All GPs described a quite similar medication management strategy. First, treatment goals 
were defined and prioritized, usually together with the patient. Second, the goals that 
were considered the primary concern in treatment were determined, and the focus of the 
current consultation was agreed. Mostly, primary goals were the reason for the 
encounter, or were regarded as important to prevent damage: 
 
 
 
 
 
 
 
Third, adjustments were made in the patient’s prescribed medications, while considering 
the formulated primary goal(s). Often, one or two adjustments were suggested 
immediately: 
 
 
 
 
Accomplishment of the strategy 
Although a similar strategy for polypharmacy was described, there was variation between 
GPs in the actual performance. There was variation in the (number of) treatment goals 
formulated for the patient, and the number of proposed primary goals; there was a focus 
on addressing several goals simultaneously versus a ‘step-by-step’ approach. Further, 
there was variation as regards focusing on optimizing clinical values by referring to 
targets described in CPGs, or focusing on the reason for an encounter. As a result, the 
proposed adjustments in the cases’ prescribed medications varied (Figures 1–4). In Box 1 
noteworthy findings per vignette are given, accompanied by statements made from GPs. 
The GPs expressed that work experience facilitates the decision-making process. 
Nevertheless, they seemed indecisive about the best approach; they repeatedly declared 
that they needed to search for information (for example, reference values, medication 
dosages, potential side effects), and were interested in the approach of other GPs. 
Besides, several prescribing options seemed possible according to the GPs. Yet, 
consulting a pharmacist or medical specialist was rarely considered, as they wanted to 
optimize the patient’s condition themselves first. Only if the patient’s condition did not 
improve, would they be likely to deliberate with a medical specialist. 
 
‘I think you should treat that first, this man’s complaints [case 4]. He is currently in a 
lot of pain.’ (GP2) 
‘In my opinion [treating] the blood pressure is always the most important because 
the lower the blood pressure, the lower the chance for a CVA, TIA, or renal failure. 
That is my consideration.’ (GP5) 
‘I don’t see, I don’t think the blood sugar level is too low [case 3], thus you could 
change a lot but I would start with [treating] the heart failure … If the HbA1c still 
decreases, then we could consider it [adjusting metformin].’ (GP11) 
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Figure 1. Case 1 (Appendix 5.1): number of GPs that reported adjusting the particular 
prescribed medication in the case vignettes. ‘Adjust’ can indicate changing the dosage or 
stopping the prescribed medication. 
 
 
 
Figure 2. Case 2 (Appendix 5.2): number of GPs that reported adjusting the particular 
prescribed medication in the case vignettes. ‘Adjust’ can indicate changing the dosage or 
stopping the prescribed medication. 
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Figure 3. Case 3 (Appendix 5.3): number of GPs that reported adjusting the particular 
prescribed medication in the case vignettes. ‘Adjust’ can indicate changing the dosage or 
stopping the prescribed medication. 
 
 
Figure 4. Case 4 (Appendix 5.4): number of GPs that reported adjusting the particular 
prescribed medication in the case vignettes. Adjust’ can indicate changing the dosage or 
stopping the prescribed medication. 
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Factors influencing the medication management process 
The patient’s age, vitality, prognosis/ life expectancy, and quality of life were mentioned 
as factors influencing medication management. For instance, the patient’s age influenced 
the GP’s adherence to CPG recommendations. GPs accepted less optimal clinical values if 
the patient’s quality of life was at stake: 
 
 
 
 
 
 
 
Furthermore, the patient’s social context was considered important for the focus of the 
treatment, as well as their perspectives, wishes, and preferences on the proposed 
treatment: 
 
 
 
Regarding medication-related factors, the number of prescribed medications and the 
dosage, together with the combination of diseases, contributed to the complexity in 
management. When deliberating with the patient on potential medication adjustments, 
GPs sometimes hesitated to change or stop a prescribed medication. For instance, when 
medications were prescribed in their current dosage for a long period, or when it 
concerned medications prescribed by a medical specialist: 
 
 
 
 
 
 
Decision-making support tools 
The GPs expressed that it was hard to think about appropriate support tools because of 
the heterogeneity of the patients. Tools regarded valuable by some GPs were 
characterized as practical and quick to use, such as the CHA2DS2-VASc score for stroke 
risk assessment[23], or the CVD risk assessment tool[24]. Tools providing insight into the 
practices’ frail older population were also mentioned. Some existing tools incorporated in 
the GPs’ electronic medical record (EMR) system to check applicable CPGs lacked the GPs’ 
preferred ability to use it only when they needed it -to use it on demand. According to 
some GPs: 
‘[If the patient was 85 years old] I would be more flexible about the blood pressure. 
That it will not result in, that he [case 2] falls or gets dizzy, or falls from a chair. I 
rather want him to be active with a higher blood pressure, than inactive with a 
lower pressure.’ (GP9) 
‘I think that you could have an interesting talk with her [case 3] about what she aims 
for, and how frail she is.’ (GP7) 
‘It is always a dilemma, a tense situation [adjusting medications]. We know that 
many hospital admissions are caused by medication … “errors” is a strong word, 
but surely due to failures in adequate medication. But we do know that stopping 
everything at once will also become counterproductive. Thus, that is really 
something to consider.’ (GP1) 
Chapter 5 
92 
 
 
 
 
 
 
Overall, two main options for support were valued. The first concerned meetings with 
GPs or pharmacists to discuss patients with complex problems, as a check of their 
expertise, and to exchange ideas and information around medication management 
decision making. About half of the GPs reported having meetings with a pharmacist at 
least bi-monthly, but only a few already discussed the older patients in multidisciplinary 
teams: 
 
 
 
 
The second option concerned medication reviews with the patient[25], executed during 
an annually extensive consultation. Some GPs stated that agreements with a pharmacist 
were made to perform a medication review, and a few participated in a program focusing 
on managing the frail older patient, that included a medication review. Nevertheless, it 
seemed that the two options for support were not yet structurally performed. Perceived 
issues related to the execution of medication reviews were; lack of time, minimal 
beneficial results, and uncertainty about the patients who may be eligible for a review. 
Subsequently, GPs stated that the means to select these eligible patients systematically 
and easily were not sufficiently applicable. 
 
 
DISCUSSION 
Summary 
Although the GPs had a similar medication management strategy, there was variation as 
regards the accomplishment of this strategy, due to differences in the GPs’ approaches 
(for example, focus on clinical values versus reason for encounter, or step-by-step versus 
simultaneous approach). Patient- and medication-related factors influenced the 
medication management process. As a result, variation existed in the proposed 
adjustments of the patients’ prescribed medications. Collaboration between GPs and 
pharmacists was valued as a medium to discuss patients with complex medication 
regimens, as well as structured medication reviews with the patient, and quick tools that 
work on demand. 
‘It would be nice if you can do that on demand. That there would be a button in your 
system which would automatically compare the medications and lab results, and 
then would report “the advice would be to …” But only when you press the button, 
and not that it goes “plop, plop” every time.’ (GP6) 
‘It is not such a bad idea to do [talking about complex patients], and to discuss them 
together, like we are doing right now. When doing so, you come up with new ideas 
sooner, like, I should pay more attention to those factors.’ (GP10) 
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Box 1. Findings per case vignette, accompanied by statements given from the 
participating GPs. 
For case 1 (Appendix 5.1), it can be seen that all GPs focused on lowering blood 
pressure in this patient, which resulted in adding an ACE inhibitor. The variation 
in changes could be due to the fact that some GPs had more primary goals, 
whereas others had a more ‘step-by-step’ approach: ‘I have changed a series of 
prescribed medications. I am not sure if I will change everything at once, but this 
would be my purpose’ (GP8) and ‘[about the fact that this GP reported far less 
adjustments in the medication list] Yes, I did not want to adjust everything at the 
same time. I have recorded the medications which I would like to change at first 
place. After that you will see the patient again, and then you could focus on 
remaining goals. It is not very inspiring for the relationship of trust if you would say 
“Now we will do everything differently” after 8 years of treatment.’ (GP9) 
 
With respect to case 2 (Appendix 5.2), nearly all GPs stated that naproxen should 
be stopped immediately, but not all GPs suggested alternatives for treating the 
patient’s pain. Moreover, only some GPs mentioned pain management as a 
treatment goal. Furthermore, all GPs suggested focusing on lowering blood 
pressure, but some GPs preferred to await the effect of stopping naproxen 
before increasing the dosage of enalapril. 
 
GPs considered case 3 (Appendix 5.3) a typical ‘general practice patient’ because 
their approach would be to make one or two changes, wait a few days, and then 
determine the effect of the changes. For this patient, there was no apparent 
primary treatment goal: 10 different treatment goals were reported, and most 
GPs focused on three or four goals. This could be due to ambiguity about some 
symptoms or complaints. A GP stated, ‘That dizziness, we don’t know the type of 
dizziness. I am curious about the woman’s type of dizziness, I really want to know 
that. It hinders me.’ (GP1) 
 
As regards case 4 (Appendix 5.4), nearly all GPs said that they would wish to 
stop hydrochlorothiazide because of the patient’s gout attack, despite the fact 
that this is no longer recommended in the Dutch guidelines. Treatment goals 
mainly focused on pain management and lowering the blood pressure. 
 
Strengths and limitations 
Clinical vignette surveys are shown to be effective for the evaluation of treatment 
decisions made by GPs[29-31]. The applied study design can be seen as a major strength, 
because all GPs assessed identical hypothetical patients and thus provided insight into 
some level of variance regarding medication decision making. Further, using focus group 
meetings enabled GPs to contemplate the same patient, and to enquire about possible 
reasons for variation in their prescribing management. A limitation of this study is the 
inclusion of only experienced GPs, thus introducing possible bias. More specifically, GPs in 
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other studies mentioned lacking certain skills, or felt incompetent managing patients with 
multimorbidity[11, 26, 27]. Although this was not found in the present study, it was also 
not explicitly asked about. Also, only two meetings were organized. However, because 
the second meeting did not reveal any new themes, and the content of the discussion 
resembled the first meeting, the data-collecting process was considered saturated. 
 
Comparison with existing literature  
Contrary to the methods chosen in previous studies[11, 12, 17, 18, 22, 26, 27], this study 
incorporated the assessment of case vignettes based on fictitious patients into focus 
group sessions, which yielded information about variation in medication adjustments 
between GPs, as well as considerations for the choices made. This study therefore clearly 
showed that, for similar patients, GPs executed their medication management strategy 
quite differently. As far as the authors are aware, this has not been found in other studies. 
As to factors influencing decision making, these findings show similarities with existing 
literature. For instance, the findings that less stringent levels of disease control were 
accepted, that compromises were made between what a GP thought was best for a 
patient and the patient’s requests, and that setting priorities in management was of 
importance[17, 18]. In a study by Schuling and colleagues[11], it was stated that some GPs 
hesitated to discuss the subject of life expectancy. This is contrary to the findings in this 
study, as all GPs intended to enquire about a patient’s prognosis and quality of life. Luijks 
and colleagues[12] showed that the patient’s quality of life was a main focus of GPs’ 
professional performance, and management was adapted to personal preferences and 
vitality. Adhering to available CPGs has been described as not very realistic or as even 
unwanted in polypharmacy[11, 18, 28]. Although guideline adherence was not a main topic 
in these sessions, the GPs indicated that they did not always adhere to the CPGs, but they 
referred to CPGs as a fundamental basis for judgement. 
 
Implications for practice 
Even GPs with a lot of experience and skills perceive the need for additional support to 
facilitate decision making in polypharmacy. Considering the potential consequences of 
failure in medication management, it seems evident that decision-making support tools, 
such as BADRI[32], although not available in the Netherlands, are important. As evidence 
is available that a programmatic approach can be effective, and the availability of these 
support tools increases, it should be stressed that implementation strategies are needed 
to facilitate their usage in practice. In a systematic review on decision-making tools for 
multimorbidity[33], none of the available tools included a patient-centered approach, or 
worked on demand -components that were regarded as important by the GPs in the 
present study. Focusing on extensive collaboration between health care professionals 
seems therefore more promising as a means to facilitate medication management and to 
reduce possible inappropriate variation in medication prescribing. Although a few GPs 
Medication management strategy for older people with polypharmacy 
95 
indicated they participate in multidisciplinary team meetings, there seems to be room for 
improvement as regards embedding these meetings structurally. Because structured 
meetings with GPs and pharmacists around pharmacotherapy already exist (as in 
pharmacotherapy audit meetings)[34, 35], these seem suitable to embed discussions 
around patients with complex polypharmacy. Medication reviews with patients can also 
facilitate medication management, but currently do not seem to be structurally 
performed. More knowledge is needed on the role patients can play in these reviews, 
especially regarding their health literacy[36]. Interventions exist that include executing a 
medication review, but these are not embedded nationwide. Also, acceptable software 
that could extract eligible patients seemed insufficiently applicable to GPs. Recently, 
Sinnott and colleagues[37] described a future intervention to improve medication 
management by combining the concept of discussing complex patients with multiple 
GPs, and discussing the determined results during a medication review with the patient. It 
seems a promising intervention; however, it does not account for the uncertainty around 
the potential patient group eligible for such a review pointed out by the GPs in the 
current study. Therefore, it is worthwhile enquiring about the group eligible for such a 
review, perhaps supported by a tool incorporated into the GP’s EMR system that could 
select these eligible patients. 
In conclusion, a more extensive and structured collaboration between health care 
professionals is desired to facilitate decision making in this heterogeneous patient group, 
as well as support to simplify the process of selecting patients eligible for a structured 
medication review, and some on-demand tools for individual consultation. 
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ABSTRACT 
 
Background: Clinical medication reviews (CMR) are increasingly performed in primary care 
to evaluate patients’ prescribed medications. However, there is discussion about the 
target group for whom a CMR would be (most) useful. 
 
Objective: This study aimed to explore the selection criteria for patients considered as 
eligible for a CMR according to general practitioners (GP) and pharmacists, and the 
barriers and facilitators to organize these CMRs.   
 
Methods: Semi-structured interviews with Dutch GPs and pharmacists were held on the 
performance and organization of CMRs. The questions who they considered eligible for a 
CMR and why, were discussed based on three selection criteria, namely 1) Dutch guideline 
on polypharmacy, 2) Dutch Inspectorate of Health Care criterion for a CMR, 3) a Frailty 
Index. GPs were confronted with three patient lists selected according on these criteria. 
All interviews were audio-taped, transcribed verbatim and coded thematically. 
 
Results: Five GPs and eight pharmacists were interviewed. They underlined that CMRs 
should not be restricted to persons of 70 years and older, or solely to those with 
polypharmacy. The current selection criteria identified an older, frail population who was 
already frequently monitored, or were institutionalized in a residential home. Important 
characteristics of patients eligible for a CMR according to the health professionals were: 
Impaired renal function, signals of non-adherence, regular falls, reduced self-
management, lack of medication knowledge, and those using a multi-drug dispensing aid. 
Mentioned benefits of CMRs were increased medication adherence, increased proactive 
attitude towards appropriate prescribing, increased patient contact, and the 
interdisciplinary approach. Difficulties around GP-pharmacist collaboration, and the 
exchange of patient information hampered the performance of CMRs. 
 
Conclusions: The current selection criteria do not completely correspond with GPs’ and 
pharmacists’ perspectives of patient characteristics that are important when considering 
a CMR. To make CMRs more efficient, changes in the current selection criteria seem 
needed, as well as improvements in data sharing between health professionals. In 
addition, GPs and pharmacists together should make strict agreements about the 
practical organization of CMRs. 
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INTRODUCTION 
Appropriate medication prescribing is essential but challenging in primary care, especially 
in older multimorbid patients receiving multiple medications (i.e. polypharmacy). 
Appropriate polypharmacy refers to ‘the prescribing of individuals with multiple 
conditions where medication use has been optimized and where medications are 
prescribed according to the best evidence’[1]. However, in this patient group prescribing 
to the best medical evidence is not simple. Because of the heterogeneity of the patients 
as regards the combination of prevalent diseases and the contextual situation, 
discrepancies can arise between guideline recommendations and patients’ treatment 
priorities[2]. As a result, there is no apparent, unequivocal, medication management 
strategy[3]. In addition, these patients are often managed by several health care 
professionals with the authority to prescribe medications and due to poor inter-
professional communication, this may lead to sub-optimal coordination over the 
medicines[4]. Altogether, this poses a risk for inappropriate medication use, and may lead 
to adverse drug reactions, falls, or hospital admissions[5]. 
 
One possible strategy for the optimization of prescribing is performing a clinical 
medication review (CMR), which is a critical examination of patients’ medications, 
involving the patient, pharmacist and GP[6]. CMRs have positive effects on the number of 
medication related problems, patient satisfaction with the medications, and medication 
adherence[6]. Additionally, when there is a rather intensive GP-pharmacist-patient 
cooperation, more drug-related problems were identified and solved[6]. However, 
conclusive positive effects of CMRs on clinical outcomes such as reduced hospital 
admissions or mortality are still lacking[6]. Furthermore, consensus is lacking on which 
patients benefit most from CMRs[3, 7]. 
 
For the selection of patients for a CMR, criteria are described in available guidelines[8-10]. 
Most often, these criteria are related to factors like age, number of medications, impaired 
renal function or history of hospital admissions[9]. The described criteria differ in terms 
of strictness, which affects the number of patients eligible for a review, and as a 
consequence, the feasibility for health professionals to select patients for performing 
CMRs. It turns out to be hard to select patients eligible for a CMR based on the 
information provided in electronic health record systems[3, 7]. In addition, GPs stated 
previously that the selection criteria described in the existing guidelines identified 
patients for whom a CMR may not yet always be needed[3, 7]. 
 
When considering the current obligation for Dutch GPs and pharmacists to perform 
CMRs[10], the question rises how, and for whom, CMRs are currently performed in daily 
practice. Therefore, the objective of this study is to explore the patient group considered 
as most eligible for a CMR, by comparing GPs’ and pharmacists’ perspectives on existing 
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criteria for identifying patients potentially in need for a CMR. In addition, practical 
barriers and facilitators for performing CMRs are explored. 
 
 
METHODS 
Semi-structured interviews 
To explore opinions and experiences of GPs and pharmacists about three selection 
criteria for CMRs ( 1. Dutch guideline on polypharmacy[9]; 2. Dutch Inspectorate of Health 
Care (IGZ) criterion for a CMR[10]; and 3. Frailty index developed by Drubbel[11]), semi-
structured interviews were conducted in 2016. A detailed description of the selection 
criteria is presented in Table 1. The invited GPs were active in a practice that participated 
in the NIVEL Primary Care Database[12], by which the three sets of CMR selection criteria 
under study were applied to their own patient population. In Appendix 6.1 a description 
of the selection of GPs is given, as well as information related to privacy protection. The 
community pharmacists were invited through convenience sampling. Baseline 
characteristics of the participating GPs and pharmacists are presented in Table 2. The 
health professionals were asked about potential eligible patients, the process of 
structured medication reviews, collaboration between GPs and pharmacists, the existing 
guidelines on CMRs, and characteristics of patients considered as eligible for a CMR. The 
first author carried out the interviews, which were all audiotaped with consent of the 
participants. 
 
 
Table 1. Methods for identifying older patients potentially in need for a CMR. 
Guideline on 
polypharmacy[9]: * 
 
In this Dutch national guideline it is described that a yearly medication review is 
required for patients of 65 years and older with polypharmacy (≥ five chronically used 
medications) and having at least one of the following risk factors; impaired renal 
function, impaired cognition, increased risk for falls, (signals of) reduced medication 
adherence, institutionalized, or unplanned hospitalization.  
We focused on two risk factors that could accurately be determined with routine care 
data, namely an impaired renal function (eGFR<50 ml/min/1.73m2) or impaired 
cognition (International Classification of Primary Care (ICPC) codes P20 or P70). 
 
IGZ-criterion[10]: * 
 
The IGZ-criterion is based on the Guideline on polypharmacy, and the Dutch Health 
Care Inspectorate (IGZ) formulated a more strict criterion to select patients eligible for a 
medication review, namely ‘patients with ≥ 7 chronically used medications and an 
impaired renal function’.  
 
Drubbel frailty 
index[11]: * 
 
This frailty index can predict the risk of adverse health outcomes (e.g. emergency 
department visit, out of hours surgery visit) in the elderly. It is focused on patients’ 
health problems and diseases rather than on patients’ prescribed medications and is 
based on GPs’ routine care data. It is based on 36 health deficits which were specified 
by ICPC codes, and a frailty score was calculated. This score was subdivided into 
tertiles, and patients in the highest tertile were perceived as ‘most frail’. This patient 
group was selected as potentially eligible for a CMR. 
 
* Originally, several different age categories should be applied in the above mentioned criteria. To compare the 
criteria, only patients of 75 years and older were selected. This is also the age category formulated in the IGZ-
criterion. 
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Analysis 
To identify the potential target group for a CMR, the three criteria sets were applied to 
routine care data available in the NIVEL Primary Care database by using STATA version 
14.0. STATA was also used to describe the baseline characteristics of the patients that 
were identified. The semi-structured interviews were transcribed verbatim and coded 
thematically. A second researcher (JB) checked the thematic codes with the transcribed 
interviews and in any case of disagreement the two researchers discussed until 
consensus was reached. Data collection proceeded until saturation was reached, meaning 
that no new major themes arose from analysis. This was the case after the fifth GP 
interview and eighth pharmacist interview. 
 
 
Table 2. Background characteristics of the GPs and pharmacists that were interviewed. 
 
 
GP (N=5) Pharmacist (N=8) 
Gender; male, n 3 4 
Mean years of work experience [range] 25.5 [21−30] 16.4 [8−34] 
Mean days working in the practice [range] 4.3 [3−5] 3.9 [3−5 ] 
Mean number of GPs/pharmacists in the practice [range] 3 [2−5] 2.8 [1−7 ] 
Mean number of cooperating pharmacies/general practices [range] 3.5 [1−7] 9.4 [3−25] 
Mean number of pharmaco-therapeutic audit meetings with pharmacists 
and GPs in a year [range]  
5.8 [5−6] 6 [4−10] 
Mean number of years that CMRs were performed on a structural basis* n.a. 3.9 [1−10] 
* Only asked to the pharmacists. 
 
 
RESULTS 
Patient identification based on three selection methods 
Nearly all GPs were positive about the suggestion for a tool in the electronic medical 
record (EMR) system that could select patients for a CMR since there was no functionality 
in the GPs’ EMR system to select patients or to report that a CMR was conducted, besides 
for the option to make a notation in a free text field. When applying the three selection 
criteria to the EMR data of patients 75 years and older (61,257 patients from 240 general 
practices), 11% was considered eligible for a CMR according to the guideline on 
polypharmacy (6,629 patients), 5% was identified with the IGZ-criterion (3,034 patients), 
and 3,024 (4.9%) patients were identified with both methods. More specifically, in an 
average practice of 2168 patients of which 7.2% of the population was ≥75 years in 
2013[13], there were 17 and 8 patients eligible for a CMR according to the guideline on 
polypharmacy or IGZ-criterion, respectively. In Table 3, background characteristics of the 
identified population with the criteria defined in the guideline on polypharmacy and the 
IGZ-criterion are given. When reflecting on the identified patients, the GPs agreed that 
these patients were indeed eligible for a CMR. In fact, they mentioned that the 
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medications of the majority of the selected patients were already reviewed in the past 
year. However, the identified patients concerned the (very) frail population who were 
also frequently monitored by the GP and other health professionals, some were 
institutionalized in a residential home, and part of the patients that were selected with 
data from 2013 were already passed away at moment of the interview in 2016. The Frailty 
Index identified far more potentially eligible patients, i.e. 49 patients in an average 
practice, but not all needed a CMR according to the GPs since they used few medications 
or used a straightforward combination of medications. 
 
 
Table 3. Characteristics of the population identified with the guideline on polypharmacy and 
the IGZ–criterion. 
 
 
Guideline on 
polypharmacy 
(N=6629) 
IGZ-criterion 
(N=3034) 
Age; mean (SD) 82.9 (5.1) 83.0 (5.1) 
Women, % 64.6 65.9 
Number of health deficits; mean (SD) * 6.2 (2.5) 6.6 (2.6) 
  Heart failure, % 28.7 39.3 
  Coronary artery disease, % 22.9 26.8 
  Diabetes Mellitus, % 42.9 50.3 
  COPD, % 19.1 23.3 
  Hypertension, % 44.8 46.2 
  CVA/TIA, % 19.9 19.1 
  Cancer, % 25.2 26.2 
  Arthritis/osteoarthrosis, % 39.2 41.5 
  Urinary problems/incontinence, % 53.1 65.9 
  Cognitive impairment, % 35.8 12.5 
Number of medications; mean (SD) 13.0 (4.4) 14.9 (4.3) 
Number of medications chronically used; mean (SD)† 7.7 (2.4) 9.1 (2.1) 
Number of chronically used medications  
in categories, %   
   0 0 0 
   1-4 0 0 
   5-9 80.7 66.9 
   10-14 18.0 30.8 
    ≥ 15 1.3 2.3 
* According to health deficits used in the Drubbel frailty index (excluding the deficit ‘polypharmacy’)[11]. 
† Chronically used; at least four prescriptions of a medication (ATC3-level) and at least 90 days within the first 
and last prescription 
 
 
Eligible target group for a clinical medication review 
The IGZ-criterion was an appropriate starting point to select patients according to the 
health care professionals, but the majority of the participants considered the age limit ≥75 
years less suitable, as well as the strict focus on patients with polypharmacy. They 
indicated that patients younger than 75 years might benefit longer from optimizing their 
medication regime, and that a CMR can be equally important for those with less than five 
medications. Other characteristics of an eligible target group for a CMR were: An 
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impaired cognition, impaired renal function, medication related problems, signals of non-
adherence, and signals of problems with managing their own medication use (i.e. self-
management problems). The latter two characteristics were a signal to start the use of a 
multi-drug dispensing aid (MDD). Patients using a MDD were therefore an appropriate 
group for a CMR. Additional patients for whom extra attention to their medication 
regime was needed, according to some pharmacists, were non-Dutch speaking elderly 
and those with regular falls. 
 
Clinical medication reviews and additional activities around medication 
management 
Four out of five GPs indicated that the official pharmacist-led CMRs were conducted 
annually. These CMRs were nearly always initiated by a pharmacist. The GP, pharmacist, 
or both health care professionals together, also assessed medication lists of MDD users 
or of patients recently discharged from hospital. During these medication reconciliations, 
the patient was not always involved. Patients’ medication regime was also evaluated in 
inhabitants of residential homes, or during the annual extensive GP-consultation for 
patients involved in integrated care programs of chronic diseases (e.g. diabetes mellitus), 
or as component of a Frail elderly integrated care program offered by several Dutch 
health insurance companies. In the Frail elderly program, the GP and patient were 
involved, and occasionally a specialist in elderly care. Some GPs explicitly stated that they 
participated in the Frail elderly program to focus on patients who were not selected by 
the pharmacist for a CMR. 
 
Facilitators and barriers for clinical medication review performance 
Selection tools incorporated in the electronic pharmacy system can assist pharmacists in 
the selection of patients based on the IGZ-criterion or guideline on polypharmacy. To 
specify this target group even more, some pharmacists added criteria, like a minimal 
number of potential medication related problems displayed by the electronic tool. 
However, a limitation was that information, like renal function levels, was not always 
available or up to date in the system. So, pharmacists could not rely on the tool 
completely. Furthermore, according to the pharmacists, the initiation of a CMR should 
not solely be based on the existing selection criteria. Signals of health care providers, 
caregivers, relatives, or from the requests of patients themselves were also important in 
the decision to initiate a CMR. Collaboration difficulties between GPs and pharmacists 
hampered CMR performance. GPs often made official agreements with some -and not all- 
pharmacies in the area to perform CMRs, and as a consequence not all eligible patients 
were reviewed. Pharmacists mentioned that the time and effort for performing CMRs 
outweighed the financial compensation by the health care insurer. Pharmacists also 
experienced difficulties with organizing appointments for CMRs with GPs. According to 
the pharmacists this was partly due to the funding model of the GP that for a great part 
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relies on patient consultations, and because GPs lacked a proactive attitude to perform 
CMRs. A pharmacist mentioned to be co-located in the general practice, which facilitated 
inter-professional GP-pharmacist collaboration around pharmacotherapy. 
 
 
Benefits of clinical medication reviews 
Both groups of health care professionals were positive about CMRs. CMRs nearly always 
resulted in medication adjustments, they noticed increased medication adherence, and 
because they performed it structurally there were no major changes needed in a patient’s 
medication regime. GPs considered CMRs as an extra trigger to critically assess patients’ 
medications, they were more proactive as regards patients’ medication regime, and 
learned from the interdisciplinary approach. Pharmacists stressed that the performance 
of CMRs has positioned them more as a health care provider, which they considered 
positive. They had increased patient contact, and were more informed about patients’ 
social context and wellbeing. They also indicated that CMRs were highly appreciated by 
the patient. Some pharmacists criticized the missing positive significant clinical patient 
outcomes. 
 
 
DISCUSSION 
This study showed that the existing criteria for the selection of eligible patients had 
several disadvantages. GPs and pharmacists mentioned that selection criteria should not 
merely focus on patients with a high age and number of medications. Furthermore, the 
initiative for a CMR should be based on signals from health professionals, caregivers or 
patients themselves rather than on criteria described in guidelines alone. Important 
patient characteristics to initiate a CMR were; an impaired cognition, impaired renal 
function, medication related problems, signals of non-adherence, medication self-
management problems, regular falls, MDD users, non-Dutch speaking elderly, and those 
recently discharged from hospital. Issues around GP-pharmacist collaboration and 
organization hampered the performance of CMRs. 
 
This study underlined two important barriers for successful implementation of CMRs in 
primary care. The first barrier concerns the current selection criteria. The current 
selection criteria seem not clear enough. GPs indicated that the criteria identified patients 
who are already frequently monitored (in a residential home), and pharmacists often 
added criteria to the selection process to identify a group that is more manageable to 
review. In line with our results, Geurts et al[7] stated that patients’ number of 
medications and age were not sufficient to define the target group suitable for a CMR 
and she suggested that risk stratification might be necessary to decide which patients 
might benefit from a CMR. For patients with an impaired renal function a CMR was 
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considered important according to the GPs and pharmacists. However, since the renal 
function values were not always available or up to date, they could not use this 
information for selecting a target group. An RCT found that patients’ renal function did 
not correlate with a benefit from a CMR, and the same applied for patients’ number of 
diagnoses[14]. To benefit from a CMR, it seemed more effective to select patients with a 
high number of medications in use, with a high discrepancy between medications 
prescribed compared to medications actually taken, and with a high Medication 
Appropriateness Index score[14].  
The other barrier concerns collaboration between pharmacists and GPs around the 
organization of CMRs. GPs in our study perceived that structural agreements with 
pharmacists about CMRs were lacking. This is contrary to a recent Dutch study that found 
that 80% of the GPs and pharmacists had made agreements around the organization of 
CMRs[15]. In line with Kwint et al[16], pharmacists perceived difficulties around the 
planning and organization of the meetings with GPs about CMRs. Other studies also 
confirm that difficulties on inter-professional collaboration exist[15, 17]. A major benefit 
of CMRs for pharmacists was the increase in intensity in patient contact. Previous 
research showed that while pharmacists agreed on this, GPs disagreed that pharmacists 
should be involved in monitoring patient’s progress, or should have an active role in 
prescribing medications[18]. Both groups of health professionals did acknowledge that 
pharmacists should be actively involved in performing CMRs and have a role in supporting 
GPs in pharmacotherapy[18], but in practice they find it difficult to define each other’s 
role and act accordingly. 
 
This is the first study that investigated whether one could use routine care data for the 
identification of eligible patients for a CMR, together with views from GPs and 
pharmacists around important selection criteria and the organization of CMRs. However, 
the study has a few limitations. The pharmacists’ and GPs’ views about CMRs might only 
be partly representative for the general pharmacist and GP population since the GPs 
turned out to have an above average work experience and the majority of the 
pharmacists were involved in scientific research, of which some in the field of medication 
reviews. On the other hand, it considered a group with a lot of experience in prescribing 
and with clear perceptions about CMRs and the interviews delivered rich information on 
the subject. Another limitation is that we used data from 2013, while the interviews were 
held in 2016. As a result, our information of the patients did not always resemble the 
current status of the patient during the interview in terms of morbidity, medications, 
frailty, and living situation. 
 
Intensive GP-pharmacist collaboration around CMRs can lead to higher implementation 
rates of interventions suggested during a CMR[6]. This stresses the importance to solve 
the communicational and organizational issues around CMRs. Despite of the fact that 
pharmacies and general practices share data, some information (e.g. renal function 
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levels) is still not always available or up to date in the pharmacy system. The same applies 
for certain risk factors that are incorporated in the guideline on polypharmacy (i.e. 
impaired cognition, hospital admission)[9]. Since both the GPs as well as pharmacists 
explicitly reported that an impaired renal function, impaired cognition or recent hospital 
discharge were relevant criteria for a CMR, it is of major importance that GPs 
continuously share relevant information with the pharmacies visited by their patients 
-and vice versa. This strongly advocates for an improved exchange of patient information 
between pharmacy and GP information systems. Further, besides the selection criteria 
described in the guidelines, GPs and pharmacists seem to highly value more subjective 
selection criteria, like ‘self-management problems’ or ‘medication side effects’, which 
requires a dialogue with the patient as they are not easily detectable in electronic 
pharmacy or GP systems. Therefore, one should be alert on signals from the patient 
themselves, patient’s caregivers or relatives, or from different health care providers, like 
home care assistants. Future research could investigate if these caregivers have the 
ability to identify patients for whom a CMR has a major benefit. Additionally, one could 
also explore the possibilities for home care assistants, or community nurses to also share 
their findings on medication use and patients’ health status electronically and structurally 
with GPs and pharmacists. In this way electronic medical records are enriched with 
additional information that is relevant when selecting patients for a CMR.  
The GPs and pharmacists valued CMRs, but they both fail to implement the reviews on a 
structural basis. Lack of time and financial support were mentioned reasons, but one of 
the major issues concerned the difficulty to arrange meetings for CMRs between GPs and 
pharmacists. It is useful to investigate whether a CMR could be embedded into recurring 
consultations in the general practice, like the annual consultation for patients 
participating in integrated care programs for chronic diseases. Collaboration with GPs, as 
well as data sharing with GPs is likely to improve when a (non-dispensing) pharmacist is 
located into the general practice. In a limited number of countries this type of pharmacist 
is already successfully integrated into the general practice, and in the Netherlands this 
situation is currently under study[19]. Further, to reduce the workload for pharmacists 
and GPs, and as a result to enhance the feasibility of performing CMRs, a patient 
questionnaire on actual medication use and drug related problems could replace the face-
to-face interview[20]. 
 
In conclusion, both the GP as well as pharmacist evaluated CMRs positively as a means to 
detect medication related problems and improve patients’ medication use. Nevertheless, 
in order to make CMRs feasible in daily practice, the health care professionals should 
improve data sharing and they should invest in structural inter-professional meetings 
focused on CMRs. Since the current selection criteria do not completely correspond with 
GPs’ and pharmacists’ perspectives of patient characteristics that are regarded important 
when considering a CMR, changes in the current selection criteria seem also needed by 
focusing on criteria that are considered important by GPs and pharmacists. 
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GENERAL DISCUSSION 
Due to the ageing population, GPs increasingly manage older patients having multiple 
chronic diseases (multimorbidity). Regular use of several medications is common in this 
patient group, but appropriate prescribing of combinations of medications is often not 
evidence-based. This thesis aimed to identify and clarify the challenges and complexity of 
managing older patients with multimorbidity in general practice, with a special focus on 
medication management. The studies in this thesis examined the prevalence of 
multimorbidity patterns in general practice, inter-practice variation as regards the 
prevalence of polypharmacy, the current medication management strategy of GPs for 
patients with multimorbidity and polypharmacy, and the potential target group eligible 
for a clinical medication review (CMR). 
In this final chapter the main findings are summarized and discussed. Subsequently, the 
main methodological issues are described, and the implications for clinical practice and 
recommendations for future research are presented. 
 
 
Main findings  
Multimorbidity patterns 
Although the knowledge about the overall prevalence of multimorbidity is accumulating, 
insight into the prevalence of specific disease combinations (i.e. morbidity patterns) is 
limited. Especially this type of information is useful for healthcare providers when 
managing patients with multimorbidity, since GPs respond to patient’s reason for 
encounter by taking into account all diseases that are prevalent. In Chapter 2 we found 
that till 2012, research on the prevalence of multimorbidity patterns for the most part 
focused on disease pairs. Methodological differences in study setting, data collection 
method, and the definition of the diseases resulted in considerable variation in 
prevalence rates of the identified disease pairs. For instance, the prevalence rate of the 
disease pair depression-hypertension varied from 1.2% to 12.9% between studies. Findings 
from Chapter 3 stressed that multimorbidity is not restricted to disease pairs, but is 
characterized by the presence of complex morbidity patterns, often consisting of various 
types of chronic diseases. Depending on the disease of interest, there is variation in the 
complexity of the patterns. More specifically, certain disease triplets are at least five or 
six times more prevalent in patients with a specific disease of interest, compared to the 
population without that disease (e.g. cardiac dysrhythmia-osteoporosis or coronary 
artery disease-COPD in patients with heart failure). On the other hand, some diseases are 
not specifically bound to a certain pattern, but are equally prevalent in all chronically ill 
patients (e.g. disease triplets including hypertension or diabetes). Even patients aged 55-
69 years with at least one chronic disease had on average three chronic diseases, varying 
from five diseases for patients with heart failure to two diseases for patients with 
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migraine. These findings illustrate the heterogeneous nature of this patient group, which 
leads to a great variety in different treatment options. Furthermore, not only the oldest-
old have complex health care needs and require complex management but also those 
younger than seventy years. Inquiring about patient preferences during the consultation 
and focusing on what matters to patients seems very relevant for GPs as the disease-
specific guidelines can only partly support the treatment decisions. 
 
Variation in medication management of older patients 
Because of the limited applicability of current clinical practice guidelines (CPGs), the 
availability of multiple treatment options, and due to patient and physician perspectives, 
GPs may vary in the prescribed medications to older patients with complex 
multimorbidity. Showing this variation, as well as gaining insight into the decision making 
process as regards medication prescribing can facilitate medication management for 
these patients. Chapter 4 shows that of the older population (≥ 55 years) receiving 
medications, 20% used five of more medications chronically (i.e. polypharmacy). Yet, this 
prevalence rate varied with a factor 2.4 between general practices (from 12.4% to 30.1%) 
after accounting for differences in patient population and practice characteristics. An 
increase in the number of chronic conditions is not directly accompanied by an increase in 
the number of prescribed medications, since especially the type of diseases seems to 
influence the number of medications prescribed. Discussions with two groups of GPs 
confirmed that there is no straightforward, apparent medication management strategy 
for older patients with multimorbidity and polypharmacy (Chapter 5). GPs varied in the 
proposed adjustments of -hypothetical- patients’ currently prescribed medications, which 
is influenced by their assessment of patients’ characteristics, social context, life 
expectancy, and preferences regarding a therapy or medication. Although the GPs had on 
average 25 years of work experience, they seemed indecisive about the best treatment 
approach and indicated to value support to facilitate medication management for these 
patients. Considering the potentially negative consequences of failure in medication 
management support tools can be valuable, such as structural meetings with other GPs 
or pharmacists to discuss patients with complex health problems. 
 
Clinical medication reviews for older patients with polypharmacy 
Since GPs are receptive for support tools centered around medication management of 
patients with multimorbidity, we examined clinical medication reviews (CMRs) in more 
detail. For the selection of eligible patients, criteria are described in guidelines, but these 
differ in terms of strictness. This affects the number of patients eligible for a review and 
as a consequence, the feasibility for health care professionals to perform CMRs. In 
Chapter 6 we found that the existing selection criteria for patients eligible for CMRs 
described in the Dutch guideline on polypharmacy[1] or the criteria specified by the Dutch 
Health Care Inspectorate[2] might be too much focused on frail elderly only. Rather than 
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patients’ age, GPs and pharmacists regarded the following patient characteristics 
valuable when considering a CMR: an impaired renal function, impaired cognition, signals 
of medication non-adherence, medication self-management problems, regular falls, 
patients using a multi-drug dispensing aid, non-Dutch speaking elderly, and those recently 
discharged from hospital. The GPs as well pharmacists valued CMRs, but they both failed 
to implement the reviews on a structural basis. Issues around GP-pharmacist 
collaboration and communication may be solved by improving data sharing between the 
general practice and pharmacy, and by investing in structural inter-professional meetings 
focused on CMRs. GPs and pharmacists should put more effort to work as a team when 
managing older patients with multimorbidity and a complex medication regime. 
 
 
Interpretation of the findings 
Medication management for older patients with multimorbidity turns out to be even 
more complicated than was expected. A first challenge for GPs concerns the 
heterogeneity of these patients in terms of the combination of chronic diseases, as well 
as the patient’s unique health context. This sometimes leads to complex medication 
management, and the question rises how patients with complex medication 
management can be identified? When these patients are identified, it asks for a 
management approach involving different care givers, such as the GP and pharmacist. 
However, issues around collaboration impede adequate decision making around 
medication prescribing in individual patients. So, how should medication management for 
these patients be organized? A last challenge relates to the actual treatment approach, 
for which GPs have to balance between adhering to various disease-specific guidelines 
and considering patient’s personal abilities and preferences.  
 
How to identify patients with a complex medication management? 
Findings from chapter 3 show that older patients with multimorbidity are often 
characterized by a complex pattern of various types of chronic diseases. Yet, not all 
multimorbidity patterns lead to a complex medication management. Treatment for 
patients taking few medications is likely to be (more) straightforward, and the same 
applies for patients with a ‘logical combination’ of medications (as mentioned by GPs 
interviewed -see chapter 6). Medications that are (more) commonly combined and 
described in existing guidelines are prescribed to patients diagnosed with diseases that 
have a common pathophysiology, like diabetes mellitus and hypertension as risk factors 
for heart failure[3]. For patients with single diseases and logical disease patterns, case-
finding can rely on the recording of the diagnosis -and sometimes a corresponding 
medication prescription-, according to ICPC- and ATC-codes in GPs’ electronic medical 
records (EMR). One example of effective case-finding applies to the integrated care 
program for patients with diabetes mellitus type 2; in 2015 over 90% of the so-called ‘care 
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groups’ (i.e. a contracting entity of various health professionals that cover all primary 
care needed by patients with these chronic diseases) identified their total population of 
patients diagnosed with diabetes mellitus type 2 (DM2) by using the ICPC-code T90[4-6]. 
However, for patients with a comprehensive set of discordant diseases[7], medication 
management is far more complicated, and case-finding could not easily be based on an a-
priori defined set of ICPC- and ATC-codes, as we showed in chapter 6. Nevertheless, when 
considering a tool to identify patients with complex medication management, a first step 
could be to exclude the patients with single diseases and those with logical disease 
patterns. Future research could further investigate (combinations of) factors or patient 
characteristics that could identify patients with complex care needs, like diagnoses of 
diseases affecting different body systems, the number of GP consultations in the last 
year, hospital admission in the last year, or perhaps certain demographic characteristics 
(socioeconomic status, residential area) that turned out to be reasonable predictors for 
care burden in general practice[8-10]. 
  
Another option to identify patients with a complex medication regime is to make use of 
an already scheduled consultation at the practice. More specifically, a component of the 
care provided by the described integrated care programs for chronic diseases is an annual 
extensive check-up. This check-up can also be used to screen patients on medication 
related problems, which can indicate complex medication management. Since nearly all 
patients with DM2 are participating in a disease program[4], and diabetes turned out to 
be a disease with a comprehensive set of co-occurring diseases (Chapter 3), the annual 
diabetes check-up at the practice seems a promising opportunity for identifying patients 
with a complex medication regime. An option is to ask patients to complete a short 
questionnaire about their medication use and potential medication related problems 
when they are invited for the annual diabetes check-up. Research has shown that 
questionnaires are able to identify medication related problems, although an actual 
patient interview provided more information compared to a questionnaire[11-13]. When 
implemented during annual check-ups for several chronic diseases, it can give the GP an 
indication of the population with difficulties around the medication regime, and it can 
reach a major part of the GP’s patient population structurally. Besides, this approach fits 
the pharmacists’ and GPs’ request to rely more on signals from the patients themselves, 
rather than on selecting patients based on a predefined set of criteria (i.e. age limit , 
minimum number of medications, impaired renal function) as described in current 
guidelines (Chapter 6). An important restriction is that such a questionnaire should also 
be suitable for persons with low(er) literacy skills, which is more often the case for 
patients who are older, have multimorbidity, or have functional limitations[14]. Future 
research could elaborate this idea, explore the feasibility for GPs to focus more 
extensively on patients’ medication regime during an annual check-up, could explore 
whether such a questionnaire is suitable in this patient group, and explore the costs and 
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benefits for the general practice when GPs, in such a way, focus more proactively on 
older patients’ medication regime.   
 
Organization of care for patients with complex medication management 
To provide appropriate treatment for patients with complex medication management, 
the organization of care should be clear. This is challenged by the fact that management 
of these patients usually means that several health care professionals are involved[15]; 
the GP, and (several) medical specialist(s) who are responsible for the treatment. The 
patient is also often seen by a general practice nurse, and the pharmacist takes care of 
the patient’s medications. Caregivers from the patient’s neighborhood who may be 
involved in patient’s management are the district nurse, informal care givers, home care 
givers or a social care team. So, to have a complete overview of patient’s health care 
needs and social context, information is needed from all these parties. To whom should 
this information be provided? In several papers and policy documents it is stressed that 
patients with multimorbidity should have a principal care coordinator[16-19]. Because of 
the GP’s role as gatekeeper, he seems to be in the appropriate position to fulfill this 
function[20]. Yet, one could also think of assigning a practice nurse for chronic conditions 
as the coordinator, as she is most often the health care provider seeing patients with one 
or more chronic conditions receiving integrated care. To date, most practice nurses are 
well known with the care for patients with diabetes mellitus, and they are increasingly 
involved in the care for patients with COPD, asthma, cardiovascular diseases, and 
sometimes even the care for (frail) elderly. However, the GP still is the main care provider, 
and only he has the authority to adjust the patient’s medication regime when needed. 
The GP is experienced in providing general medicine, usually has a long-established 
relationship with the (older) patient, and is well-informed about the social context and 
abilities of the patient. Because of these aspects, the GP seems to be more suitable as a 
care coordinator than a pharmacist, who is the designated health care professional to 
maintain an appropriate medication regime, or a specialist in elderly care medicine, who is 
often only involved at moment when the patient becomes frail, and thus lacks the long 
lasting relationship and the background information of the patient. In a patient’s 
individual care plan, clear agreements about the designated care coordinator should be 
made. 
 
A clear organization of care does also mean excellent collaboration and cooperation 
between the various health care professionals involved. This thesis indicated some of the 
perceived difficulties when several health care professionals are involved in a patient’s 
management (Chapter 5 and Chapter 6). Other studies also showed that there are 
difficulties around inter-professional collaboration, care coordination and task 
distribution[21-25]. For instance, eight percent of chronically ill adults in the Netherlands 
mentioned that they received conflicting information from their clinicians in the last two 
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years[21], and GPs and pharmacists differ in their perception who is -and should be-, 
responsible for the monitoring of patients’ medications[22]. So, for the management of 
patients with a complex medication regime, each of the professionals involved should 
know his specific role in management and together, they should provide integrated care. 
This could for instance mean that for older patients with complex multimorbidity GPs, 
pharmacists and medical specialists work in multidisciplinary care teams in which patient 
consultations are synchronized, and meetings are regularly organized to maintain the 
multidisciplinary integrated approach. Even patients, or their representatives, could 
participate in these meetings to share their experiences. Such a multidisciplinary 
approach focused on proactive elderly care turned out to be successful on a regional 
scale in the Netherlands[26]; patients were positive about the proactive approach and 
healthcare providers perceived improvements in coordination of care, and considered 
multidisciplinary meetings valuable for the quality of care[26]. This asks for a shared 
responsibility of the involved health care professionals, and above all the willingness to 
pursue this multidisciplinary approach. Furthermore, this also requires patients to be 
more proactive in managing their health. A prerequisite for a shared -and equal- 
responsibility perhaps also means that certain aspects related to funding should be 
improved. For instance around the organization of clinical medication reviews (CMR), 
since lack of sufficient funds was an often heard barrier for implementation according to 
pharmacists (Chapter 6). Appropriate funding, in relation to the time needed to perform a 
CMR and the time that can’t be spent on regular consultations, could facilitate a 
structural implementation of CMRs in primary care and as such, could improve a 
multidisciplinary treatment approach. 
 
As mentioned, a multidisciplinary treatment approach does also mean multidisciplinary 
meetings in which the several health care professionals -at least GPs and pharmacists- can 
exchange views around pharmacotherapy and medication management. In chapter 5 we 
found that GPs would highly appreciate meetings in which they could discuss patients 
with a complex medication regime. Since medication management for patients with 
complex multimorbidity often is not completely evidence-based, a common view about a 
certain pharmaceutical treatment at least could support GPs to follow a consensus-based 
approach. Besides for the involvement of pharmacists and GPs, perhaps also the patient 
could attend multidisciplinary meetings, to provide information about his lifestyle, 
context, social situation, values or preferences. Such information, besides clinical details, 
could guide the discussion on what kind of medication management would be 
appropriate[27]. Further, it would lead to patients being more informed and empowered, 
provide them with an opportunity to ask questions, and would improve communication 
between the patient and the health care team[28].  
A possibly suitable existing meeting to exchange views is the pharmacotherapy audit 
meeting (in Dutch: Farmacotherapie Overleg (FTO))[29]. In these meetings, GPs and 
pharmacists discuss medication related topics to gain new and shared insights. The 
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importance of these FTO-meetings is reflected by the fact that nearly all GPs and 
pharmacists participate in a FTO-group, and that over 40% of the groups have the highest 
level of functioning, which is a measure of the quality of these meetings[30]. There is 
material available to discuss during a FTO-meeting, this concerns for instance topics 
around diseases, medication transfer, medication reviews, polypharmacy, or medication 
safety in frail elderly[29]. Some of these topics are likely to be highly valuable for health 
care professionals to gain insight into the medication management of other 
professionals. However, a certain topic is most likely on the agenda once or twice a year. 
In order to structurally imbed a discussion around the pharmacotherapy of patients with 
a complex medication regime, it seems more valuable that a discussion about a difficult 
patient case is scheduled for each FTO-meeting. 
 
A multidisciplinary approach is hindered by issues around arranging meetings with all 
relevant care providers, and perhaps also with the patient (Chapter 6). Nevertheless, this 
could also be reached by structurally gathering the required expertise to one location. 
More specifically, in several countries a non-dispensing pharmacist is introduced into the 
general practice, and this is currently investigated in the Netherlands[31-35]. The 
introduction of the pharmacist in general practice has led to an enhanced ongoing 
relationship with patients and turned out to make the medication processes run more 
efficiently. It would enhance knowledge about pharmacology and pharmacotherapy in 
the practice, and it would enable successful collaboration between the GP and 
pharmacist as they both have access to important information in patients’ medical 
records, they will share the same vision when working together, which can result in 
unambiguous pharmaceutical care[36-38]. Future research should especially focus on 
investigating and solving potential barriers from the GP’s perspective, as he does not 
always thinks pharmacists should have a bigger role as health care providers in primary 
care[22, 36].  
 
For optimal collaboration and coordination of care, involving several health care 
professionals, attention should be paid to practical issues as regards patient information 
sharing, and adequate recording into the various electronic medical record systems 
(EMR). A patient’s individual care plan should be accessible for all health care 
professionals involved, as well as for the patient himself. For instance, pharmacists and 
GPs both need the most up to date information about patients’ medication history, 
contra-indications, medication side effects, and biomedical parameters. This information 
should be exchanged between the various health care providers. To date, the most up to 
date information is not always available for health care providers, often due to the fact 
that it is not automatically exchanged between the various systems (Chapter 6)[39]. 
Attention for adequate data sharing and information technology is also perceived a core 
vision of the Royal Dutch Pharmacists Association (in Dutch: KNMP), the National Dutch 
General Practitioners Association (in Dutch: LHV) and the Dutch College of General 
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Practitioners (in Dutch: NHG)[20, 40]. Fortunately, there is a tendency of sharing medical 
information through electronic tools, and recording systems. Relevant Dutch examples 
are the ‘Landelijk Schakelpunt’[41] and the ‘Informatie standaard medicatieproces’[42]. 
Components of the care for patients with a complex medication regime, like the 
outcomes of a clinical medication review and the accompanying action points, could also 
be incorporated into the pharmacist’s and GP’s EMR system[43]. Again, to accomplish 
successful information sharing, important prerequisites for the health care professionals -
-and also for the patient- are a proactive attitude and the willingness to share patient 
data. In addition, sharing of medical information is -of course-, only possible with explicit 
consent of patients.  
 
Treatment of patients with complex medication management 
When patients with a complex medication regime are identified, appropriate 
management is necessary. However, this is not easy. To a great extent prescribing of 
medications relies on the GP’s approach because patients with multimorbidity often visit 
their GP and GPs turn out to be reluctant in consulting a pharmacist or medical specialist 
when facing a difficult medication regime, as mentioned in chapter 5[9, 15]. GPs seem to 
adhere to the clinical practice guidelines (CPG) when possible, but also (highly) rely on 
their own previous experience and preferences for a therapy. For decades, GPs are 
encouraged and educated to adhere to the rapidly increasing collection of CPGs[44], but 
to date adhering strictly to the disease-specific guidelines is inappropriate when 
managing patients with multiple diseases with a complex medication regime. This 
resembles the findings that guidelines do not fit when providing appropriate care to 
patients during the final stages of life[45]. For this patient group, there is a movement 
that guidelines should be directed not only at ‘action’ but also at ‘inaction (alternative 
action)’, that shared-decision making is one of the most important basic principles for 
ensuring appropriate care, and that a multidisciplinary consultative team should be in 
place that can assist with complex treatment decisions[45]. What should treatment look 
like for patients with a complex medication management? 
 
Most importantly, management should be highly tailored to the person, and focused on 
maintaining or improving patient’s abilities, and patient’s capacity to cope and participate 
in social activities, in line with the concept of positive health defined by Huber et al[46]. 
Asking the patient ‘what he wants’ and ‘what is bothering him most’ can help to prioritize 
management to the aspects that will have the highest impact on patients[16, 18, 47]. To 
elucidate what the patient wants and what he needs to manage his life independently to 
the very best of his abilities, clear communication is essential. More specifically, it means 
clear communication from the GP towards the patient, but also from the patient towards 
the GP. The patient should be adequately informed by the GP about the expected 
benefits and harms of different medications and treatment options, by also taking into 
account the patient’s level of health literacy[48, 49]. On the other hand, the patient 
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should have the opportunity, but also take the opportunity and responsibility, to share his 
concerns about current treatment. For instance about (potential) medication side effects, 
the complexity of the medication regime, or about non-adherence. This seems a 
challenge, since patients nowadays still find it hard to express their concerns openly or 
spontaneously[50, 51]. To create an environment where both parties can actively discuss 
their concerns and preferences about current treatment, GPs and patients might profit 
from training or support. For patients, one could think of a patient information leaflet 
describing patient’s ‘rights’ during a consultation with the GP, or with possible ‘example 
questions’ to ask to the GP. An individualized care plan can be used to report the agreed 
management approach with patient’s treatment priorities and abilities. It is necessary to 
evaluate this plan frequently because of the changes in conditions of life (due to 
treatment), changing treatment priorities, and to pay attention to possible future 
problems. Generally, such kind of approach is visualized by the Ariadne principles, see 
Figure 1[18]. 
 
 
 
Figure 1. Schematic overview of the management approach based on the Ariadne principles (Muth et al, 2014)[18] 
 
 
Two promising treatment programs for older patients with a complex medication regime 
are a clinical medication review, and the integrated care program for frail elderly. Clinical 
medication reviews have proven to decrease the number of medication related problems 
and improve patient satisfaction with the medication regime, which seem valuable goals 
for a patient[52-54]. Embedding a structural medication review as a component of the 
medication management approach of GPs (and pharmacists) seems therefore promising. 
However, detecting (potentially) inappropriate medications is only the first step. It should 
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also result in appropriate action (e.g. adjusting medications, stopping medications, 
maintaining the current strategy), and GPs sometimes turn out to be indecisive about the 
best approach, as described in chapter 5. So, it is necessary to support GPs in their 
decision-making process, by providing evidence on appropriate medication combinations 
and the experience of other health professionals when facing a difficult regime, as 
described earlier. Future research on medication reviews should still focus on examining 
clinical outcomes, such as decreased hospital admission rates or improved quality of life, 
and should investigate potential solutions around organizational issues, for instance the 
issue around the target group who will benefit most from a medication review.  
Integrated care programs for (frail) elderly which are currently only offered on regional 
level can improve the integrated approach of pharmacists and GPs in the management of 
patients with -most likely- multiple diagnosed chronic diseases and prescribed 
medications[26, 55-57]. In line with GPs’ and pharmacists’ preferences, (Chapter 6), case-
finding for eligible older patients in these programs also relies on signals of the care 
providers in general practice, and on signals of caregivers from patients’ neighbourhood. 
In addition, attention for appropriate prescribing is a main element of these programs. 
Hence, nationwide use of such a care program is suggested to facilitate the medication 
management process. Future research should investigate its feasibility and effectiveness.   
 
 
Methodological reflections 
The studies in this thesis used various research methods and study populations in order to 
give an answer on the research questions. Table 1 provides an overview of the study 
setting and population per study. 
Half of the studies described in this thesis make use of data from the NIVEL Primary Care 
Database (formerly known as LINH). One of the strengths of using this database is that it 
already exists for more than two decades. It was therefore possible to determine 
patients’ chronic diseases in a period of 10 years. It also enabled us to use information of 
at least 40,000 patients and 120 general practices. Furthermore, participating general 
practices receive quality feedback information about their recordings in the electronic 
health record system. With this, the participating GPs are particularly aware of their 
recording habits, and anticipate on the feedback results[58]. So, there is continuous 
attention for recording uniformly and completely, and therefore the NIVEL Primary Care 
Database most likely provides complete and reliable patient data. 
A second major strength of this thesis is that the findings rely on both quantitative as well 
as qualitative research. With the quantitative studies we provided important information 
about multimorbidity patterns and medical practice variation. We used this information 
as a basis for the focus group interviews and the semi-structured interviews with the GPs 
and pharmacists. The qualitative studies, therefore, actually explored the perspective of 
the main healthcare professionals in primary care involved in the (medication) 
management of patients with multimorbidity. By applying these mixed methods, this 
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thesis provided suggestions for improvements in the care for patients with 
multimorbidity. 
 
 
Table 1. Overview of the examined study population per chapter. 
 Systematic 
review 
(Chapter 2) 
Multimorbidity 
patterns 
(Chapter 3) 
Variation in 
polypharmacy 
(Chapter 4) 
Medication 
management 
strategy  
(Chapter 5) 
Medication 
review  
(Chapter 6) 
Setting General 
population and 
general practice 
 
General 
practice 
General 
practice 
General 
practice 
General 
practice 
Type of study 
population 
Patient data 
from surveys, 
GPs’ EMR 
 
Patient data 
from GPs’ EMR 
Patient data 
from GPs’ EMR 
GPs discussing 
hypothetical 
patients 
GPs and 
pharmacists 
discussing 
patients in 
general  
 
Age patients At least half of 
the population 
in each 
included study 
≥55 years 
 
≥55 years ≥55 years Hypothetical 
patients from 
68-84 years 
≥75 years  
Age 
GPs/pharmacists 
n.a. n.a. n.a. Mean age 56yrs 
 
n.a.* 
      
Minimum number of 
diseases criterion 
2 1 0 2 
 
 
2 
Minimum number of 
medications criterion 
0 0 1 5 
 
 
5 
≥1 chronic disease n.a. 100% 84.6% n.a. 
 
n.a. 
≥1 chronic 
medication 
n.a. n.a. 81.6% n.a. n.a. 
* GPs and pharmacists with on average 22 and 16 years of work experience, respectively 
 
 
There are some points of deliberation of the work described in this thesis that need to be 
acknowledged too. One can for instance debate about the chosen disease list in this 
thesis, because it is known that the number of chosen diseases under study influence the 
prevalence rate of multimorbidity[59]. To date, this debate is still ongoing and present on 
the research agenda[60]. From the research perspective, it is wise to have a uniform 
definition of multimorbidity with the diseases comprising this definition. On the other 
hand, it still remains complex to manage patients with multimorbidity, regardless of how 
multimorbidity is defined.  
The findings from the two qualitative studies rely on a subgroup of GPs and pharmacists. 
The GPs in the focus groups were all active as a GP-trainer, which means that they have 
sufficient work experience and the correct competences, to guide GP residents in their 
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education. Moreover, it considered a group of GPs interviewed during one of their 
training days and as such, this group might be extra motivated to provide care according 
to the guidelines or are perhaps highly alert on a specific topic discussed at the training 
day. Some pharmacists interviewed about the clinical medication reviews were engaged 
in research or the development of the guideline criteria for the execution of CMRs. In the 
two qualitative studies input from less experienced GPs and of pharmacists less involved 
in research is lacking. In addition, the view of the patients themselves about medication 
management is missing. This could have enriched the findings in the way that they could 
have told us about their priorities in medication management. 
 
 
Implications for research and practice 
Based on the studies presented in this thesis, some important points of action can be 
defined for future research and for health care professionals involved in (medication) 
management of patients with multimorbidity.  
 
Research implications 
Research focused on the concept and outcomes of multimorbidity has received 
increasing attention over the last decades[61], but comparisons between multimorbidity 
studies -for instance about the occurrence of multimorbidity- is still hampered by the lack 
of a uniform definition of multimorbidity. Researchers in the field of multimorbidity 
should therefore carefully consider (and describe) the number of included diseases, the 
type of included diseases, and the study setting. Moreover, it may be important to 
develop a disease list with uniformly defined diseases. When considering the study 
setting, the general practice setting might be ideal, at least in countries with a strong 
primary care system. This because there is usually routine care data available, which 
enables an accurate estimation of patients’ full range of morbidity, and it enables 
longitudinal research to determine the order of the diseases that are diagnosed in a 
patient. When deliberating a management strategy with the patient, the GP could 
anticipate on the information that certain diseases -or disease patterns-, are likely to 
develop in (near) future. Longitudinal research could also contribute to a better 
understanding of the variation in medication management by following patients with an 
equal case mix of health conditions and background characteristics and to see what kind 
of decisions GPs make in management. Yet, one should keep in mind that management in 
this patient group is most often influenced by several health care providers, and not just 
the GP. Future research on (medication) management of patients with complex 
multimorbidity therefore can incorporate the decisions made by medical specialists and 
pharmacists. Tools could facilitate medication management, but currently none included 
a patient-centered approach or worked on demand[62], components that were regarded 
as important by the GPs and pharmacists interviewed in this thesis. Future research can 
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especially focus on (electronic) tools that can work on demand, to avoid that specific 
alerts are ignored, and to focus on a target group most in need of additional support. One 
of such tools could be the annually medication review. However, in its current format it 
does not focus on the most appropriate target group and difficulties hamper structural 
implementation. So, future research still should investigate ways to implement this 
activity efficiently and to perform it effectively.   
 
Practice implications 
This thesis showed that medication management for older patients with a complex 
medication regime asks for a multidisciplinary team managing the patient. It is suggested 
to at least involve the GP and pharmacist, the practice nurse to support the GP, and to 
involve a medical specialist for older frail patients. This requires the health care 
professionals to have the competences and skills to adequately collaborate and 
communicate to each other and towards the patient. Therefore, training to develop and 
strengthen these skills during medical education seems necessary, as well as frequently 
recurring post academic training. Training could also focus on a patient-centered 
approach to identify patients’ needs and preferences and to incorporate these into a 
feasible treatment plan. For the next generation GPs and pharmacists it should be 
everyday practice to collaborate intensively with each other when managing patients 
with complex multimorbidity. Post academic training topics around polypharmacy, 
medication transfer and medication safety that include GPs as well as pharmacists can 
stimulate the discussion and exchange ideas and views on a structural basis. Possibilities 
to facilitate (medication) management in general practice for patients with 
multimorbidity are to synchronize the appointments of one patient as much as possible 
so that GPs have the time to focus on what matters to the patient, and in order to reduce 
the consultation burden for the patient. Furthermore, health care professionals could 
focus on optimizing the exchange of medical information of patients, to avoid an 
unnecessary repetition of questions and tests by the various health care providers 
involved. Besides, it enables all health care providers to have the most up to date patient 
information which could prevent some of the medication related problems. To facilitate 
management of patients with a complex medication regime, it also asks for a (policy) 
system that is more focused on integrated patient-centered care, offering generic care 
programs with a proactive focus on the care of (frail) elderly. Yet, appropriate attention 
for the medication regime of younger patients with complex care needs should not be 
forgotten. Because of the tendency that patients should fulfil an active role in their 
management[46], it is valuable to enhance patient education as regards disease 
management, e.g. by providing e-health education, or patient versions of guidelines to 
involve them in the management process. 
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General conclusion 
Current challenges in general practice as regards managing older patients with 
multimorbidity concern the heterogeneity of the patients and the absence of a clear 
medication management strategy. The primary health care system can probably be 
improved by accounting better for the comprehensive disease patterns that affect the 
vast majority of the elderly. Our findings show that GPs vary as regards prescribing 
medications to similar patients. Achieving a more shared vision about the best 
therapeutic treatment for these patients is likely to add to the effectiveness of patient 
care, and in addition, would strengthen GPs in their decision-making process. A more 
structured and adequate collaboration between health care professionals who are 
involved in patient’s medication management may offer better patient outcomes. Such a 
multidisciplinary approach requires structural meetings between health care providers 
-and patients- to exchange views and experiences about complex medication 
management. It also asks for adequate data sharing of patient information in the various 
electronic medical record systems of the care providers who are involved. Paramount is 
that the management of patients with multimorbidity and a complex medication regime 
asks for an approach that is tailored to the person, is evaluated on a frequent basis, and 
accounts for the patient’s specific needs and preferences.   
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SUMMARY 
The presence of multiple (chronic) diseases within one person is known as 
multimorbidity. Due to the aging population, general practitioners (GP) increasingly 
manage older patients with multimorbidity. Around 55-98% of the persons of 60 years and 
older is diagnosed with multimorbidity, depending on how multimorbidity is defined and 
measured. Information is lacking about the prevalence of multimorbidity patterns, i.e. 
specific combinations of diseases that are likely to occur. Many patients with 
multimorbidity are recommended to use multiple different medications, also referred to 
as polypharmacy. Patients with polypharmacy are at increased risk for inappropriate 
prescribing, that is the use of medications that should be avoided, and doses or 
frequencies of medications that should not be exceeded. So, attention for appropriate 
management and medication prescribing is important. However, issues like 
fragmentation of care and poor inter-professional communication challenge medication 
management of older patients with multimorbidity. Furthermore, also the disease-
centered approach characterizing the current health care system complicates appropriate 
management. More specifically, prescribing medications according to recommendations 
in clinical guidelines may result in an excessive amount of medications with the increased 
risk of drug interactions, poor adherence and adverse effects. In this older patient group 
other considerations like patients’ quality of life, prognosis, and their treatment 
preferences can become complementary or even superior to medical motives. A logical 
result of the limitedly applicable guidelines, the multiple treatment options, and the 
influence of the physician and patient themselves on the treatment is variation in medical 
practice between physicians. For instance, variation in the (number of) prescribed 
medications to patients with similar background characteristics. A better understanding 
of the rational part of medication prescribing variation is needed, as well as insight into 
factors that influence medication management. Tools or support centered around 
medication management of patients with multimorbidity seem important. 
 
This thesis aimed to identify and clarify the challenges and complexity of managing older 
patients with multimorbidity in general practice, with a special focus on medication 
management.  
 
In Chapter 1, we gave an introduction of the concept of multimorbidity and we 
introduced the problem of medication management of older patients with multimorbidity 
and polypharmacy. The remaining gaps in knowledge on various aspects of (medication) 
management for patients with multimorbidity have led to the research questions for this 
thesis, namely: 
1. In an international perspective, which disease combinations are most prevalent? 
2. What is the multimorbidity rate in patients with common chronic diseases in the 
Netherlands, and what kind of multimorbidity patterns occur in older patients with 
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specific chronic diseases? 
3. What is the variation between general practices in polypharmacy rates of older 
patients? 
4. What is the GP’s medication management strategy for patients with 
multimorbidity and polypharmacy? 
5. What is the target group eligible for a medication review, from the GP’s and 
pharmacist’s perspective, and what are practical barriers and facilitators for 
performing a medication review? 
 
In Chapter 2, we examined the various prevalent disease combinations (i.e. disease 
patterns) in older patients with multimorbidity, as described in available literature. Our 
search yielded 3,070 potentially eligible articles of which 23 studies met our quality and 
inclusion criteria. We found that research on the prevalence of multimorbidity patterns 
for the most part focused on disease pairs, and there were twenty chronic diseases that 
were often assessed in patients with multimorbidity. Depression, hypertension, and 
diabetes mellitus were the most commonly clustered diseases. Methodological 
differences in study setting, data collection method, and the definition of the diseases 
resulted in considerable variation in prevalence rates of the identified disease pairs (e.g. 
the prevalence rate of the disease pair depression-hypertension varied from 1.2% to 12.9% 
between studies). The identified disease patterns could serve as a first priority setting 
towards the development of multimorbidity guidelines. A likely option is to start with the 
most frequently occurring disease combinations and to evaluate possible treatment 
conflicts, in order to adjust existing clinical guidelines, or to develop new guidelines. 
 
In Chapter 3, we determined the multimorbidity rate in older patients with common 
chronic diseases. We also identified multimorbidity patterns for patients with heart 
failure, diabetes mellitus, migraine or dementia. We used clinical data of over 120,000 
older patients (≥55 years) registered in 158 different general practices in the period 2002-
2011. Overall, the multimorbidity rate was 86% for patients with at least one chronic 
disease, but it varied between 70% for patients with migraine to 98% for patients with 
heart failure. Chapter 3 stressed that multimorbidity is not restricted to disease pairs, but 
is characterized by the presence of comprehensive disease patterns, often consisting of 
various types of chronic diseases. Certain disease patterns were at least five or six times 
more prevalent in patients with the disease of interest, compared to the population 
without that disease (e.g. cardiac dysrhythmia-osteoporosis in patients with heart 
failure). On the other hand, some diseases were not specifically bound to a certain 
pattern, but were equally prevalent in all chronically ill patients (e.g. disease triplets 
including hypertension or diabetes). The study also found that multimorbidity is highly 
prevalent among patients 55-70 years (84%). This study stresses the complexity of 
multimorbidity, especially because of the heterogeneous nature of the patients. It also 
illustrates that not only the oldest-old have complex health care needs and require 
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complex management, but also those younger than seventy years. Guideline developers 
should be aware of this complexity, and GPs should focus on what matters to the patient, 
rather than on what is the matter in this patient group. 
 
In Chapter 4, we determined the inter-practice variation in polypharmacy prevalence of 
44,917 older patients from 86 different general practices. Of the patients of 55 years and 
older receiving medications, 27% used five of more medications chronically (i.e. 
polypharmacy). Yet, this prevalence rate varied from 12.4% to 30.1% between general 
practices after accounting for differences in patient and practice characteristics, with an 
overall mean of 19.8%. Because considerable inter-practice variation in polypharmacy 
prevalence existed after accounting for differences in patient and practice characteristics, 
this suggests that there is not always agreement between GPs concerning medication 
management in this complex patient group. Physician initiatives to achieve a common 
vision about the best therapeutic treatment will add to the value and effectiveness of 
patient care. 
 
In Chapter 5, we explored GPs’ medication management strategies and their perspectives 
and needs on decision making support to facilitate medication management. In two focus 
group meetings, 12 GPs discussed their medication management by means of four clinical 
case vignettes of patients with multimorbidity and polypharmacy. The discussions 
confirmed that there is no straightforward, apparent medication management for these 
patients. GPs varied in the proposed adjustments of -hypothetical- patients’ currently 
prescribed medications. This is influenced by GPs’ assessment of patients’ background 
characteristics, social context, life expectancy, and GPs´ preferences regarding a therapy 
or medication. The GPs seemed indecisive about the best treatment approach, they 
would like to discuss their choices with other health care professionals, and valued 
medication reviews with patients. A more structured collaboration between health care 
professionals is desired, as well as support to facilitate the feasibility of medication 
reviews with eligible patients.  
 
In Chapter 6, we focused on clinical medication reviews (CMR) as a tool to reduce 
inappropriate medication use. We explored the target group for a CMR, by comparing 
existing selection criteria with GPs’ and pharmacists’ perspectives. Furthermore, we 
explored the barriers and facilitators to organize CMRs. Five GPs and eight pharmacists 
were interviewed. They both valued CMRs as positive. Important characteristics of 
patients eligible for a CMR were an impaired renal function, signals of non-adherence, 
regular falls, reduced self-management, lack of medication knowledge, and a multi-drug 
dispensing aid. CMRs were nearly always initiated by pharmacists and they selected 
patients by using electronic selection tools incorporated in their pharmacy system. 
However, patient information (e.g. renal function levels) in the pharmacy system was not 
always up to date or available. Patients’ medication lists were sometimes evaluated 
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during the yearly GP-consultation for patients participating in integrated care programs 
for chronic diseases (e.g. diabetes mellitus), and in patients living in residential homes. 
The current selection criteria were critically considered by GPs and pharmacists. They 
mentioned that the initiative for a CMR should be based on signals from health care 
professionals, caregivers or patients themselves rather than on criteria described in 
guidelines (e.g. certain age limit). GPs and pharmacists experienced difficulties around 
inter-professional communication, the arrangement of meetings, and issues around the 
exchange of patient information between the GP and pharmacist. These organizational 
issues hamper successful performance of CMRs on a structural basis in daily practice. 
 
In Chapter 7, we gave an overview of the results, and discussed the interpretation of the 
overall findings in this thesis. We addressed three areas of discussion, namely (1) how 
patients with complex medication management can be identified, (2) how management 
for patients with a complex medication regime can be organized, and (3) important 
aspects of treatment of patients with complex medication management. We further 
addressed some methodological reflections, and we discussed the implications from this 
thesis for research and practice. To conclude, the research described in this thesis found 
that the primary health care system can probably be improved by accounting better for 
the comprehensive disease patterns that affect the vast majority of the elderly. Further, 
achieving a common vision about the best therapeutic treatment for these patients is 
likely to add to the effectives of patient care, and in addition, would strengthen GPs in 
their decision-making process. A more structured and adequate collaboration between 
health care professionals who are involved in patient’s medication management may 
offer better patient outcomes. Such a multidisciplinary approach asks for structural 
meetings between health care providers -and patients- to exchange views and 
experiences about complex medication management. It also requires adequate sharing 
of patient information in the various electronic medical record systems of the care 
providers who are involved. Paramount is that the management of patients with 
multimorbidity and a complex medication regime asks for an approach that is tailored to 
the person, is evaluated on a regular basis, and accounts for the patient’s specific needs 
and preferences.  
 
  
   
Samenvatting 
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SAMENVATTING 
Multimorbiditeit wil zeggen dat één persoon meerdere (chronische) aandoeningen 
tegelijkertijd heeft. De levensverwachting van mensen stijgt nog steeds en onder andere 
door de vergrijzing van de samenleving behandelt de huisarts steeds vaker oudere 
patiënten die multimorbiditeit hebben. Ongeveer 55% tot 98% van de 60-plussers heeft 
multimorbiditeit, afhankelijk van de gekozen meetmethode en definitie van 
multimorbiditeit. Er is weinig informatie over de omvang van specifieke combinaties van 
aandoeningen (ziekteclusters) die vaak voorkomen bij patiënten met multimorbiditeit. 
Veel patiënten met multimorbiditeit gebruiken verschillende geneesmiddelen tegelijk, 
ook wel polyfarmacie genoemd, en hebben daardoor een grotere kans op onjuist en 
onveilig geneesmiddelengebruik. Aandacht voor een juist medicatiebeleid is daarom 
belangrijk. Toch wordt het medicatiebeleid bij patiënten met multimorbiditeit bemoeilijkt 
door een gebrekkige afstemming en continuïteit in de zorg en communicatieproblemen 
tussen zorgverleners. Een ander knelpunt is de ziektegerichte benadering in de 
organisatie van de gezondheidszorg. Het voorschrijven van geneesmiddelen zoals 
aanbevolen in ziekte-specifieke richtlijnen en standaarden kan bij deze groep leiden tot 
(te) veel geneesmiddelen met het risico op geneesmiddeleninteracties, slechte 
therapietrouw en andere nadelige effecten. Bij deze oudere patiëntengroep kunnen 
andere zaken -zoals de kwaliteit van leven van de patiënt, de prognose, of 
behandelvoorkeuren-, belangrijker worden dan medische motieven. Een logisch gevolg 
van de beperkt toepasbare richtlijnen, de verscheidenheid aan keuzes in behandelopties, 
en de invloed van de arts en patiënt zelf op de behandeling is variatie in medisch 
handelen tussen artsen. Bijvoorbeeld, variatie in (het aantal) voorgeschreven 
geneesmiddelen bij patiënten die dezelfde achtergrondkenmerken hebben. Inzicht in 
deze medische praktijkvariatie is belangrijk, net als inzicht in factoren die het 
medicatiebeleid beïnvloeden. Daarnaast is het belangrijk om meer te weten over tools en 
ondersteuning die als doel hebben het medicatiebeleid bij patiënten met multimorbiditeit 
te vergemakkelijken en eenduidiger te maken.   
 
Het doel van dit proefschrift was de complexiteit in de behandeling van oudere patiënten 
met multimorbiditeit in de huisartsenpraktijk in kaart te brengen en te verklaren, met een 
specifieke focus op het geneesmiddelengebruik en medicatiebeleid.  
 
In Hoofdstuk 1 gaven we een introductie op het onderwerp multimorbiditeit, als ook een 
introductie op problemen rondom het medicatiebeleid bij oudere patiënten met 
multimorbiditeit en polyfarmacie. Dit leidde tot de volgende onderzoeksvragen die in dit 
proefschrift zijn beantwoord: 
1. Welke combinaties van aandoeningen komen vaak voor, zoals beschreven in 
internationale literatuur? 
2. Wat is de omvang van multimorbiditeit in Nederland bij patiënten met 
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veelvoorkomende chronische aandoeningen, en welke ziekteclusters zie je vaak bij 
patiënten met enkele specifieke chronische aandoeningen? 
3. Wat is de variatie in het percentage oudere patiënten met polyfarmacie tussen 
huisartsenpraktijken? 
4. Hoe ziet het medicatiebeleid eruit van de huisarts bij patiënten met 
multimorbiditeit en polyfarmacie? 
5. Wat zijn de ideeën en opvattingen van huisartsen en apothekers ten aanzien van 
de criteria voor de selectie van patiënten voor een medicatiebeoordeling, en wat 
zijn mogelijke praktische faciliterende en belemmerende factoren voor de 
organisatie van medicatiebeoordelingen? 
 
Hoofdstuk 2 betrof een literatuurstudie naar veelvoorkomende ziektecombinaties -ook 
wel ziekteclusters genoemd-, bij oudere patiënten met multimorbiditeit. Dit leverde 3.070 
mogelijk geschikte artikelen op, waarvan uiteindelijk 23 studies voldeden aan onze 
kwaliteits- en inclusiecriteria. Onderzoek naar de prevalentie van ziekteclusters bij 
multimorbiditeit was vooral gericht op ziekteparen en twintig chronische aandoeningen 
bleken vaak onderzocht te worden. De aandoeningen die het vaakst als cluster 
voorkwamen waren depressie, hypertensie en diabetes mellitus. Door verschillen in de 
gekozen studiesetting, methode van dataverzameling, en de gebruikte definitie van de 
chronische aandoeningen varieerden de prevalentiecijfers van de geïdentificeerde 
ziekteparen (bijv. de prevalentie van de combinatie depressie-hypertensie varieerde van 
1,2% tot 12,9% tussen de studies). De gevonden ziekteclusters zouden als uitgangspunt 
kunnen dienen bij de ontwikkeling van richtlijnen over multimorbiditeit. Men zou kunnen 
starten met de meest voorkomende ziektecombinaties, met als doel de mogelijke 
behandelconflicten te beschrijven, waarmee bestaande richtlijnen kunnen worden 
aangevuld, of nieuwe ontwikkeld kunnen worden. 
 
In Hoofdstuk 3 bepaalden we de omvang van multimorbiditeit bij oudere patiënten met 
veelvoorkomende chronische aandoeningen. Ook brachten we ziekteclusters in kaart van 
patiënten met hartfalen, diabetes mellitus, migraine of dementie. Hiervoor maakten we 
gebruik van gegevens van meer dan 120.000 oudere patiënten (≥55 jaar) die ingeschreven 
waren bij 158 verschillende huisartsenpraktijken in de periode 2002-2011. In totaal had 86% 
van de patiënten -met een chronische aandoening- multimorbiditeit, maar dit verschilde 
van 70% voor patiënten met migraine, tot 98% voor patiënten met hartfalen. Deze studie 
benadrukt dat multimorbiditeit meestal niet betekent dat men twee chronische 
aandoeningen heeft, maar vaker bestaat uit een cluster van verschillende typen 
aandoeningen. Bepaalde ziekteclusters kwamen vijf of zes keer zo vaak voor bij patiënten 
met de specifieke index-ziekte, in vergelijking met de populatie zonder de index-ziekte 
(bijv. hartritmestoornis-osteoporose bij patiënten met hartfalen). Toch waren er ook 
aandoeningen die niet specifiek waren voor een bepaald ziektecluster, maar voorkwamen 
bij alle chronisch zieke patiënten, namelijk ziektecombinaties met hypertensie en diabetes 
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mellitus. Multimorbiditeit kwam ook vaak voor bij patiënten van 55-70 jaar (84%). Dit 
onderzoek benadrukt de complexiteit van multimorbiditeit, vooral vanwege de 
heterogeniteit van de patiënten. Het maakt ook duidelijk dat niet alleen de alleroudsten 
een complexe zorgvraag hebben welke een complexe behandeling vereist, maar dat dit 
ook geldt voor patiënten jonger dan 70 jaar. Richtlijnontwikkelaars moeten zich bewust 
zijn van deze complexiteit, en bij deze patiënten zouden huisartsen zich meer moeten 
focussen op wat de patiënt belangrijk vindt, in plaats van strikt alle diagnoses willen 
behandelen.   
 
In Hoofdstuk 4 onderzochten we de inter-praktijkvariatie in de prevalentie van 
polyfarmacie bij 44.917 oudere patiënten van 86 verschillende huisartsenpraktijken. Van 
de patiënten van 55 jaar en ouder die geneesmiddelen gebruikten, gebruikte 27% ten 
minste vijf geneesmiddelen chronisch (polyfarmacie). De spreiding in het percentage 
oudere patiënten met polyfarmacie tussen praktijken liep van 12,4% tot 30,1%, nadat 
gecorrigeerd was voor verschillen in patiënt- en praktijkkenmerken. Gemiddeld had 19,8% 
van de patiënten polyfarmacie. Omdat de verschillen in het percentage oudere patiënten 
met polyfarmacie bleven bestaan, nadat er rekening was gehouden met verschillen in 
patiënt- en praktijkkenmerken, lijkt het erop dat de behandelstijl tussen huisartsen 
verschilt en er tussen huisartsen onvoldoende overeenstemming is in het medicatiebeleid 
bij deze complexe patiëntengroep. Initiatieven die leiden tot een gezamenlijke praktijkstijl 
van artsen over de beste medicamenteuze behandeling zullen bijdragen aan de waarde 
en effectiviteit van patiëntenzorg.  
 
In Hoofdstuk 5 brachten we het medicatiebeleid van huisartsen in kaart bij patiënten met 
multimorbiditeit en polyfarmacie. Ook gingen we na bij huisartsen wat hun opvattingen 
waren over en hun behoeften aan beslissingsondersteuning om het medicatiebeleid te 
vergemakkelijken. In twee focusgroepen discussieerden twaalf huisartsen over hun 
behandelstrategie aan de hand van vier klinische case vignetten van patiënten met 
multimorbiditeit en polyfarmacie. De gesprekken bevestigden dat er geen eenduidig 
medicatiebeleid is bij de huisartsen. Huisartsen varieerden in het medicatiebeleid dat zij 
voorstelden bij deze (hypothetische) patiënten. Dit werd beïnvloed door de afwegingen 
die zij maakten op basis van de patiënt zijn of haar achtergrondkenmerken, sociale 
context, levensverwachting en de voorkeuren van de arts wat betreft een behandeling of 
geneesmiddel. De huisartsen leken niet zeker over de beste behandeling, ze wilden hun 
keuzes in de behandeling graag bespreken met andere zorgverleners en waardeerden 
medicatiebeoordelingen met patiënten. Een meer gestructureerde samenwerking tussen 
zorgprofessionals is daarom gewenst, net als ondersteuning bij de uitvoering van 
medicatiebeoordelingen bij de juiste doelgroep.  
 
In Hoofdstuk 6 richtten we ons op medicatiebeoordelingen als een middel om onjuist 
geneesmiddelengebruik te verminderen. We focusten ons op de mogelijke doelgroep 
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voor een medicatiebeoordeling door selectiecriteria beschreven in richtlijnen te 
vergelijken met de visie van huisartsen en apothekers. Daarnaast brachten we in kaart 
welke knelpunten en faciliterende factoren er zijn bij de organisatie van 
medicatiebeoordelingen. Vijf huisartsen en acht apothekers werden geïnterviewd en zij 
bleken allen positief over gezamenlijke medicatiebeoordelingen. Volgens de huisartsen 
en apothekers waren de volgende kenmerken belangrijke factoren om een 
medicatiebeoordeling te starten: Een verminderde nierfunctie, signalen van 
therapieontrouw, geschiedenis van vallen, problemen met zelfmanagement, weinig 
kennis van de geneesmiddelen, en patiënten die gebruik maken van een medicijnrol. Het 
initiatief voor een medicatiebeoordeling lag bijna altijd bij de apotheker, die voor de 
selectie van patiënten vaak gebruik maakte van een tool welke in hun apothekerssysteem 
ingebouwd is. Echter, bepaalde informatie van de patiënt, zoals nierfunctiewaarden, was 
niet altijd actueel of aanwezig in het systeem van de apotheek. Het medicatieoverzicht 
van patiënten die deelnamen aan ketenzorgprogramma’s voor chronisch zieken (bijv. 
voor diabetes mellitus) werd soms geëvalueerd tijdens de jaarcontrole bij de huisarts, en 
het werd geregeld beoordeeld bij inwoners van verzorgingstehuizen. De huisartsen en 
apothekers waren kritisch over de huidige selectiecriteria beschreven in de richtlijnen. 
Het initiatief voor een medicatiebeoordeling zou volgens hen veel meer moeten 
afhangen van specifieke signalen van zorgverleners, verzorgers of de patiënt zelf in 
plaats van dat de patiënt voldoet aan bepaalde criteria beschreven in richtlijnen, zoals 
een leeftijdscriterium. Huisartsen en apothekers benoemden verschillende knelpunten op 
het gebied van communicatie tussen de twee zorgverleners, het vastleggen van overleg 
over medicatiebeoordelingen, en er waren problemen rondom de uitwisseling van 
patiëntinformatie tussen huisartsen en apothekers. Deze knelpunten bemoeilijken de 
succesvolle uitvoering van medicatiebeoordeling op een structurele basis in de dagelijkse 
praktijk.  
 
In Hoofdstuk 7 gaven we een overzicht van de resultaten en bespraken we de 
interpretatie van de bevindingen van dit proefschrift. We behandelden drie onderwerpen 
in de discussie, namelijk (1) hoe patiënten met een complex medicatiebeleid 
geïdentificeerd kunnen worden, (2) hoe het beleid bij patiënten met een complex 
medicatieregime georganiseerd zou kunnen worden, en (3) belangrijke aspecten van de 
behandeling van patiënten met een complex medicatiebeleid. Ook bespraken we 
methodologische kwesties en de implicaties van dit proefschrift voor onderzoek en 
praktijk. We concludeerden dat de huisartsenzorg verbeterd kan worden door meer 
rekening te houden met complexe ziekteclusters waar een groot deel van de ouderen 
mee te maken heeft. Daarnaast kan een meer gezamenlijke visie over de beste 
medicamenteuze behandeling bij deze patiënten bijdragen aan effectiviteit van de zorg 
voor de patiënt, en kan het de huisarts helpen in zijn besluitvormingsproces. Een meer 
gestructureerde en adequate samenwerking tussen zorgverleners die betrokken zijn bij 
het medicatiebeleid van een patiënt faciliteert het realiseren van betere 
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patiëntuitkomsten. Zo’n multidisciplinaire benadering vraagt om structurele 
overlegmomenten tussen de zorgverleners -en patiënten- om ideeën en ervaringen uit te 
wisselen. Ook vraagt het om optimale uitwisseling van gegevens in de elektronische 
informatiesystemen van de betrokken zorgverleners. Duidelijk is dat de behandeling van 
patiënten met multimorbiditeit en een complex medicatieregime vraagt om een 
benadering die op maat gemaakt is, regelmatig wordt geëvalueerd, en rekening houdt 
met de specifieke behoeften en voorkeuren van de patiënt. 
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APPENDICES 
Appendix 2.1. Electronic literature search strategy for MEDLINE. 
Step Search terms  Studies found 
1 multimorbid*[tiab] OR multi-morbid*[tiab] OR multiple morbidit*[tiab] OR multiple 
diseas*[tiab] OR multiple illness*[tiab] OR multiple diagnos*[tiab] OR multiple chronic 
diseas*[tiab] OR multiple chronic illness*[tiab] OR multiple chronic diagnos*[tiab] OR 
multiple chronic condition*[tiab] 
2878 
2 comorbidity[Mesh] OR comorbid*[ti] OR co morbid*[ti] 58970 
3 “chronic disease”[Mesh] 206793 
4 #2 AND #3 2969 
5 measure[tiab] OR measured[tiab] OR measurement[tiab] OR measurements[tiab] OR 
measures[tiab] OR index[tiab] OR indexes[tiab] OR indexed[tiab] OR indices[tiab] OR 
list[tiab] OR listed[tiab] OR lists[tiab] OR classification[tiab] OR classifications[tiab] OR 
classified[tiab] OR classifies[tiab] OR classify[tiab] OR classifying[tiab] OR 
instrument[tiab] OR instruments[tiab] OR definition[tiab] OR define[tiab] OR defined[tiab] 
OR scale[tiab] 
3342139 
6 #1 AND #5 921 
7 #4 AND #5 1230 
8 #6 OR #7 2071 
9 articles with an abstract available 2064 
10 limit #9 to English or Dutch language 1835 
11 limit #10 to publications from the year 2000 to current 1602 
 
 
Appendix 3.1. ICPC-1 codes of the 29 examined chronic diseases. 
  ICPC-1 codes 
1 Hypertension K86, K87 
2 Diabetes Mellitus T90 
3 Osteoarthritis L89-L91 
4 Coronary artery disease K74-K76 
5 Cancer A79, B72-B74, D74-D77, L71, N74, R84, R85, S77, T71, 
U75-U77, W72, X75-X77, Y77, Y78 
6 Chronic back or neck disorder L83, L84, L86 
7 COPD R91, R95 
8 Visual disorder F83, F84, F92-F94 
9 Cardiac dysrhythmia K78-K80 
10 Depression (and psychosis) P73, P76 
11 Heart failure K77 
12 Asthma R96 
13 Hearing disorder H84-H86 
14 Osteoporosis L95 
15 Stroke K90 
16 Rheumatoid arthritis L88 
17 Dementia (incl. Alzheimer’s disease) P70 
18 Anxiety disorder P74 
19 Migraine N89 
20 Heart valve disorder K83 
21 Neuraesthenia/surmenage/burn-out P78 
22 Chronic alcohol abuse P15 
23 Parkinson’s disease N87 
24 Epilepsy N88 
25 Personality disorder P80 
26 Schizophrenia P72 
27 Intellectual disability P85 
28 Congenital cardiovascular anomaly K73 
29 HIV/AIDS B90 
ICPC= International Classification of Primary Care 
Appendices 
151 
Appendix 3.2. Detailed information about the analytic techniques of the multiple membership 
model. 
We regarded the diseases of a patient, the patient itself, and the general practices/general practitioners as potential 
sources of variation for the outcome level. A patient was hierarchical clustered to a specific general practice, and 
patients were diagnosed with one or multiple diseases, which were not hierarchical distributed to a specific general 
practice. The focus of this study was to determine the impact of diseases (ranges from 1 to 17 per patient) on the 
outcome per patient, i.e. multimorbidity (yes/no). This was illustrated in the table below (that showed part of the results 
also presented in Table 2). The first row of this table (i.e. overall mean) showed the results solely from the perspective 
of the patient (and thus ignoring the diseases); of the 120,480 patients 62% had multimorbidity (45747 patients with 
single morbidity and 74733 with multimorbidity). The next 24 rows showed the results from the disease specific 
perspective; the number of patients with that specific index-disease and the proportion with multimorbidity.  
The sum of all numbers in the first column was 273,761 patient-disease cases. This was much more than the actual 
number of unique patients (120,480). Subsequently, if one calculated the number of patients with single morbidity and 
multimorbidity per index-disease, the sum was 45747 patients with single morbidity (similar to the number from the 
patient’s perspective) but the multimorbidity number was much higher, namely 228,014 patients. This indicated that 
patients with multimorbidity were counted several times. This effect was most apparent when one checked the observed 
proportion of multimorbidity; the 62% of the patient’s perspective was outside the range of all disease specific 
multimorbidity proportions (75%-94%), with an observed average of 85%. To control for the bias due to the fact that 
patients were counted several times, the effect of the diseases were distributed, proportional to the number of diseases 
per patient. The multiple membership structure accounts for that; per patient record, each of the 24 diseases allocated 
a weight. If a disease was present, the weight was one divided by the total number of the diseases per patient. For 
each patient, the disease weights added up to one. For example, if a patient was diagnosed with five chronic diseases, 
each of these diseases allocated a weight of 0.20. The disease specific adjusted rate was calculated as the sum of the 
overall adjusted rate and the disease specific residual estimated from the disease level random effect (the between 
disease variance). Note that the overall adjusted rate will be more similar to the observed average rate based on the 
disease specific rates (closer to 85%). 
 
 N= number of patients; chr= chronic 
 
Diseases N Observed % Multimorbidity 
N observed 
single morbidity 
N observed 
multimorbidity 
Overall mean 120480 62.0 45747 74733 
Heart failure 9520 94.4 537 8983 
Heart valve disease 2297 91.9 186 2111 
Stroke 7084 90.3 687 6397 
Cardiac dysrhythmia 10780 89.6 1124 9656 
Coronary artery disease 19145 87.6 2381 16764 
Diabetes Mellitus 27007 84.7 4134 22873 
COPD 14696 86.7 1950 12746 
Visual disorder 13384 88.3 1567 11817 
Dementia 3549 85.5 516 3033 
Rheumatoid arthritis 3678 85.8 524 3154 
Parkinson’s disease 1413 84.5 219 1194 
Asthma 8774 85.2 1295 7479 
Anxiety disorder 3546 84.7 544 3002 
Osteoporosis 7981 85.2 1184 6797 
Hearing disorder 8076 85.9 1139 6937 
Osteoarthritis  20487 83.7 3341 17146 
Depression 9758 83.4 1619 8139 
Chr. Back or neck disorder 17605 81.6 3234 14371 
Alcohol abuse 1528 80.7 295 1233 
Cancer 18479 80.5 3606 14873 
Epilepsy 1364 81.5 252 1112 
Burnout 2288 79.2 475 1813 
Hypertension 58658 75.7 14283 44375 
Migraine 2664 75.4 655 2009 
Total disease-specific N,% 273761 84.7 45747 228014 
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Appendix 5.1. Adams: description of fictionalized case vignette with possible treatment 
considerations. 
Mrs Adams, 71 years old, visits her GP after completing her high-dosage prednisolone treatment. For 10 years, Mrs 
Adams has been diagnosed with moderate COPD. The GP is her main clinician, because she is considered a patient 
with stable COPD. In the last 14 months, Mrs Adams experienced three acute exacerbations of COPD, for which short 
courses of systemic corticosteroids were prescribed (prednisolone 30 mg o.d. for 7 days). During the consultation, Mrs 
Adams tells the GP that she does not experience severe shortness of breath any more, but she does feel somewhat 
airless, and, until recently, she has had headaches quite often, she feels tired, and she has a frequent need to urinate. 
In 2007, Mrs Adams was diagnosed with diabetes mellitus type 2, and at the end of 2012 she suffered a TIA. Moreover, 
she has high blood pressure and impaired renal function. Mrs Adams and her husband still live together independently 
at home. For over 40 years, Mrs Adams had been a heavy smoker, but she gave up smoking in 2004, when diagnosed 
with COPD. Mrs Adams works in a library one afternoon in the week, and walks with her daughter twice a week. 
  
Prescribed medications:  (laboratory) test results: Visit: 
(20/05/2014) 
Visit: 
(30/07/2014) 
Current 
visit: 
(01/10/2014) 
Metformin 1000 mg t.i.d.  
Gliclazide 80 mg b.i.d. 
Acetylsalicylic acid 80 mg o.d. 
Dipyridamole 200 mg b.i.d. 
Simvastatin 40 mg o.d. 
Hydrochlorothiazide 25 mg o.d. 
Salbutamol 200μg q.i.d., prn. 
Tiotropium 18μg o.d. 
Omeprazole 20 mg o.d. 
Alendronic acid 10 mg o.d. 
Blood pressure (mmHg): 150/91 150/92  149/91 
eGFR (ml/min/1.73m2): 42 42 41 
Albumin/Creatinine ratio 
(mg/mmol): 
3.6 3.6  3.6 
LDL cholesterol (mmol/l): 3.0 3.0  2.8 
HbA1c (mmol/mol): 52 57 61 
Fasting blood glucose level 
(mmol/l): 
7.0 7.1  8.1 
BMI (kg/m2): 30 30  30 
    
    
    
 
 
Points of concern: Diabetes control, impaired renal function, blood pressure, dyspnoea 
Possible treatment considerations based on separate Dutch CPGs: 
 •Lower the metformin dosage. In patients with a renal function at 30–50 ml/min, the maximum metformin dose 
 is 500 mg b.i.d.[38]. 
 
•Consider starting with insulin. Insulin is considered since the HbA1c target (<58 mmol/mol) was not met, despite 
the maximum metformin dosage[39]. 
 
•Change the dosage of hydrochlorothiazide into 12.5 mg o.d. For hypertension treatment, an ACE inhibitor is 
preferred in patients with diabetes mellitus type 2 and microalbuminuria (loss of 3.5–35 mg albumin/mmol 
creatinine in women)[24]. 
 
•Start with an ACE inhibitor. Despite the current hydrochlorothiazide dose, the recommended systolic blood 
pressure level of ≤140 mmHg was not achieved, therefore additional medication is recommended. An ACE 
inhibitor is preferred in patients with type 2 diabetes mellitus and microalbuminuria (loss of 3.5– 35 mg 
albumin/mmol creatinine in women)[24]. The recommendation is to stop the hydrochlorothiazide for 2–3 days, 
and then start with the ACE inhibitor and hydrochlorothiazide. 
 
•Change simvastatin into atorvastatin 20 mg o.d. If the LDL cholesterol target of <2.5 mmol/l is not met with 
simvastatin, the recommendation is to change to the preferred second step in cholesterol therapy[24]. 
 
•A common side effect of dipyridamole is headache. In patients with complaints related to dipyridamole, one 
can consider giving acetylsalicylic acid alone[24] Clopidogrel is an alternative to prevent myocardial infarction 
(MI) and stroke; if complaints occur related to the use of acetylsalicylic acid, change acetylsalicylic acid into 
clopidogrel. 
 
•Consider starting with inhaled corticosteroids. Inhaled corticosteroids are considered for patients with frequent 
exacerbations[40]. If it is decided not to start with inhaled corticosteroids, stop with omeprazole; the patient 
finished the 7-day high-dose oral corticosteroids course, and consequently the use of a proton pump inhibitor 
is no longer indicated for this patient[41]. 
 
•Consider consulting a nephrologist. Recommended in patients >65 years with an eGFR between 30 and 45 
ml/min/1.73 m2 [38]. 
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Appendix 5.2. Brown: description of fictionalized case vignette with possible treatment 
considerations. 
Mr Brown, 68 years old, was asked to visit his GP, as laboratory tests showed a decline in renal function. At the end of 
2012, he suffered an MI and since then he uses several medicines as measures for secondary prevention after MI. In 
2009, Mr Brown was diagnosed with osteoarthritis. An NSAID was prescribed for pain management because treatment 
with paracetamol had insufficient effect, and during treatment with tramadol he experienced nausea. Mr Brown lives 
alone, and quited smoking at the age of 60. He intended to cycle every day, but is not always able to do this because of 
pain, especially in the knees. Last August, a diuretic was prescribed because of his high blood pressure, and the GP 
evaluated Mr Brown’s sodium intake and lifestyle. In November, his blood pressure was hardly lowered, and therefore an 
ACE inhibitor was prescribed. 
 
Prescribed medications: (laboratory) test results: Visit: 
(21/08/2014) 
Visit: 
(12/11/2014) 
Current visit: 
(15/12/2014) 
Naproxen 250 mg b.i.d. 
Acetylsalicylic acid 80 mg o.d. 
Metoprolol 100 mg o.d. 
Simvastatin 40 mg o.d. 
Hydrochlorothiazide 12.5 mg o.d. 
Enalapril 5mg o.d. 
Omeprazole 20 mg o.d. 
Blood pressure (mmHg): 165/100  160/100  158/96  
eGFR (ml/min/1.73m2): 52  50  42  
Albumin/Creatinine ratio 
(mg/mmol): 
2.3  2.4  2.8  
LDL cholesterol (mmol/l): 3.0  3.1  3.1  
Fasting blood glucose level 
(mmol/l): 
4.8  4.7  4.8  
    
    
 
 
Points of concern: Blood pressure, cholesterol, use of naproxen, pain 
Possible management considerations based on separate Dutch CPGs: 
•Stop naproxen. Use of an NSAID, in combination with acetylsalicylic acid, is discouraged due to gastric 
complications, and because NSAIDs stimulate sodium and water retention, which increases the risk for (or 
worsens) impaired renal function, high blood pressure, and heart failure. It is further discouraged in patients 
with an MI[19, 42]. 
 
•Start with paracetamol/acetaminophen (with codeine) as an alternative for naproxen, or consider morphine 
therapy, or corticosteroid injections in the knee. All as possible alternatives for pain treatment[18, 40]. 
 
•Increase ACE inhibitor dosage. The recommended systolic blood pressure level of ≤140 mmHg is not achieved 
with the current dosage of hydrochlorothiazide and enalapril[24]. 
 
•Consider changing simvastatin into atorvastatin 20 mg o.d. If the LDL cholesterol target of <2.5 mmol/l is not 
met with simvastatin, the recommendation is to change to the preferred second step in cholesterol therapy [24]. 
 
•Assess possibilities for a knee brace, or knee arthroplasty. In view of the patient’s age and physical condition, 
surgery could be considered as an option[43]. 
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Appendix 5.3. Smith: description of fictionalized case vignette with possible treatment 
considerations. 
Mrs Smith, 84 years old, visits her GP with complaints about dizziness. During the consultation, she further indicates that 
she has sleeping problems due to shortness of breath and a frequent need to urinate. Mrs Smith was weighed and had 
gained 4 kg since her last visit. She has had hypertension since 1999, and osteoporosis since 2000. Concerning her 
osteoporosis treatment, she used alendronic acid for 5 years. In 2002, Mrs Smith was diagnosed with type 2 diabetes 
mellitus, and in 2008 she was diagnosed with cardiac dysrhythmia, for which she receives anticoagulation medication 
from an anticoagulation clinic. Since 2014, she has had heart failure with symptoms of fluid retention, and therefore 
furosemide is prescribed. She lives alone, and generally stays indoors. Mrs Smith’s daughter visits her twice a week with 
groceries, and to give practical household help. 
 
Prescribed medications: (laboratory) test results: Visit: 
(03/10/2014) 
Current visit: 
(06/11/2014) 
Calcium/vitamin D 600/400 o.d. 
Paracetamol 500 mg t.i.d. 
Metoprolol 100 mg o.d. 
Lisinopril 5 mg o.d. 
Furosemide 40 mg o.d. 
Simvastatin 40 mg o.d. 
Metformin 500 mg b.i.d. 
Phenprocoumon from an 
anticoagulation clinic 
Blood pressure (mmHg): 148/92 149//92 
Ventricular rate (bpm):  89 92 
eGFR (ml/min/1.73m2): 46 42 
Albumin/Creatinine ratio (mg/mmol): 2.4 2.6 
LDL cholesterol (mmol/l): 2.5 2.5 
HbA1c (mmol/mol): 58 58 
Fasting blood glucose level (mmol/l): 4.8  
Random blood glucose level (mmol/l):  6.3 
Sodium (mmol/l): 138 132 
Potassium (mmol/l): 4.0 3.9 
INR:  2.8 2.5 
 
 
Points of concern: Dizziness, dyspnoea, oedema/increase in weight, blood pressure 
Possible treatment considerations based on separate Dutch CPGs: 
•Increase furosemide dosage. Patient’s rapid increase in weight, and dyspnoea at night, can indicate fluid 
retention, possibly insufficiently treated by the current dosage of furosemide; furosemide promotes the loss of 
excess fluid in patients with heart failure[20]. Monitor serum electrolytes frequently, in view of the increased 
furosemide dosage and her decreased sodium values. 
 
•Enquire as to type of dizziness. There are several reasons for dizziness, for instance, dizziness due to 
orthostatic hypotension, or due to a side effect of the medications. Insight into the type (or cause) of dizziness 
can influence treatment. 
 
•Increase lisinopril dosage to control the blood pressure, and to improve the blood flow[20]. 
 
•Consider increasing the metoprolol dosage, but only after treatment for the heart failure exacerbation[20]. 
 
•Consider starting with spironolactone if adjusting the furosemide, lisinopril, and metoprolol dosages does not 
result in reduced fluid retention and dyspnoea[20]. 
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Appendix 5.4. Turner: description of fictionalized case vignette with possible treatment 
considerations. 
Mr Turner, 71 years old, visits the GP with a severe pain attack in his big toe. It is too painful to even touch his toe. During 
the consultation, Mr Turner points out that he had experienced several attacks of severe pain in his foot; however, up 
until now, using paracetamol was often an adequate analgesic and, therefore, he had not mentioned it to his GP. This 
week, paracetamol could not alleviate the pain. A blood test demonstrated an elevated uric acid level, and considering 
his previous pain attacks Mr Turner was diagnosed with gout. Since 2008, Mr Turner has cardiac dysrhythmia and in 
2012 he suffered a TIA. He also has high blood pressure. In 2014, his wife passed away, which resulted in depression. 
Paroxetine was prescribed, and he has been using paroxetine for 6 months. 
 
Prescribed medications: (laboratory) test results: Visit: 
(07/10/2014) 
Current visit: 
(03/11/2014) 
Acenocoumarol from an anticoagulation 
clinic 
Paroxetine 20 mg o.d. 
Metoprolol 50 mg o.d. 
Hydrochlorothiazide 12.5 mg o.d. 
Simvastatin 40 mg o.d. 
Omeprazole 20 mg o.d. 
Blood pressure (mmHg): 150/92  148/91 
Ventricular rate (bpm): 92 92 
eGFR (ml/min/1.73m2): 49 49 
Albumin/Creatinine ratio 
(mg/mmol): 
2.6  2.6 
LDL cholesterol (mmol/l): 2.4  2.4 
Fasting blood glucose level 
(mmol/l): 
4.8   
Uric acid (mmol/l):  0.46 
INR: 3.1 3.6 
BMI (kg/m2): 27  27 
 
 
Points of concern: (Pain due to) gout attack, blood pressure, depression treatment 
Possible treatment considerations based on separate Dutch CPGs: 
•Stop omeprazole. It is unknown if the patient has gastric complaints, and the patient does not use an NSAID 
or a low-dose acetylsalicylic acid (LDASA), and therefore a proton pump inhibitor is not indicated[41]. 
 
•Start prednisolone 30 mg o.d. for 5 days. Short-term use of systemic corticosteroids can be effective in treating 
gout attacks, when NSAIDs are contraindicated[44]. 
 
•Add an ACE inhibitor. The recommended systolic blood pressure level of ≤140 mmHg is not achieved with the 
current dosage of metoprolol. It is recommended to stop the hydrochlorothiazide for 2–3 days, and then start 
again with the ACE inhibitor and hydrochlorothiazide[24]. 
 
•Monitor use of paroxetine. Enquire about effects of treatment and consider stopping or changing the medication 
if the patient does not perceive any effect. Long-term use of paroxetine is discouraged[45]. 
 
 
 
 
Appendix 6.1. Selection of the interviewed GPs and patients and information related to privacy 
protection. 
The selection of GPs to interview preceded in several steps. The selection criteria were applied to data of patients 
from 240 different general practices. General practices were excluded when more than 60 patients were 
identified with the IGZ-criterion, and practices were excluded with less than five patients identified when 
combining all three criteria. GPs from ten general practices were invited by email to participate. These ten 
practices were chosen based on accessibility of the practice location. Data of practices that agreed to participate 
was inspected to select a final patient group that was discussed during the interview. We intended to choose 
distinct patients as regards age, gender, number of medications, type and number of diagnoses and chronic 
diseases.  
NIVEL handles the NIVEL Primary Care Database data in accordance with the Dutch Data Protection Act which 
ensures that researchers do not have access to identifiable patient information. Therefore, a data manager of 
the database sent a secured email to the participating GPs with instructions how to select the patients according 
to the three criteria sets. For this action, we had permission by an internal privacy protection committee. In 
addition, both the participating GPs as well as the researcher carrying out the interviews signed a document 
ensuring privacy protection of the discussed patients.   
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ging. Ik dacht dat ze op zoek waren naar een junior onderzoeker óf een promovenda. Doe 
mij die junior onderzoekersfunctie maar, dacht ik voordat ik aan het sollicitatiegesprek 
begon. Gaandeweg het gesprek werd het mij steeds duidelijker dat ik niet kon kiezen uit 
het één of het ander, het ging toch echt om een volledig PhD traject. Ik ben ontzettend 
blij dat ik de kans kreeg om dit traject te doorlopen, al was het niet altijd gemakkelijk. Elk 
promotietraject heeft zijn uitdagingen, en het mijne bestond uit het feit dat er alleen een 
startpunt was; multimorbiditeit in de huisartsenpraktijk. Er was geen onderzoeksvoorstel, 
het ging niet om een randomised controlled trial waar je duidelijk na een aantal jaar je 
effecten kunt meten, analyseren en daarover kan rapporteren. Het promotietraject had 
geen duidelijk eindpunt. Dit vond ik lastig. Zo moesten er soms beslissingen genomen 
worden over de weg die we zouden inslaan. Laat het nemen van beslissingen nou niet 
mijn allersterkste eigenschap zijn. Ik heb het gelukkig ontzettend getroffen met mijn 
promotieteam. De eindstreep is gehaald, en dat was niet gelukt zonder steun van 
verschillende personen. 
 
Allereerst gaat er veel dank uit naar mijn promotoren en copromotoren. Vier in totaal 
maar liefst. Gert en François, ik was in het begin van mijn traject best wel onder de indruk 
(lees: nerveus) wanneer wij overleg hadden. Gert, als hoofd van IQ Healthcare, en 
François als expert op het gebied van multimorbiditeit. En natuurlijk beiden professoren. 
Onze gesprekken vielen gelukkig alles mee en ik ben jullie ontzettend dankbaar voor jullie 
deskundigheid, opbouwende kritiek en feedback. Jozé en Joke  -als wij samen overleg 
hadden stond dit altijd als Overleg 3Js in mijn agenda-, ook met jullie als copromotoren 
heb ik het getroffen. Joke, vooral de eerste drie jaar spraken wij elkaar geregeld. Je deur 
stond letterlijk altijd voor mij open en je hebt mij in dit traject echt op weg geholpen met 
je duidelijke antwoorden en adviezen. Dankjewel daarvoor. Jozé, in mijn jaar bij IQ 
Healthcare hadden wij structureel overleg en ik was altijd heel blij met je waardevolle 
feedback. Onze overleggen gingen niet alleen over werk. Dankjewel dat je mij ook 
gesteund hebt op persoonlijk vlak, als ik weer eens worstelde met mijn onzekere ik en 
voor je interesse in mijn privé leven. 
 
Mijn dank gaat ook uit naar alle anderen die hebben bijgedragen aan de artikelen in dit 
proefschrift. Irina Stirbu, je hebt mij wegwijs gemaakt in ‘LINH’, en nam altijd de tijd om 
mijn vragen te beantwoorden. Karin Hek, ik heb mij met jou gestort op de medicatie-data 
van NIVEL Zorgregistraties, de SFK, en ook letterlijk in de HIS’sen van huisartsen. Het was 
leerzaam en gelukkig ook erg gezellig om met jou op stap te gaan voor de interviews. 
Met je kritische blik hebben we de data van de verschillende databases in een mooi artikel 
kunnen verwerken. Peter Spreeuwenberg, wat heb ik vaak in jouw deuropening gestaan. 
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Je hebt mij geholpen met het artikel over de ‘multimorbidity patterns’, maar ook voor het 
‘polypharmacy’ artikel heb jij veel vragen van mij beantwoord. En weer opnieuw, als ik de 
gang van de derde etage had doorkruist, weer aan mij bureau zat en toch nog steeds niet 
alles begreep. Je nam hier altijd de tijd voor en daar ben ik erg blij mee geweest. Jan van 
Lieshout, als huisarts en onderzoeker hebben wij samen de case-vignetten in elkaar 
gezet. Bedankt voor alle feedback. Zonder jou waren de vignetten nooit zo realistisch en 
complex geworden en had ik niet zulke interessante focusgroepen gehouden. 
Bedankt Rodrigo voor alle hulp rondom NIVEL Zorgregistraties, bedankt Ernie Wentink en 
Elsbeth de Leeuw-Stravers voor jullie inzet bij de praktische organisatie van de interviews. 
Bedankt Alfons Olde Loohuis, als voorzitter bij de focusgroepen heb jij de huisartsen goed 
bij de les gehouden. Bedankt Tim Schoenmakers, via jou heb ik verschillende heel 
interessante gesprekken met apothekers gevoerd over medicatiebeoordelingen. En 
natuurlijk bedankt Jolanda van Haren, voor je hulp bij het daadwerkelijk maken van het 
boekje. 
 
Prof. dr. M.G.M. Olde Rikkert, prof. dr. W.J.J. Assendelft en prof. dr. R.J. van Marum, jullie 
vormden samen de manuscriptcommissie die dit proefschrift heeft beoordeeld en heeft 
goedgekeurd. Hartelijk dank hiervoor. 
 
Ik heb enkele maanden bij IQ Healthcare op de flexkamer in de kelder gezeten. Hoewel 
het voor mij altijd wel een verrassing was wie ik elke week zou aantreffen, werd ik er altijd 
hartelijk ontvangen. Ook schoof ik graag aan bij de lunches daar, bedankt daarvoor. Maar 
bijna mijn gehele promotietraject heb ik doorgebracht op kamer 3.07 van het NIVEL. 
Tessa, Lisa en ik vormden daar denk ik toch wel de ‘harde kern’. Alle drie in hetzelfde jaar 
gestart, en inmiddels alle drie bezig met (het afronden van) ons proefschrift. Gedurende 
mijn loopbaan bij het NIVEL zijn er nog verschillende andere kamergenootjes geweest, en 
altijd was het gezellig. Dank daarvoor Karien, Karin, Linda en Maaike. Het laatste jaar 
deelden wij een bureau, Anne-Karien, maar gelukkig betekende dit niet dat wij elkaar 
nooit zagen. Ik vond het erg gezellig samen met jou in 3.07, je was altijd in voor een 
praatje, en je had altijd wel wat beleeft in het weekend om over te kletsen.  Lisa en Tessa, 
wat was ik blij met jullie als roomies. Beiden harde werkers en gefocust. Ik kon altijd met 
jullie sparren over het één of ander, even zeuren als het niet ging zoals ik wilde, of mijn ei 
kwijt als ik ergens mee zat. Gelukkig ging het niet altijd over werk. Lisa, in 2015 waren wij 
alle twee zwanger. Dat schept toch een band. Jouw dochter was net een paar maanden 
eerder geboren, en als kersverse moeder heb ik je altijd om advies kunnen vragen :-). 
Tessa, beiden fanatieke volleybalsters. Iedere week deelden we een wedstrijdverslag. We 
zouden goed in een team passen, jij als lange middenaanvalster en ik als snelle setupster. 
Met mijn verdediging staan jullie naast mij, Lisa en Tessa, bedankt dat jullie mijn 
paranimfen willen zijn! 
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Het leven bestaat gelukkig niet alleen uit werk. Bedankt meiden, duinrellers, en de dames 
van mijn volleybalteam voor alle prettige afleiding! Bedankt Marrie en Peter, jullie zijn 
geweldige schoonouders, ik voel mij altijd welkom bij jullie! Bedankt Derk, Irene, Rob en 
Melanie, wat een leuk stel schoonbroertjes en zusjes samen! Bedankt mam en pap, dat 
jullie mij altijd steunen en achter mijn beslissingen staan. Ruben, wat een gekke grote 
broer heb ik, bedankt daarvoor!  
 
Lieve Kay, jij bent mijn kleine vriendje, en wat ben ik ongelooflijk blij met jou! Ik kijk uit 
naar alle avonturen die wij samen gaan beleven. Lieve Frank, bedankt voor alles! Jij zou er 
niet aan moeten denken om zo in het middelpunt te staan. Toch ben jij mijn middelpunt, 
zonder jou had ik het niet gekund en zou het leven niet zo mooi zijn.  
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PHD PORTFOLIO 
Name PhD student: E.J. (Judith) Sinnige 
Department:        IQ healthcare 
Graduate School:     Radboud Institute for Health  
        Sciences 
PhD period:  15-07-2012 – 15-11-2016 
Promotor(s):  Prof. dr. GP Westert,  
  Prof. dr. FG Schellevis 
Co-promotor(s): Dr. JC Braspenning,  
  Dr. JC Korevaar 
 
   
TRAINING ACTIVITIES Year(s) ECTS 
a) Courses & Workshops 
- Literature search in Pubmed (NIVEL) 
- STATA introduction course (NIVEL) 
- Applied statistics with STATA (NIVEL)  
- Academic writing in English (BABEL) 
- NCEBP Introduction course (NCEBP) 
- Quality system NIVEL and performing intern audits (NIVEL) 
- Presenting your research in Dutch (Radboud University) 
- Presenting in English (BABEL) 
- STATA advanced course (NIVEL) 
- Multilevel Analysis (EpidM) 
- eBROK course (NFU) 
- Scientific journalism (Radboud University) 
- Career Guidance (Radboud University) 
 
2012 
2012 
2013 
2013 
2013 
2013 
2013 
2014 
2014 
2014 
2015 
2015 
2016 
 
0.1 
0.3 
2.0 
2.1 
1.0 
0.2 
1.5 
1.5 
0.3 
1.5 
1.5 
3.0 
1.5 
b) Seminars & lectures 
- Dag van het Advies thema ‘Implementatie van 
Kwaliteitsstandaarden’, Zorginstituut 
- SFK Raad van Toezicht: oral presentation 
- NIVEL Zorgregistraties huisartsendag: oral presentation 
 
 
2014 
2015 
2015 
 
 
0.1 
0.5 
0.5 
c) Symposia & congresses 
- Congres ‘Multimorbiditeit: onze uitdaging’ 
- NHG Wetenschapsdag LUMC (Leiden)  
- CARE RIHS Symposium: laptop presentation 
- NHG Wetenschapsdag UMCG (Groningen): oral presentation 
- NHG Wetenschapsdag Erasmus MC (Rotterdam): poster 
presentation with short oral presentation 
- European General Practice Research Network (EGPRN) 
conference Edirne (Turkey): oral presentation 
- NHG Wetenschapsdag AMC (Amsterdam): poster 
presentation with short oral presentation 
- WONCA Europe Copenhagen (Denmark): two oral 
presentations 
 
2013 
2013 
2014 
2014 
 
2015 
 
2015 
 
2016 
2016 
 
0.25 
0.25 
0.5 
0.5 
 
0.5 
 
0.75 
 
0.5 
1.25 
 
d) Other 
- Themagebiedoverleg Huisartsenzorg (NIVEL) (including 
several oral presentations) 
- Kennisgroep transparantie (IQ Healthcare) 
- Reviewing scientific papers for multiple journals 
 
2012-2016 
 
2012-2015 
2015, 2016 
 
1.5 
 
0.5 
0.3 
TOTAL 24.4 
 
 

